

Draft Recommended Infection Control Practices for Dentistry, 2003

Disclaimer: This draft document is intended for public comment only. Healthcare personnel should not quote this document or modify practices or policies based on these preliminary recommendations.

The following CDC staff members prepared this report:

Coordinators

Jennifer L. Cleveland, D.D.S., M.P.H.

Amy S. Collins, B.S., B.S.N., M.P.H., C.I.C.

William G. Kohn, D.D.S.

Division of Oral Health

National Center for Chronic Disease Prevention and Health Promotion

Contributors

Barbara F. Gooch, D.M.D., M.P.H.

Dolores M. Malvitz, Dr.P.H.

Division of Oral Health

National Center for Chronic Disease Prevention and Health Promotion

Elizabeth A. Bolyard, R.N., M.P.H.

Lynne Schulster, Ph.D.

Division of Healthcare Quality Promotion

National Center for Infectious Diseases

In collaboration with:

Jennifer Harte, D.D.S., M.S.

Consultant

Kathy Eklund, R.D.H., B.S., M.H.P.

The Forsyth Institute

Working Group

Joseph Bartoloni, B.S., D.M.D.

Consultant

Nancy Bjerke, B.S.N., M.P.H., C.I.C.

Consultant

Walter Bond, M.S.

Microbiologist and Consultant

Eve Cuny, R.D.A., M.S.

University of Pacific School of Dentistry

Curt Hamann, M. D.

Consultant

Chris Miller, Ph.D.

Indiana University School of Dentistry

Shannon Mills, D.D.S.

Consultant

John Molinari, Ph.D.

University of Detroit Mercy School of Dentistry

William A. Rutala, Ph.D., M.P.H.

University of North Carolina, School of Medicine

Brian Shearer, Ph.D.

Consultant

Table of Contents

Summary	1
Introduction.....	3
Part I. Review of the Scientific Data Regarding Dental Infection Control	
Infection Control Elements of a Personnel Health Program.....	5
Preventing Transmission of Bloodborne Pathogens	8
Preventing Transmission of <i>Mycobacterium tuberculosis</i>	15
Transmissible Spongiform Encephalopathies (Prion Diseases)	17
Personal Protective Equipment	19
Contact Dermatitis and Latex Hypersensitivity	23
Hand Hygiene	24
Sterilization or Disinfection of Patient-Care Items.....	30
Environmental Infection Control	38
Dental Unit Waterlines, Biofilm, and Water Quality	41
Program Evaluation	44
Special Considerations:	
Dental Handpieces and Other Devices Attached to Air and Waterlines	46
Aseptic Technique for Parenteral Medications.....	47
Single-Use (Disposable) Devices	47
Pre-procedural Mouth Rinses	48
Surgical Procedures	48
Handling of Biopsy Specimens.....	49
Handling of Extracted Teeth.....	50
Dental Laboratory	50
Part II. Recommendations.....	52
References.....	65
Appendix 1 Sample Resources for Infection Control Recommendations.....	85
Appendix 2 Immunizing Agents Strongly Recommended for Health-Care Personnel.....	86
Appendix 3 Suggested Work Restrictions for Health-Care Personnel Exposed to or Infected with Infectious Diseases.....	88
Appendix 4 Methods for Sterilization and Disinfection of Patient Care Items and Environmental Surfaces.....	91
Appendix 5 Additional Research.....	93
Appendix 6 Glossary of Terms.....	96

Draft Recommended Infection Control Practices for Dentistry, 2003

Summary

Draft Recommended Infection Control Practices for Dentistry, 2003 consolidates recommendations for the prevention and control of infectious diseases and the management of occupational health and safety issues related to infection control in dental settings. This document: 1) updates and revises previous recommendations of the Centers for Disease Control and Prevention (CDC) regarding infection control for dental settings (CDC 1986, CDC 1993); 2) incorporates relevant infection control measures from several other CDC guidelines (Table 1); and 3) discusses several issues not addressed in previous CDC recommendations for dentistry. These updates and additional topics include:

- Standard precautions
- Work restrictions for health-care personnel occupationally exposed to or infected with infectious diseases (Appendix 3)
- Management of occupational exposures to bloodborne pathogens, including postexposure prophylaxis (PEP)
- Selection and use of devices with features engineered to prevent sharps injury
- Transmissible spongiform encephalopathies (TSEs)
- Hand hygiene products and surgical hand antisepsis
- Contact dermatitis and latex hypersensitivity
- Flash sterilization limitations
- Dental water quality
- Boil-water advisories
- Discontinued flushing dental unit waterlines at the beginning of the day
- Program evaluation
- Aseptic technique for parenteral medications
- Pre-procedural mouth rinsing for patients
- Definition of a surgical procedure
- Use of sterile water for surgical procedures
- Further research needs (Appendix 5)

These recommendations represent a consensus from a panel of experts in infection control regarding strategies for the prevention of disease transmission in dental health-care settings. Whenever possible, the recommendations are based on data from well-designed scientific studies. Only a few studies, however, have characterized risk factors and the effectiveness of prevention measures for infections associated with dental healthcare. Because transmission of infectious agents should be similar in dental and medical settings, pertinent sections of infection control recommendations from other CDC guidelines have been included where applicable (Table 1). Infection control updates are continually published in the literature. Thus, CDC recommends that readers review future publications of new or updated guidelines and documents to stay apprised of current infection control recommendations (Appendix 1).

43 Some infection control practices routinely used by dental practitioners (e.g., use of sterile water
44 for surgical procedures) cannot be rigorously studied for ethical or logistical reasons (due to
45 attaining an adequate sample size). In the absence of proven scientific evidence for certain
46 practices, some recommendations are based on a strong theoretical rationale, suggestive
47 evidence, or the opinions of respected authorities based on clinical experience, descriptive
48 studies, or reports of expert committees. In addition, some recommendations are derived from
49 existing federal regulations. No recommendation is offered for some practices for which there is
50 insufficient scientific evidence or lack of expert consensus supporting their effectiveness. For
51 practices related to unresolved issues, practitioners should formulate a policy within their own
52 facility.
53

53 **Table 1. Referenced Guidelines for Infection Control for Health-Care Settings**

Document Title	Year	Author	Advisory Committee
Guidelines for Handwashing and Hospital Environmental Control	1985	Garner	None
Recommendations for Preventing Transmission of Human Immunodeficiency Virus and Hepatitis B Virus to Patients During Exposure-Prone Invasive Procedures	1991	CDC	None
Guidelines for Preventing the Transmission of <i>Mycobacterium tuberculosis</i> in Health-care Facilities	1994	CDC	None
Guideline for Hand Washing and Hand Antisepsis in Health-Care Settings	1995	Larson	APIC*
Guideline for Isolation Precautions in Hospitals	1996	Garner	HICPAC [†]
Guideline for Selection and Use of Disinfectants	1996	Rutala	APIC*
Immunization of Health-Care Workers	1997	CDC	ACIP [§] /HICPAC [†]
Guideline for Infection Control in Health-Care Personnel	1998	Bolyard	HICPAC [†]
Guideline for Prevention of Surgical Site Infection	1999	Mangram	HICPAC [†]
Recommendations for Infection Control for the Practice of Anesthesiology	1999	ASA#	None
Updated US Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis	2001	CDC	HICPAC [†]
Draft Guideline for Environmental Infection Control in Health-Care Facilities	2001	CDC	HICPAC [†]
Draft Guideline for Cleaning, Disinfection, and Sterilization in Health-Care	2002	Rutala	HICPAC [†]
Guideline for Hand Hygiene in Health-Care Settings	2002	CDC	HICPAC [†]
Guidelines for the Prevention of Intravascular Catheter-Related Infections	2002	CDC	HICPAC [†]

54 * Association for Professionals in Infection Control and Epidemiology, Inc.
 55 [†] Healthcare Infection Control Practices Advisory Committee, formerly the Hospital Infection Control
 56 Practices Advisory Committee (national advisory committee to CDC).
 57 [§] Advisory Committee on Immunization Practices (national advisory committee to CDC).
 58 # American Society of Anesthesiologists
 59

60 **Introduction**

61 In the United States an estimated 9.0 million persons work in health-care professions (health-care
 62 personnel [HCP]), including approximately 168,000 dentists, 112,000 registered dental
 63 hygienists, 218,000 dental assistants (US Census Bureau 2001), and 53,000 dental laboratory
 64 technicians (HRSA 2000). In this document the term dental health-care personnel (DHCP) refers
 65 to all paid and unpaid personnel in the dental health-care setting who could be occupationally
 66 exposed to infectious materials, including body substances, and contaminated supplies,
 67 equipment, environmental surfaces, water, or air. These personnel include dental hygienists,
 68 dental assistants, dental laboratory technicians, students and trainees, contractual staff, and other

69 persons not directly involved in patient care but potentially exposed to infectious agents (e.g.,
70 administrative, clerical, housekeeping, maintenance, volunteer personnel). These
71 recommendations are designed to prevent or reduce the potential for disease transmission from
72 patient-to-DHCP, from DHCP-to-patient, and from patient-to-patient. Although these guidelines
73 focus mainly on outpatient, ambulatory dental health-care settings, the recommended infection
74 control practices are applicable to all settings in which dental treatment is provided.
75

76 Dental patients and DHCP may be exposed to a variety of microorganisms in blood, oral, or
77 respiratory secretions, including cytomegalovirus (CMV), hepatitis B virus (HBV), hepatitis C
78 virus (HCV), herpes simplex virus types 1 and 2, human immunodeficiency virus (HIV),
79 *Mycobacterium tuberculosis* (*M. tuberculosis*), staphylococci, streptococci, and other viruses and
80 bacteria that colonize or infect the oral cavity and respiratory tract. Infections may be transmitted
81 in dental settings through several routes, including direct contact with blood, oral fluids, or other
82 body fluids; indirect contact with contaminated instruments, operatory equipment, or
83 environmental surfaces; and contact with airborne contaminants present in either droplet, spatter,
84 or aerosols of oral and respiratory fluids. Infection via any of these routes requires that all of the
85 following conditions be present: 1) a pathogenic organism of sufficient virulence and in adequate
86 numbers (i.e., dosage) to cause disease; 2) a suitable reservoir or source that allows the pathogen
87 to survive and multiply (e.g., blood); 3) a mode of escape from the reservoir; 4) a mechanism of
88 transmission from the source to the host; 5) a portal of entry through which the pathogen may
89 enter the host; and 6) a susceptible host (i.e., one who is not immune). The occurrence of these
90 events is considered the "chain" of infection. Effective infection control strategies are intended to
91 break one or more of these "links" in the chain, thereby preventing infection. Such strategies
92 include: vaccinations; hand hygiene and barrier precautions; proper cleaning, disinfection, and
93 sterilization procedures; and aseptic techniques and practices (e.g., the use of safer devices and
94 behaviors) to reduce the risk of exposure to blood, other body fluids, or infectious agents.
95

96 Previous CDC recommendations on infection control for dentistry focused primarily on the use
97 of universal precautions to reduce the risk of transmission of bloodborne pathogens among
98 DHCP and patients (CDC 1986, CDC 1988, CDC 1989, CDC 1993). Because many patients
99 with bloodborne infections are asymptomatic or unaware that they are infected, these
100 recommendations emphasized the need to treat blood and other body fluids contaminated with
101 blood from all patients as potentially infectious (Garner 1985, CDC 1986, CDC 1987, CDC
102 1988, CDC 1989, CDC 1993). In 1996, CDC developed guidelines that combined the major
103 components of universal precautions and body substance isolation (designed to reduce the risk of
104 transmission of pathogens from moist body substances) into one set of precautions known as
105 standard precautions (Garner 1996). Standard precautions are similar to universal precautions in
106 that they are designed to reduce the risk of transmission of pathogens from both recognized and
107 unrecognized sources of infection to other patients and to DHCP. Standard precautions apply to
108 contact with 1) blood; 2) all body fluids, secretions, and excretions except sweat, regardless of
109 whether they contain blood; 3) non-intact skin; and 4) mucous membranes. Standard precautions
110 should be used in the care of all patients, regardless of their infection status.
111

112 For the vast majority of infectious diseases, standard precautions are adequate. Additional
113 precautions (transmission-based precautions) are necessary for interrupting the spread of certain
114 diseases (e.g., tuberculosis, influenza, chicken pox) transmitted by air, droplets, or indirect or

115 direct contact with contaminated sources (Garner 1996, Bolyard 1998). Such precautions can
116 include patient placement (e.g., isolation), adequate room ventilation, respiratory protection for
117 workers, and postponement of non-emergent dental procedures. Precautions for preventing the
118 transmission of tuberculosis in dental health-care settings are discussed in a section entitled
119 Preventing the Transmission of *Mycobacterium tuberculosis*.

120
121 Dental facilities should develop a written infection control program to prevent or reduce the risk
122 of disease transmission. This should include an Exposure Control Plan to eliminate or minimize
123 employee exposure (OSHA 1991). Such a program should include the establishment and
124 implementation of policies, procedures, and practices (in conjunction with the selection and use
125 of technologies and products) to prevent work-related injuries and illnesses in health-care
126 personnel as well as health-care-associated infections in patients. The program should: 1)
127 embody the principles of infection control and occupational health; 2) reflect current science; 3)
128 adhere to relevant federal, state, and local regulations and statutes; and 4) be reviewed and
129 updated at least annually. An infection control coordinator (e.g., a dentist or other staff member)
130 knowledgeable or willing to be trained in the principles of infection control should be assigned
131 responsibility for coordinating the program. Strategies and tools can be developed and used to
132 evaluate the effectiveness of the infection control program (such strategies will be addressed in
133 the section entitled Program Evaluation).

134
135 Resources are available to DHCP regarding the proper procedures for handling or working with a
136 particular substance (e.g. chemical) and are not discussed in this guideline. Product information
137 about physical data, health effects, first aid, reactivity, storage, disposal, and spill/leak
138 procedures can be referenced in the manufacturer's Material Safety Data Sheet (MSDS) and
139 should be available to all employees (OSHA 1994).

140
141

142 **Part I. Review of the Scientific Data Regarding Dental Infection Control**

143

144 **Infection Control Elements of a Personnel Health Program**

145 An occupational personnel health program for DHCP is an integral part of the infection control
146 program. The infection control objectives of the program are to educate DHCP about the
147 principles of infection control, to identify work-related infection risks and institute appropriate
148 preventive measures, and to ensure prompt and appropriate provision of preventive services for
149 exposure management and medical follow-up. These preventive services will be part of the
150 occupational personnel health program, and coordination between the attending dental
151 professional and other qualified health-care professionals will be important in providing DHCP
152 with appropriate services. Dental programs in institutional settings, such as hospitals, health
153 centers, and educational institutions, can coordinate with other departments that provide
154 personnel health services. Most dental practices, however, are in ambulatory, private settings that
155 do not have the appropriately licensed staff and facilities to provide complete on-site health
156 service programs. It is important that the responsible infection control coordinator in these
157 settings establish programs that arrange site-specific infection control services with external
158 health-care facilities and providers (e.g., qualified health-care professionals) before DHCP are
159 placed at risk of exposure. Referral arrangements can be made with qualified health-care

160 professionals in an occupational health program of a hospital, educational institutions, or with
161 health-care facilities that offer personnel health services.

162
163 *Education and Training*

164 Personnel are more likely to comply with an infection control program if they understand its
165 rationale (Bolyard 1998, OSHA 1991, Gershon 2000). Clearly written policies, procedures, and
166 guidelines can help ensure consistency, efficiency, and effective coordination of activities.
167 Education and training in infection control should be appropriate to both the risk of exposure and
168 assigned duties of specific personnel. For DHCP who perform tasks or procedures likely to result
169 in occupational exposure to potentially infectious agents, training should include a description of
170 their exposure risks; a review of prevention strategies, infection control policies and procedures
171 for the facility; discussion on how to manage work-related illness and injuries, including
172 postexposure prophylaxis (PEP); and a review of work restrictions appropriate for the exposure
173 or infection. Inclusion of personnel with minimal exposure risks (e.g., administrative staff) in
174 education and training programs may enhance facility-wide understanding of infection control
175 principles and the importance of the program. Educational materials should be appropriate in
176 content and vocabulary for the person's educational level, literacy, and language and consistent
177 with existing federal, state, and local regulations (Bolyard 1998).

178
179 *Immunization Programs*

180 DHCP are at risk for exposure to, and possible infection with, vaccine-preventable diseases.
181 Appropriate immunizations substantially reduce both the number of DHCP susceptible to these
182 diseases and the potential for disease transmission to other DHCP and patients (Bolyard 1998,
183 CDC/ACIP 1997). Thus, immunizations are an essential part of prevention and infection control
184 programs for DHCP and dental health-care facilities are encouraged to formulate a
185 comprehensive immunization policy (AHA 1992, CDC/ACIP 1997). These policies should
186 include a checklist of required and recommended vaccinations for specific job categories,
187 including appropriate vaccination and booster schedules; determination of the immune status of
188 newly hired employees; and considerations for DHCP unable or unwilling to be vaccinated as
189 required or recommended. Policies also should reflect the regulations and recommendations on
190 the vaccination of HCP established by individual states and professional organizations.

191
192 Immunization of DHCP before they are placed at risk remains the most efficient and effective
193 use of vaccines in health-care settings. Many professional educational institutions and site-
194 specific infection control programs provide appropriate immunization schedules for students and
195 practicing DHCP. Personnel who do not provide direct patient care (e.g., administrators,
196 laboratory personnel) but come into contact with patients, patient materials, and other DHCP
197 also should receive recommended vaccinations. DHCP unable or unwilling to be vaccinated as
198 required or recommended should be educated on their exposure risks, infection control policies
199 and procedures for the facility, and the management of work-related illness and work restrictions
200 (if appropriate) for exposed or infected DHCP.

201
202 National guidelines for immunization of, and PEP for, HCP, which includes DHCP, are provided
203 by the US Public Health Service's Advisory Committee on Immunization Practices (ACIP)
204 (CDC/ACIP 1997 and 2001). Based on studies of health-care infections, susceptible HCP are
205 considered to be at occupational risk for acquiring HBV or HCV infection, and at risk for

206 acquiring or transmitting influenza, measles, mumps, rubella, and chicken pox (varicella). The
207 ACIP recommends that all HCP be vaccinated or have documented immunity to all vaccine-
208 preventable diseases (Bolyard 1998, CDC/ACIP 1997) (Appendix 2). The committee does not
209 recommend routine immunization of HCP against tuberculosis (i.e., inoculation with Bacille
210 Calmette-Guérin [BCG] vaccine) or hepatitis A (CDC/ACIP 1997). ACIP guidelines also
211 provide recommendations on immunization of HCP with special conditions (e.g., pregnancy,
212 HIV infection, diabetes) (Bolyard 1998, CDC/ACIP 1997).

213

214 *Exposure Prevention and Postexposure Management*

215 Avoiding exposure to blood and other potentially infectious body fluids, as well as protection by
216 immunization, remain primary strategies for reducing occupationally acquired infections, but
217 occupational exposures will still occur (MMWR 2001). A combination of standard precautions
218 and administrative, engineering, and work practice controls is the best means of eliminating or
219 minimizing occupational exposures. Written policies and procedures to facilitate the prompt
220 reporting, evaluation, counseling, treatment, and medical follow-up of all occupational exposures
221 should be available to all DHCP. Written policies and procedures should be consistent with
222 federal, state, and local requirements addressing education and training, postexposure
223 management, and exposure reporting (OSHA 1991).

224 Recommendations for postexposure management and prophylaxis for exposures to blood are
225 addressed in the section entitled Preventing the Transmission of Bloodborne Pathogens. DHCP
226 may have contact with persons suspected or confirmed infectious tuberculosis and should have a
227 baseline tuberculin skin test (preferably using a two-step test) at the beginning of employment. If
228 an unprotected exposure occurs, tuberculin skin test (TST) conversions can be distinguished
229 from positive TST results caused by previous exposures (CDC tuberculosis 1994, Cleveland
230 1995). The facility's level of TB risk will determine the need for routine follow-up TST. Further
231 information is addressed in the section entitled Preventing the Transmission of *Mycobacterium*
232 *tuberculosis*.

233

234 *Medical Conditions, Work-Related Illness, and Work Restrictions*

235 DHCP are responsible for monitoring their own health status. DHCP who have acute or chronic
236 medical conditions (that render them more susceptible to opportunistic infection) should discuss
237 with their personal physician or other qualified authority whether the condition may affect their
238 ability to safely perform their duties. Under certain circumstances, however, health-care facilities
239 may need to implement additional measures to prevent further transmission of infection that
240 warrant exclusion of personnel from work or patient contact (Herwaldt 1997). Decisions on work
241 restrictions are based on the mode of transmission and the epidemiology of the disease (Bolyard
242 1998) (Appendix 3). Exclusion policies should be written, include a statement of authority
243 defining who may exclude personnel (e.g., personal physician), and be clearly communicated to
244 personnel through education and training. Policies also need to be designed to encourage
245 personnel to report their illnesses or exposures and not to penalize them with loss of wages,
246 benefits, or job status.

247

248 With increasing concerns about bloodborne pathogens and the introduction of universal
249 precautions, the use of latex gloves among health-care workers has increased markedly (CDC
250 1988, Nash 1992). Increased use of these gloves has been accompanied by more reports of

251 allergic reactions to natural rubber latex among HCP (including DHCP) and patients (Berky
252 1992, Bubak 1992, Fisher 1992, Smart 1992, Yassin 1994, Zaza 1994, Hunt 1995).

253
254 DHCP should be familiar with the signs and symptoms of latex sensitivity (Bolyard 1998,
255 American Dental Association 1999, CDC NIOSH 1997, Terezhalmly Personal 1996). A
256 physician should evaluate DHCP experiencing symptoms of latex allergy, because further
257 exposure could result in a serious allergic reaction. A diagnosis is made through the medical
258 history, physical examination, and tests. Procedures should be in place for minimizing latex-
259 related health problems in DHCP and patients while protecting them from infectious materials.
260 These procedures include reducing exposures to latex containing materials, using appropriate
261 work practices, training and educating DHCP, monitoring symptoms, and substituting non-latex
262 products when appropriate (CDC/NIOSH 1997). Further information on contact dermatitis in
263 DHCP and patients can be found in the section entitled Contact Dermatitis and Latex
264 Hypersensitivity.

265
266 *Maintenance of Records, Data Management, and Confidentiality*
267 Maintenance of records on work-related medical evaluations, screening tests, immunizations,
268 exposures, and post exposure management allows monitoring of the health status of personnel.
269 Such records must be kept in accordance with all applicable state and federal laws. Some
270 examples of laws that may apply, include the Privacy Rule of the Health Insurance Portability
271 and Accountability Act of 1996, 45 C.F.R. 160 & 164 (HIPAA) and the Occupational Safety and
272 Health Administration (OSHA) Occupational Exposure to Bloodborne Pathogens; Final Rule 29
273 C.F.R. 1910.1030(h)(1)(i-iv) (HIPAA 2000, OSHA 1991). HIPAA applies to covered entities
274 including certain health providers, health care clearinghouses, and health plans as defined by the
275 Privacy Rule. OSHA also requires that employers ensure that certain information contained in
276 employee medical records are: 1) kept confidential; 2) not disclosed or reported without the
277 employee's express written consent to any person within or outside the workplace except as
278 required by this Final Rule or as may be required by law, and 3) maintained by the employer for
279 at least the duration of employment plus 30 years. Dental facilities that coordinate their infection
280 control program with off-site providers may want to consult OSHA's Final Rule mentioned
281 above and other applicable local, state, and federal laws in order to determine the preferable
282 location to maintain health records.

283
284
285 **Preventing Transmission of Bloodborne Pathogens**
286 The transmission of bloodborne pathogens (e.g., HIV, HBV, and HCV) in dental health-care
287 settings can have serious consequences but is fortunately a rare event. Transmission can occur as
288 a result of exposure to infected blood; from patient-to-DHCP, from DHCP-to-patient, and from
289 one patient to another. The opportunity for transmission is most likely from patient to DHCP,
290 who frequently contact patient blood and blood-contaminated saliva during dental procedures.
291 Exposures occur through percutaneous injury (e.g., a needlestick or cut with a sharp object) as
292 well as through contact between potentially infectious blood, tissues, or other body fluids and
293 mucous membranes of the eye, nose, mouth, or nonintact skin (e.g., exposed skin that is chapped,
294 abraded, or afflicted with dermatitis). The risk of occupational exposure to bloodborne viruses is
295 largely determined by their prevalence (frequency) in the patient population and the nature and
296 frequency of contact with blood and body fluids through percutaneous or permucosal routes of

297 exposure. The risk of infection after exposure to a bloodborne virus is influenced by inoculum
298 size (i.e., viral titer in the source, volume of material), route of exposure, and susceptibility of the
299 exposed HCP (Chiarello 2001).

300
301 Avoiding occupational exposures to blood is the primary way to prevent transmission of HBV,
302 HCV, and HIV to HCP in health-care settings (CDC NIOSH 1999). Methods to reduce the risk
303 of blood contacts have included the use of standard precautions (which incorporates universal
304 precautions), modifications of work practices, and more recently, the use of devices with features
305 engineered to prevent sharp injuries. These three measures have been proved effective in
306 decreasing percutaneous injuries among dentists over recent years (Klein 1988; Gruninger 1992;
307 Siew 1995; Cleveland 1997), but needlesticks and other blood contacts continue to occur, a
308 concern because percutaneous injuries pose the greatest risk of transmission. A comprehensive
309 program to prevent sharps injuries and infection following occupational blood exposures
310 includes immunization against HBV and prompt postexposure management.

311
312 *Hepatitis B Virus*

313 HBV is a well-recognized occupational risk for DHCP. Among HCP, occupational infections
314 have declined over the past two decades because of the use of vaccine and adherence to the use
315 of universal precautions (Shapiro 1995). Of U.S. dentists, over 90% have been vaccinated, and
316 serologic evidence of past HBV infection decreased from pre-vaccine levels of 14% in 1972 to
317 8-9% in 1989 (Cleveland 1996). From 1989 to 2001, levels remained relatively unchanged
318 (Chakwan Siew, PhD, American Dental Association, Chicago, IL, personal communication,
319 November 2002). It is reasonable to expect that infection rates will decline further as
320 vaccinations remain high among young dentists and as older dentists with lower vaccination
321 rates, and higher rates of infection, retire.

322
323 Although the potential for transmission of bloodborne infections from dental personnel to
324 patients is considered very small, (CDC 1991, Chamberland 1992, Robert 1995), precise risks
325 have not been quantified by carefully designed epidemiologic studies (CDC dentistry 1993, CDC
326 1991 exposure prone, Siew 1992). Reports published from 1970 through 1987 indicate nine
327 clusters in which patients were thought to be infected with HBV through treatment by an
328 infected DHCP (Ahtone 1983, Hadler 1981, CDC 1985, Levin 1974, Rimland 1977, Goodwin
329 1976, Reingold 1982, Goodman 1982, Shaw 1986, CDC 1987 hepatitis B). Transmission of
330 HBV from dentist to patient has not been reported since 1987, however, possibly reflecting such
331 factors as incomplete ascertainment and reporting, improved adherence to other preventive
332 measures (e.g., standard precautions—including routine glove use by dentists), and increased
333 levels of immunity due to use of hepatitis B vaccine. Furthermore, since the adoption of
334 universal precautions and the implementation of the Occupational Safety and Health
335 Administration's Occupational Exposure to Bloodborne Pathogens: Final Rule in 1991, there has
336 only been one documented case of patient-to-patient transmission of hepatitis B virus in the
337 dental setting (Redd 2003).

338
339 HBV is transmitted by percutaneous or mucosal exposure to blood or body fluids of a person
340 with either acute or chronic HBV infection. A person who is infected with HBV can transmit the
341 virus for as long as they are hepatitis B surface antigen (HBsAg) positive. In addition, if the
342 source is also positive for hepatitis B e antigen (HBeAg), the risk of infection is 10 times higher

343 than for exposure to a source positive for HBsAg alone (Werner 1982). Because of the high risk
344 of HBV infection among HCP, DHCP who perform tasks involving contact with blood, blood-
345 contaminated body fluids, other body fluids, or sharps should be vaccinated (CDC 1991
346 Hepatitis B virus: a comprehensive strategy, CDC dentistry 1993, CDC Immunization 1997,
347 OSHA 1991). Vaccination can protect both DHCP and patients from HBV infection and should
348 be completed when dentists or other DHCP are still in their training program and before they
349 have contact with blood. Pre-vaccination serological testing for previous infection is not
350 indicated for persons being vaccinated because they have an occupational risk, though it would
351 be useful in individuals who have immigrated from areas with high rates of HBV infection.
352 DHCP should be tested for antibody to HBsAg (anti-HBs) 1 to 2 months after completion of the
353 3-dose vaccination series (CDC Immunization 1997). Knowledge of the antibody response aids
354 in determining appropriate PEP or the need for additional vaccine doses (CDC Immunization
355 1997). DHCP who do not respond adequately to the vaccine should complete a second 3-dose
356 series (CDC Immunization 1997). Approximately half of nonresponders to the primary series
357 will respond to a second series. Persons in whom a protective antibody response (>10mIU/ml)
358 develops 1–2 months after completion of the 3-dose or 6-dose series of vaccinations, are
359 considered immune. If there is no antibody response after the second series, testing for HBsAg
360 should be performed (CDC Immunization 1997).

361
362 Vaccine-induced antibodies decline gradually over time, and 60% of persons who initially
363 respond to vaccination will lose detectable antibodies over 12 years. Even so, immunity
364 continues to prevent clinical disease or detectable viral infection (CDC Immunization 1997).
365 Booster doses of vaccine and periodic serologic testing to monitor antibody concentrations after
366 completion of the vaccine series are not necessary for vaccine responders (CDC Immunization
367 1997).

368

369 *Hepatitis C Virus*

370 HCV is not transmitted efficiently through occupational exposures to blood. Follow-up studies of
371 HCP exposed to HCV-infected blood through percutaneous or other sharps injuries have found a
372 low incidence of seroconversion (mean, 1.8%; range, 0%-7%) (Alter 1997, Puro 1995, Lanphear
373 1994, Mitsui 1992). One study found that transmission occurred from hollow-bore needles but
374 not other sharps (Puro 1995). Although these studies have not documented seroconversion
375 associated with mucous membrane or nonintact skin exposure, at least two cases of transmission
376 of HCV from a blood splash to the conjunctiva (Sartori 1993, Ippolito 1998) and one case of
377 simultaneous transmission of HCV and HIV after nonintact skin exposure have been reported
378 (Beltrami 2002). There is little data to allow estimation of the occupational risk of HCV infection
379 among HCP, but most studies suggest that the prevalence of HCV infection among dentists,
380 surgeons, and hospital-based HCP is similar to that among the general population, about 1-2%,
381 and is 1/10 that of HBV infection (Cooper 1992, Panlilio 1995, Polish 1993, Shapiro 1996,
382 Gerberding 1994, Klein 1991, Thomas 1996, Cleveland 1999, Gruninger 2001). In a study that
383 evaluated risk factors for infection, a history of accidental needlesticks was the only occupational
384 risk factor independently associated with HCV infection (Polish 1993).

385

386 *Human Immunodeficiency Virus*

387 The risk of HIV transmission in dental settings appears to be extremely low. As of June 2001
388 there were 57 U.S. HCP but no DHCP with documented HIV seroconversion following a

389 specific occupational exposure to a known HIV-infected source (CDC 2001). Transmission of
390 HIV to six patients of a single dentist with AIDS has been reported, but the mode of transmission
391 could not be determined (CDC dentistry 1993, CDC investigation 1993, Ciesielski 1992). As of
392 September 30, 1993, CDC was aware of test results of more than 22,000 patients of 63 HIV-
393 infected HCP, including 33 dentists or dental students (Robert 1995, CDC investigation 1993).
394 No additional cases of transmission were documented during these extensive investigations.
395

396 Prospective studies worldwide indicate that the average risk of HIV infection after a single
397 percutaneous exposure to HIV-infected blood is 0.3% (range: 0.2%-0.5%) (Bell 1997) after an
398 exposure of mucous membranes in the eye, nose, or mouth, the risk is approximately 0.1%
399 (Ippolito 1993). The precise risk of transmission after skin exposures remains unknown but is
400 believed to be even smaller.
401

402 Several factors affect the risk of HIV transmission after an occupational exposure. Laboratory
403 studies have found that if needles that pass through latex gloves are solid rather than hollow-bore
404 or are of small gauge (e.g., anesthetic needles commonly used in dentistry) they transfer less
405 blood (Mast 1993). In a retrospective case-control study of HCP, an increased risk for HIV
406 infection was associated with exposure to a relatively large volume of blood (as indicated by a
407 deep injury), injury with a device that was visibly contaminated with the patient's blood, or a
408 procedure that involved a needle placed in a vein or artery (Cardo 1997). The risk was also
409 increased if the exposure was to blood from patients with terminal illness, possibly reflecting the
410 higher titer of HIV in late-stage AIDS.
411

412 *Preventing and Managing Exposures to Blood*

413 From 1990 to 1998, the US Public Health Service (USPHS) published several guidelines for the
414 management of exposures to HBV, HCV, or HIV that included considerations for PEP and
415 management (CDC 1990, CDC 1991 Hepatitis B virus: a comprehensive strategy, CDC 1996,
416 CDC 1998 control of hepatitis C, CDC 1998 exposure HIV). In 2001, the USPHS consolidated
417 into one set of guidelines all previous USPHS recommendations. Current guidelines reflect the
418 availability of new antiretroviral agents, new information about the use and safety of HIV PEP,
419 and considerations about employing HIV PEP when resistance of the source patient's virus to
420 antiretroviral agents is known or suspected. In addition, the 2001 document provides guidance to
421 clinicians and exposed HCP on deciding when to consider HIV PEP and recommendations for
422 PEP regimens. The USPHS will periodically review scientific information on antiretroviral
423 therapies and publish updated recommendations for their use as PEP (CDC 2001).
424

425 *Risk of Percutaneous Injury Among DHCP*

426 Observational studies and surveys indicate that percutaneous injuries among general dentists not
427 only occur less frequently than among general and orthopedic surgeons but also that they have
428 decreased in frequency since the mid-1980s (Klein 1988, Gruninger 1992, Cleveland 1995, Siew
429 1995). This decline has been attributed to safer work practices, safer instrumentation or design,
430 and continued worker education (Cleveland 1997, Gooch 1998). Percutaneous injuries among
431 dental personnel generally occur outside the patient's mouth, involve very small amounts of
432 blood, and are caused by burs, syringe needles, and other sharp instruments (Gruninger 1992,
433 Cleveland 1995, Gooch 1995, Siew 1995). Among oral surgeons, limited data suggest that
434 injuries may occur more frequently during fracture reductions using wires (Gooch 1998, Carlton

435 1997). Experience, as measured by years in practice, does not appear to affect the risk of injury
436 among general dentists or oral surgeons (Siew 1995, Carlton 1997, Gooch 1998).

437
438 From June 1995 to March 2000, participating dentists, oral surgeons, hygienists, and dental
439 assistants reported 104 percutaneous injuries to CDC's National Surveillance System for Health-
440 care Workers (NaSH) (CDC unpublished data). Small-gauge syringe needles caused 28% of
441 injuries, overall representing 35% of injuries among assistants, 30% among dentists, and 26%
442 among oral surgeons. Most injuries (97%) were superficial to moderately deep; only 3% were
443 described as deep punctures or wounds. Less than half of syringe needles, burs, and scalpels
444 were visibly contaminated with blood prior to the injury. In contrast, most of the suture needles
445 and scalers were visibly bloody. More than half (54%) of all injuries occurred during use of the
446 device. Injuries with syringe needles frequently occurred during insertion or withdrawal of the
447 needle or when the patient moved unexpectedly (46%); 19% took place during recapping and
448 19% during cleanup; 10% were environmentally related (involved bumping into an exposed
449 syringe needle left in an unexpected location); and 6% occurred during passing or handling.
450 None took place while the DHCP was putting the syringe needle into a sharps container, as often
451 occurs in medical practice settings.

452
453 *Prevention Methods*

454 Most exposures are preventable. Methods used to prevent occupational exposures in dental
455 settings include standard precautions, engineering and work practice controls, and the use of
456 personal protective equipment.

457
458 Whenever possible, engineering controls should be the primary method to reduce exposures to
459 bloodborne pathogens with sharp instruments and needles. These controls are frequently
460 technology based and often incorporate safer designs of instruments and devices, (such as self-
461 sheathing anesthetic needles and dental units designed to shield burs in handpieces) to reduce
462 percutaneous injuries (Cleveland 1995, Cleveland 1997, Harte 1998). Used disposable syringes
463 and needles, scalpel blades, and other sharp items should be placed in appropriate puncture-
464 resistant containers located as close as practical to where the items were used (CDC HIV 1987,
465 CDC 1988, CDC 1989, CDC dentistry 1993, CDC NIOSH Containers 1998).

466
467 Work practice controls should incorporate specific work practices to protect personnel whose
468 responsibilities include handling, using, assembling, or processing sharp devices or sharps
469 disposal containers. Used needles should never be recapped or otherwise manipulated using both
470 hands or any other technique that involves directing the point of a needle toward any part of the
471 body (CDC HIV 1987, CDC 1988, CDC 1989, CDC dentistry 1993, OSHA 1991, NIOSH 1999).
472 Either a one-handed "scoop" technique or a mechanical device designed for holding the needle
473 sheath should be employed (CDC HIV 1987, CDC 1988, CDC 1989, CDC 1993, OSHA 1991).
474 DHCP should never bend or break needles before disposal as this practice requires unnecessary
475 manipulation. Before attempting to remove needles from non disposable aspirating syringes,
476 DHCP should recap them to prevent injuries. Either of the two acceptable techniques may be
477 used. For procedures involving multiple injections with a single needle, the unsheathed needle
478 should be placed in a location where it will not become contaminated or contribute to
479 unintentional needlesticks between injections. Other work practice controls include removing
480 burs before disassembling the handpiece from the dental unit, restricting the use of fingers during

481 suturing and administration of anesthesia, and minimizing potentially uncontrolled movements
482 of instruments such as scalers or laboratory knives (Gooch 1995, Cleveland 1995).

483
484 Personal protective equipment, such as gloves, masks, protective eyewear with solid side shields,
485 and gowns, is intended to prevent skin and mucous membrane exposures. Other protective
486 equipment, such as plastic finger guards, has been suggested to reduce injuries during dental
487 procedures (Gooch 1998).

488
489 Mandated by the Needlestick Safety and Prevention Act [Public Law No. 106-430, November 6,
490 2000], changes to OSHA's bloodborne pathogens standard were published January 18, 2001, and
491 became effective April 18, 2001 (OSHA 2001 needlestick, OSHA 2001 CPL). The revisions
492 clarify the need for employers to select safer needle devices as they become available and to
493 involve employees in identifying and choosing such devices (OSHA needlestick 2001). Many
494 safer versions of sharp devices used in hospital settings have become available, and their impact
495 on reducing injuries has been studied (CDC 1997 blunt suture needles, CDC 1997 phlebotomy
496 procedures). Aspirating anesthetic syringes that incorporate safety features have been developed
497 for dental cases, but the low injury rates in dentistry limit assessment of their effect on reducing
498 injuries among DHCP. Nonetheless, the impact of safer medical devices in other settings
499 suggests that devices with engineered safety features could reduce percutaneous injuries in dental
500 settings as well.

501
502 A program to prevent sharps injuries that includes a process to identify, screen, and evaluate
503 safer dental devices should be developed by all dental practices and integrated into existing
504 infection control and safety programs. The infection control coordinator should identify a team to
505 develop, implement, and monitor the safety program. Under the revised OSHA bloodborne
506 pathogen standard, this team should include employees directly responsible for patient care (e.g.,
507 dentists, hygienists, and dental assistants) (Department 2001 Federal Register, Department 2001
508 CPL). The following activities are important elements of a successful safety program:

- 509 • Promote safety awareness by encouraging management and employees to actively
510 participate in ensuring a safe workplace.
- 511 • Facilitate prompt reporting and post exposure management of injuries.
- 512 • Identify unsafe work practices and devices.
- 513 • Determine intervention priorities.
- 514 • Coordinate the identification, screening, and evaluation of devices to prevent sharps
515 injury.
- 516 • Organize staff education and training.
- 517 • Complete the necessary reporting forms and documentation.
- 518 • Monitor safety performance.

519
520 These activities should be developed into a written plan, and mechanisms for staff feedback
521 should be provided. Such feedback will assist the infection control coordinator in reviewing the
522 effectiveness of the plan and in making modifications as needed. Although the infection control
523 coordinator is responsible for the overall management of the program, creating a safe work
524 environment ultimately will require the commitment and accountability of all DHCP. The US
525 Food and Drug Administration (FDA) is responsible for regulating medical products, including
526 drugs, devices (such as medical and dental instruments), and biological products. FDA

527 encourages the reporting of a problem or an adverse event associated with medical or dental
528 products. To report such an event, contact MedWatch (telephone: 1-800-FDA-1088; Web site:
529 www.fda.gov/medwatch/index.html). The identities of both patients and persons who make the
530 reports will be kept confidential upon request. Accidental needlesticks are not reported to
531 MedWatch but are reported through mechanisms established in the Exposure Control Plan.
532 Additional information for developing a safety program and for identifying and evaluating safer
533 dental devices can be found at the following web sites:

- 534 • Forms for screening and evaluating safer dental devices:
535 http://www.cdc.gov/OralHealth/infection_control/forms.htm
 - 536 • Current list of available safer dental devices: <http://www.osap.org>
 - 537 • State legislation on needlestick safety: <http://www.cdc.gov/niosh>
- 538
539

540 *Postexposure Management*

541 Postexposure management is an integral component of a complete program to prevent infection
542 after an occupational exposure to blood. During dental procedures it is predictable that saliva
543 will be contaminated with blood (CDC 1988, CDC 1989). If blood is not visible, it is likely that
544 it is still present in very small quantities and the risk for transmission of HBV, HCV, and HIV is
545 extremely small (CDC 2001). Despite this small risk, a qualified health-care professional should
546 evaluate any occupational exposure incident to saliva in dental settings, regardless of whether
547 any blood is visible (OSHA 1991).

548
549 Dental practices should establish a written, comprehensive program that includes hepatitis B
550 vaccination and postexposure management protocols that: 1) describe the types of blood contact
551 that may place DHCP at risk for infection; 2) describe procedures for promptly reporting and
552 evaluating such exposures; and 3) identify a health-care professional who is qualified to provide
553 counseling and perform all medical evaluations and procedures in accordance with the most
554 current recommendations of the USPHS, including PEP when indicated. DHCP (including
555 students) who might reasonably be considered at risk of occupational exposure to blood or other
556 potentially infectious fluids should be taught strategies to prevent blood contacts and the
557 principles of postexposure management, including options for PEP, as part of their job
558 orientation and ongoing training. Educational programs for dental staff and students should
559 emphasize reporting all exposures as soon as possible, because certain interventions must be
560 initiated promptly to be effective. Policies must be consistent with the practices and procedures
561 for worker protection required by OSHA and with current USPHS recommendations for
562 managing occupational exposures to blood (CDC 2001, OSHA 1991, OSHA 2001 CPL).

563
564 After an occupational blood exposure, first aid should be administered as necessary. Puncture
565 wounds and other injuries to the skin should be washed with soap and water; mucous membranes
566 should be flushed with water (CDC 2001). Exposed personnel should immediately report the
567 exposure to the infection control coordinator, who should initiate referral to the qualified health-
568 care professional and complete necessary reports. Because many factors contribute to the risk of
569 infection after an occupational exposure to blood, the following information must be included in
570 the exposure report, recorded in the exposed person's confidential medical record, and provided
571 to the qualified health-care professional:
572

- 573 • Date and time of exposure.
- 574 • Details of the procedure being performed, including where and how the exposure
- 575 occurred and whether the exposure involved a sharp device, the type and brand of device,
- 576 and how and when during its handling the exposure occurred.
- 577 • Details of the exposure, including its severity and the type and amount of fluid or
- 578 material. For a percutaneous injury, severity might be measured by the depth of the
- 579 wound, gauge of the needle, and whether fluid was injected; for a skin or mucous
- 580 membrane exposure, by the estimated volume of material, duration of contact, and the
- 581 condition of the skin (e.g., chapped, abraded, or intact).
- 582 • Details about the exposure source: whether the source material was known to contain
- 583 HIV or other bloodborne pathogens, and, if the source was infected with HIV, the stage
- 584 of disease, history of antiretroviral therapy, and viral load, if known.
- 585 • Details about the exposed person (e.g., hepatitis B vaccination and vaccine-response
- 586 status).
- 587 • Details about counseling, postexposure management, and follow-up.
- 588

589 Each occupational exposure should be evaluated individually for its potential to transmit HBV,
590 HCV, and HIV. This evaluation should be based on:

- 591 • The type and amount of body substance involved.
- 592 • The type of exposure (e.g., percutaneous injury, mucous membrane or non-intact skin
- 593 exposure, bites resulting in blood exposure to either person involved).
- 594 • The infection status of the source.
- 595 • The susceptibility of the exposed person (CDC 2001).

596 All of these factors should be considered in assessing the risk of infection and the need for
597 further follow-up (e.g., PEP).

598
599

600 **Preventing Transmission of *Mycobacterium tuberculosis***

601 Patients infected with *M. tuberculosis* (TB) occasionally present at outpatient dental settings for
602 urgent dental treatment. Understanding the pathogenesis of the development of TB will help the
603 DHCP to make decisions on managing such patients.

604

605 *M. tuberculosis* is a bacterium carried in airborne particles, called droplet nuclei, that can be
606 aerosolized from persons with pulmonary or laryngeal TB. These small particles (1-5 μ) can stay
607 suspended in the air for several hours (Wells 1955). Infection could occur if a susceptible person
608 inhales the droplet nuclei containing *M. tuberculosis*, which then travel to the alveoli of the
609 lungs. Usually within 2-12 weeks after initial infection with *M. tuberculosis*, the immune
610 response prevents further spread of the TB bacteria, although the bacteria remain alive in the
611 lungs for many years, a condition termed latent TB infection (LTBI). Persons with LTBI usually
612 demonstrate a reactive tuberculin skin test (TST), have no symptoms of active disease, and are
613 not infectious, but they may develop active disease later in life if they do not receive treatment
614 for their latent infection.

615

616 Approximately 5% of persons who have been recently infected and have not been treated for
617 latent TB infection will progress from infection to active disease in the first year or two after
618 infection; another 5% will develop active disease much later in life. Thus, about 90% of U.S.

619 persons with latent TB infection do not progress to active TB disease. Some
620 immunocompromised medical conditions such as HIV, increase the risk that TB infection will
621 progress to active disease at a faster rate (CDC 1998). A person with active TB disease has
622 clinical symptoms, is contagious, and can transmit TB to others. Symptoms of active TB disease
623 include a productive cough, night sweats, fatigue, malaise, fever, and unexplained weight loss.
624

625 Both latent TB infection and active TB disease are described as TB, but only the person with
626 active disease is contagious and presents a risk of transmission in the dental health-care setting.
627

628 *Risk of Transmission*

629 Transmission of TB is via airborne exposure and standard precautions are not sufficient to
630 prevent transmission. Recommendations for additional precautions to prevent transmission of *M.*
631 *tuberculosis* and other organisms that may be spread by airborne, droplet or contact routes are
632 covered in detail elsewhere (Bolyard 1996, Garner 1996).
633

634 Overall, the risk borne by DHCP for exposure to a patient with active TB disease is probably
635 quite low (CDC 1994, Cleveland 1995). There has been only one report of TB transmission in a
636 dental office (Smith 1982), and TST conversions among DHCP also appear low (CDC 1994
637 tuberculin, Mikitka 1995). In some instances, the community population served by the dental
638 facility or the DHCP, may be at relatively high risk for TB.
639

640 TB transmission is controlled through a hierarchy of measures, which include administrative
641 controls, environmental controls, and personal respiratory protection. The main administrative
642 goals of a TB infection control program are early detection of a person with active TB disease
643 and prompt isolation from susceptible persons to reduce the risk of transmission. Because there
644 is the potential for transmission of *M. tuberculosis* in dental settings, dental offices should
645 develop a TB control program appropriate for their level of risk (CDC 1994, Cleveland 1995),
646 including:
647

- 648 • A community risk assessment should be done periodically, and TB infection-control policies
649 for each dental setting should be based on the risk assessment. The policies should include
650 provisions for detection and referral of patients who may have undiagnosed active TB;
651 management of patients with active TB, relative to provision of urgent dental care; and
652 employer-sponsored DHCP education, counseling, and tuberculin skin test screening.
653
- 654 • While taking patients' initial medical histories and at periodic updates, dental DHCPs should
655 routinely ask all patients whether they have a history of TB disease and symptoms suggestive
656 of TB.
657
- 658 • Patients with a medical history or symptoms suggestive of undiagnosed active TB should be
659 referred promptly for medical evaluation to determine possible infectiousness. Such patients
660 should not remain in the dental-care facility any longer than required to evaluate the dental
661 condition and arrange a referral. While in the dental health-care facility, the patient should
662 wait and be evaluated in a room with a closed door, wear a surgical mask when not being
663 evaluated, or should be instructed to cover their mouth and nose when coughing or sneezing.
664

- 665 • Elective dental treatment should be deferred until a physician confirms that the patient does
666 not have infectious TB. If the patient is diagnosed as having active TB, elective dental
667 treatment should be deferred until the patient is no longer infectious.
668
- 669 • If urgent dental care must be provided for a patient who has, or is suspected of having active
670 TB disease, the care should be provided in a previously identified facility that provides
671 engineering controls such as TB isolation rooms and air filtration (e.g., hospital). Standard
672 face masks do not protect against TB transmission. Respiratory protection (e.g., a fit-tested,
673 disposable N-95 respirator) should be used by the DHCP.
674
- 675 • Any DHCP who has a persistent cough (i.e., a cough lasting >3 weeks), especially in the
676 presence of other signs or symptoms compatible with active TB (e.g., weight loss, night
677 sweats, fatigue, bloody sputum, anorexia, or fever), should be evaluated promptly for TB.
678 The DHCP should not return to the workplace until a diagnosis of TB has been excluded or
679 the DHCP is on therapy and a determination has been made that the DHCP is noninfectious.
680

681

682 **Transmissible Spongiform Encephalopathies (Prion Diseases)**

683 Transmissible spongiform encephalopathies (TSEs) are a group of rapidly progressive,
684 invariably fatal, degenerative neurological disorders that affect both humans and animals and are
685 thought to be caused by infection with prions. Prions are isoforms of a normal protein, and
686 capable of self-replication, but they lack nucleic acid.
687

688 TSEs occur naturally in some animal species (e.g., sheep, goats, deer, elk), but they may also
689 result from exposure of susceptible species (e.g., mink, cattle, felines) to infected animal tissues.
690 Bovine spongiform encephalopathy (BSE), is a progressive neurological disorder of cattle
691 commonly known as “mad cow disease.” The major means of BSE transmission appears to be
692 the consumption of prion-infected animal feed.
693

694 In humans, TSEs include Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker
695 syndrome, fatal familial insomnia, kuru, and variant CJD (vCJD). Prion diseases have a long
696 incubation period and are usually fatal within 1 year after onset. CJD occurs in sporadic, familial,
697 and acquired (iatrogenic) forms and has an annual incidence in many countries of the world,
698 including the United States, of approximately 1 case/million (CDC 1996, Johnson 1998). In
699 about 85% of affected patients, CJD occurs as a sporadic disease with no recognizable pattern of
700 transmission. A smaller proportion of patients (5-15%) develop familial CJD because of
701 inherited mutations of the prion protein gene. According to published reports, iatrogenic
702 transmission of CJD has occurred in humans under three circumstances: after use of
703 contaminated EEG depth electrodes (Bernoulli 1977); after use of extracted pituitary hormones
704 (Brown 1985, CDC 1985); and after implant of contaminated corneal (Duffy 1974) and dura
705 mater grafts (CDC 1997, Thadani 1988) from humans. The equipment-related cases occurred
706 before the routine implementation of sterilization procedures currently used in health-care
707 facilities.
708

709 Both Gerstmann-Straussler-Scheinker syndrome and fatal familial insomnia are inherited. Kuru
710 is not inherited and has been described only in the Fore population of New Guinea, but it has

711 almost disappeared since the cessation of ritualistic cannibalism that had facilitated disease
712 transmission there (Gajdusek 1977, Gajdusek 1957, King 1975, Liberski 1997).

713
714 A new variant of CJD, vCJD, was reported first in the United Kingdom in 1996 (Will 1996) and
715 subsequently in other European countries (World Health Organization 2001). To date, only one
716 case of vCJD has been reported in the United States, in an immigrant from the United Kingdom
717 (CDC Florida 2002, CDC MMWR Probably vCJD 2002). Although there is strong evidence that
718 the agent responsible for vCJD is the same one responsible for the BSE outbreaks in cattle, the
719 foods that may be associated with the transmission of this agent from cattle to humans are
720 unknown. Compared to patients with CJD, patients with vCJD are younger (28 years vs. 68 years
721 median age at death), and have a longer duration of illness (13 months vs. 4.5 months); in
722 addition, they characteristically present with sensory and psychiatric symptoms that are
723 uncommon with CJD. Another difference is that lymphoreticular tissues (e.g., tonsil) are
724 consistently infected with prions in vCJD patients (Hill 1999).

725
726 CJD is a transmissible disease but it cannot be transmitted through the air, or through casual
727 contact. As for iatrogenic CJD, all known cases have resulted from exposure to infected central
728 nervous tissue (e.g., brain and dura mater), pituitary, or eye tissue. Studies in experimental
729 animals have determined that other tissues are considered to have low or no detectable infectivity
730 (Brown 1994, Brown 1996, Rutala 2002 draft). Limited experimental studies have demonstrated
731 that scrapie (a TSE in sheep) can be transmitted to healthy hamsters and mice by exposing oral
732 tissues to infectious homogenate (Carp 1982, Ingrosso 1999). These animal models and
733 experimental designs may not be directly applicable to human transmission and clinical
734 dentistry, but they suggest a theoretical risk of transmitting prion diseases through oral tissues.

735
736 Epidemiological investigation has not revealed any evidence that dental procedures increase the
737 risk of iatrogenic transmission of TSEs among humans. There are no published reports of CJD
738 transmission associated with dental procedures (e.g., root canals, extractions), of DHCP
739 occupationally infected with CJD, or convincing evidence of prions detected in human blood,
740 saliva, or oral tissues (Kondo 1982, Van Duijn 1998, Collins 1999). In 2000, prions were not
741 detected in the dental pulps of eight patients with neuropathologically confirmed sporadic CJD in
742 an analysis that used electrophoresis and a Western blot technique (Blanquet-Grossard 2000).

743
744 Prions exhibit unusual resistance to conventional chemical and physical decontamination
745 procedures. Considering this resistance and the invariably fatal outcome of CJD, the procedures
746 for disinfecting and sterilizing instruments potentially contaminated with the CJD prion have
747 been both conservative and controversial for many years. Yet, based on the long history and low
748 prevalence of sporadic CJD in the U.S., available scientific data, and current epidemiology, the
749 risk, if any, of sporadic CJD transmission during dental and oral surgical procedures is very low.

750
751 Until additional scientific information is available regarding the transmissibility of CJD or vCJD,
752 special precautions may be indicated when treating the known CJD or vCJD patient; a list of
753 such precautions is provided for consideration without recommendation (Favero Asia 1998,
754 Favero 2001, Rutala 1996, World Health Organization 1999).

- 755
756
- Use single-use disposable items and equipment whenever possible.

- 757 • Consider items difficult to clean (e.g., endodontic files, broaches, carbide and diamond
758 burs) as single-use disposable and discard after one use.
- 759 • To minimize drying of tissues and body fluids on a device, keep the instrument moist
760 until cleaned and decontaminated.
- 761 • Use personal protective equipment when cleaning and disinfecting environmental
762 surfaces.
- 763 • Those items constructed so that cleaning procedures result in effective tissue removal can
764 be cleaned by immersing in 1N NaOH for 1 hour, rinsing in water, and sterilizing by
765 autoclaving for 1 hour at 134°C in a prevacuum sterilizer or at 121°C in a gravity
766 displacement sterilizer.
- 767 • Do not use flash sterilization for reprocessing instruments or devices.

768
769 The CDC maintains an active surveillance program on CJD; as additional scientific information
770 becomes available, it can be accessed at <http://www.cdc.gov/ncidod/diseases/cjd/cjd.htm>.

771 772 773 **Personal Protective Equipment**

774 Personal protective equipment (PPE) is designed to protect the skin and the mucous membranes
775 of the eyes, nose, and mouth of DHCP from exposure to infectious or potentially infectious
776 materials. The primary barrier equipment used in oral health care settings includes gloves,
777 masks, protective eyewear, face shields, and protective apparel (e.g., gowns, jackets). All
778 personal protective equipment must be removed before DHCP leave patient-care areas (OSHA
779 1991). Reusable PPE (e.g, protective eyewear, face shield) should be cleaned and disinfected
780 between patients (CDC 1993, OSHA 1991). The wearing of gloves, masks, protective eyewear,
781 and protective apparel in specified circumstances to reduce the risk of exposures to bloodborne
782 pathogens is mandated by the OSHA bloodborne pathogens final rule (OSHA 1991). General
783 work clothes (e.g., uniforms, pants, shirts) not intended to protect against a hazard are not
784 considered personal protective equipment.

785 786 *Masks, Protective Eyewear, Face Shields*

787 A surgical mask that covers both the nose and the mouth, and protective eyewear with solid side
788 shields should be worn by DHCP during procedures and patient care activities that are likely to
789 generate splashes or sprays of blood or body fluids. A surgical mask protects DHCP against
790 exposure to large-particle droplet spatter (larger than 5µm) that may contain bloodborne
791 pathogens or other infectious microorganisms. Droplets are transmitted by close contact and
792 generally travel short distances (up to 3 feet). If a surgical mask becomes wet, it should be
793 changed between patients or during patient treatment (CDC 1993, OSHA 1991). Surgical masks
794 are not designed to provide adequate protection of DHCP against exposure to airborne
795 microorganisms or droplet nuclei less than 5µm (e.g., *M. tuberculosis*). In these situations,
796 personal respiratory protection using particulate respirators (e.g., N-95 respirator) would be
797 necessary for adequate protection. Protective eyewear and a surgical mask are adequate for
798 procedures where small amounts of spatter or splashes are likely. Adding a face shield may be
799 useful when more protection is desired.

800
801
802

803 *Protective Apparel*
804 Various types of protective apparel should be worn to prevent contamination of clothing
805 and to protect the skin of personnel from blood and body fluid exposures (OSHA 1991,
806 Garner 1996, Mangram 1999, CDC 1987, CDC 1988). The OSHA bloodborne pathogens
807 final rule mandates that the sleeves should be long when the gown is worn as personal
808 protective equipment (e.g., when spatter and spray of blood, saliva, or other potentially
809 infectious material is anticipated) (OSHA 1991). Protective apparel should be changed if
810 visibly soiled (Mangram 1999) and should be changed immediately or as soon as feasible
811 if penetrated by blood or other potentially infectious fluids (OSHA 1991). All protective
812 apparel shall be removed prior to leaving the work area (OSHA 1991).

813
814 *Gloves and Gloving*
815 Medical gloves—both patient examination and surgical gloves—are manufactured as single-use
816 disposable items that should be used for only one patient, then discarded. Gloves must be
817 changed between patients or when torn. DHCP wear gloves to provide a protective barrier and to
818 prevent contamination of their hands when touching mucous membranes, blood, saliva, or other
819 potentially infectious materials. In addition, gloves reduce the likelihood that microorganisms
820 present on the hands of DHCP will be transmitted to patients during invasive or other patient
821 care procedures (CDC 1986, CDC 1987, CDC 1988, CDC 1993).

822
823 Wearing gloves does not replace the need for handwashing. Hand hygiene should be performed
824 immediately prior to donning gloves. Gloves may have small, inapparent defects or may be torn
825 during use, and hands can become contaminated during their removal (DeGroot-Kosolcharoen
826 1989, Korniewicz 1989, Kotilainen 1989, Olsen 1993, Larson 1995, Murray 2001, Burke 1996,
827 Burke 1990, Nikawa 1994, Nikawa 1996, Otis 1989). These circumstances increase the risk of
828 operative wound contamination and exposure of the DHCP's hands to microorganisms from
829 patients. In addition, bacteria can multiply rapidly in the moist environments underneath gloves,
830 and thus, the hands should be dried thoroughly before donning gloves and washed immediately
831 after glove removal.

832
833 *Types of Gloves*
834 Because gloves are task specific, their selection and fit must be based on the type of procedure to
835 be performed (e.g., surgical, patient examination) (Table 2). Sterile surgical gloves must meet
836 standards for sterility assurance established by the FDA and are more likely than patient
837 examination gloves to harbor pathogens that could contaminate an operative wound.

838 **Table 2. Types of Gloves**

Glove Type	Indications	Comments	Commercially Available Glove Materials*	
			Materials	Comments††
Patient examination gloves†	Patient care, examinations, and other nonsurgical procedures involving contact with mucous membranes	Medical device regulated by the FDA should be labeled as a medical or dental glove Nonsterile and sterile single-use disposable. Use for one patient and discard appropriately	-Natural-rubber latex (NRL) -Nitrile -Nitrile & chloroprene (Neoprene) blends -Nitrile & NRL blends -Butadiene methyl methacrylate -Polyvinyl chloride (PVC, vinyl) -Polyurethane -Styrene-based copolymer	1, 2 2, 3 2, 3 1, 2, 3 2, 3 4 4 4, 5
Surgical gloves†	Surgical procedures	Medical device regulated by the FDA should be labeled as a medical or dental glove Sterile and single-use disposable. Use for one patient and discard appropriately Orthopedic surgical gloves may be thicker and more resistant to tear than other surgical gloves.	-NRL -Nitrile -Chloroprene (Neoprene) -NRL & nitrile or chloroprene blends -Synthetic polyisoprene -Styrene-based copolymer -Polyurethane	1, 2 2, 3 2, 3 2, 3 2 4, 5 4
Non-medical gloves	Housekeeping procedures (e.g., cleaning and disinfection) Handling contaminated sharps or chemicals Do not use during patient care	Not a medical device regulated by the FDA Commonly referred to as utility, industrial, or general purpose gloves and should be puncture- and chemical resistant. Latex gloves do not provide adequate chemical protection Sanitize after use	-NRL & nitrile or chloroprene blends -Chloroprene (Neoprene) -Nitrile -Butyl rubber -Fluoroelastomer -Polyethylene and ethylene vinyl alcohol copolymer	2, 3 2, 3 2, 3 2, 3 3, 4, 6 3, 4, 6

839 * Physical properties can vary by material, manufacturer, and protein and chemical composition.
840 † Medical or dental patient examination gloves and surgical gloves are medical devices regulated by the FDA. Only FDA cleared medical or dental patient
841 examination gloves and surgical gloves can be used for patient care.
842 †† Material: 1—contains allergenic NRL proteins; 2—vulcanized rubber, contains allergenic rubber processing chemicals; 3—likely to have enhanced chemical
843 and/or puncture resistance; 4)—nonvulcanized and does not contain rubber processing chemicals; 5)—inappropriate for use with methacrylates; and 6)—resistant to
844 most methacrylates.

845 *Glove Integrity*

846 Limited studies of the penetrability of various glove materials under conditions of use have been
847 conducted in the dental environment. Consistent with observations in clinical medicine, leakage
848 rates have varied by glove material (e.g., latex, vinyl, nitrile), duration of use, and type of
849 procedure performed (Morgan 1989, Otis 1989, Burke 1990, Albin 1992, Merchant 1992,
850 Nikawa 1996). The frequency of perforations in surgical gloves used during outpatient oral
851 surgical procedures has ranged from 6% to 16% (Avery 1998, Burke 1996, Schwimmer 1994,
852 Patton 1995).

853
854 The FDA regulates the medical glove industry, which includes gloves marketed as sterile
855 surgical and sterile or nonsterile patient examination gloves. General-purpose utility gloves are
856 also used in dental health-care settings but are not regulated by FDA because they are not
857 promoted for medical use. More rigorous standards are applied to surgical than to examination
858 gloves. The FDA has identified failure rates for glove manufacturers (Food and Drug
859 Administration 1990), but gloves eventually fail with exposure to mechanical (e.g., sharps,
860 fingernails, jewelry) and chemical (e.g., dimethacrylates) hazards and over time. These
861 variables can be controlled, ultimately optimizing glove performance, by: 1) maintaining short
862 fingernails; 2) minimizing or eliminating hand jewelry; and 3) properly using engineering and
863 work practice controls to avoid injuries with sharps.

864
865 Studies have shown that medical and DHCP are frequently unaware of small tears in gloves that
866 occur during use and thus for enhanced protection it may be good to change gloves during a long
867 procedure (Merchant 1992, Albin 1992, Otis 1989, Gerberding 1990). These four studies found
868 that gloves developed defects over 30 minutes to 3 hours depending upon glove and procedure
869 type. There was no consensus on the optimal time for changing gloves during procedures.

870
871 Examination and surgical gloves commonly contact many types of chemicals and materials (e.g.,
872 disinfectants and antiseptics, composite resins, bonding agents) during dental procedures that
873 may compromise the integrity of latex as well as vinyl, nitrile, and other synthetic glove
874 materials (Klein 1990, Mellstrom 1992, Jordon 1996, Cappuccio 1997, Monticello 1999,
875 Baumann 2000, Ready 1989, Richards 1993, Andersson 1999). In addition, latex gloves can
876 compromise the setting of vinyl polysiloxane impression materials (Reitz 1988, Kahn 1989,
877 Matis 1997), although it appears that the setting is not adversely affected by synthetic vinyl
878 gloves (Reitz 1988, Kahn 1989). Given the diverse selection of dental materials on the market,
879 dental facilities should consult with the glove manufacturer about the chemical compatibility of
880 glove material.

881
882 If the integrity of a glove is compromised (e.g., punctured), it should be changed as promptly as
883 safety permits (OSHA 1991, Wright 1991, Dodds 1988). Washing latex gloves with plain soap,
884 chlorhexidine, or alcohol can lead to the formation of glove micropunctures (Adams 1992,
885 Martin 1988, DeGroot-Kosolcharoen 1989) and hand contamination (Doebbeling 1988). Because
886 this condition, known as "wicking," may allow penetration of liquids through undetected holes in
887 the gloves, washing gloves is not recommended. After a hand rub with alcohol, the hands must
888 be thoroughly dried before gloving, because hands still wet with an alcohol-based hand hygiene
889 product may increase the risk of glove perforation (Pitten 2000).

890

891 **Contact Dermatitis and Latex Hypersensitivity**

892 Occupationally related contact dermatitis can develop from frequent and repeated use of hand
893 hygiene products, exposure to chemicals, and glove use. Contact dermatitis is classified as either
894 irritant contact dermatitis or allergic contact dermatitis. Irritant contact dermatitis, is very
895 common and develops as dry, itchy, irritated areas on the skin around the area of contact. Irritant
896 contact dermatitis is not due to an allergy. By comparison, allergic contact dermatitis (type IV
897 hypersensitivity) may result from exposure to accelerators and other chemicals used in the
898 manufacture of rubber gloves (e.g., natural rubber latex, nitrile, neoprene), and other chemicals
899 found in the dental office (e.g., methacrylates, glutaraldehyde). Allergic contact dermatitis often
900 manifests as a rash beginning several hours after contact and like irritant dermatitis, is usually
901 confined to the area of contact.

902
903 Latex allergy (type I hypersensitivity to latex proteins) can be a more serious whole-body
904 allergic reaction; here, reactions usually begin within minutes of exposure but can occur hours
905 later and may produce varied symptoms. More common reactions include skin, nose, and eye
906 symptoms such as runny nose, sneezing, itchy eyes, scratchy throat, hives, and itchy burning skin
907 sensations. More severe symptoms include asthma (marked by difficult breathing, coughing
908 spells, and wheezing), cardiovascular and gastrointestinal symptoms, and in rare cases,
909 anaphylaxis and death (CDC/NIOSH 1997, Dillard 2002).

910
911 Natural rubber latex proteins responsible for latex allergy have been shown to attach to glove
912 powder. When powdered latex gloves are worn, more latex protein reaches the skin. In addition,
913 when powdered latex gloves are donned or removed, latex protein/powder particles become
914 aerosolized, where they can be inhaled and contact mucous membranes (Heilman 1996). As a
915 result, allergic DHCP can experience cutaneous, respiratory, and conjunctival symptoms related
916 to latex protein exposure. Other DHCP may become sensitized to latex protein with repeated
917 exposure (Baur 1990, Turjanmaa 1990, Baur 1998, Trape 2000, Allmers 1998). In contrast, work
918 areas where only powder-free low-allergen latex gloves are used, show low or undetectable
919 amounts of the latex allergy-causing proteins (Tarlo 1994, Swanson 1994, Hermesch 1999) and
920 healthcare workers have lower levels of symptoms related to natural rubber latex allergy.
921 Because of the increasing role of glove powder in exposure to latex protein, the National Institute
922 for Occupational Safety and Health (NIOSH) recommends that if latex gloves are chosen, the
923 health-care facility provide personnel with reduced-protein, powder-free gloves (NIOSH 1997).
924 Non-latex, powder-free, and low-protein gloves are available to help address these situations
925 (ADA 1999, Miller Therapeutics 2000). While rare, potentially life-threatening anaphylactic
926 reactions to latex can occur; dental facilities should be appropriately equipped and have
927 procedures in place to handle such emergencies.

928
929 DHCP and dental patients with latex allergy should not have direct contact with latex containing
930 materials and should be in a “latex safe” environment (NIOSH 1997). Individuals may also be
931 allergic to the chemicals used in the manufacturing of natural rubber latex and synthetic rubber
932 gloves as well as to metals, plastics, or other materials used in dental care. A thorough health
933 history and appropriate avoidance of contact with potential allergens will minimize the
934 possibility of adverse reactions. Among the considerations in providing safe treatment for
935 patients with possible or documented latex allergy are the following:

936

- 937 • Screen all patients for latex allergy (e.g., health history, medical consultation when latex
938 allergy is suspected)
- 939 • Be aware of some common predisposing conditions (e.g., previous history of allergies, a
940 history of spina bifida, urogenital anomalies, or allergies to avocados, kiwis, nuts, or
941 bananas)
- 942 • Be familiar with the different types of hypersensitivity—immediate and delayed—and the
943 risks they pose for patient and staff
- 944 • Consider sources of latex other than gloves. Dental patients with histories of latex allergy
945 may be at risk from a variety of dental products, such as prophylaxis cups, rubber dams,
946 orthodontic elastics, anesthetic carpule stoppers, and medication vials
- 947 • Ensure a latex-safe environment, one in which no DHCP wears latex gloves and no
948 patient has contact with other latex devices, materials, or products
- 949 • Remove all latex-containing products from the patient’s vicinity. Adequately
950 cover/isolate any latex-containing devices that cannot be removed from the treatment
951 environment
- 952 • Be aware that latent allergens in the ambient air can cause respiratory or anaphylactic
953 symptoms in people with latex hypersensitivity. It may be advisable to schedule patients
954 with latex allergy for the first appointment of the day to minimize their inadvertent
955 exposure to airborne latex particles. Frequently clean all working areas contaminated
956 with latex powder/dust
- 957 • Frequently change ventilation filters and vacuum bags used in latex-contaminated areas
- 958 • Have latex-free kits (e.g., dental treatment and emergency) available at all times
- 959 • Be aware that allergic reactions can be provoked from indirect contact as well as direct
960 contact (e.g., being touched by someone who has worn latex gloves). Hand hygiene,
961 therefore, is essential
- 962 • Communicate with other personnel about latex allergy (e.g., by verbal instructions,
963 written protocols, posted signage) to prevent them from bringing latex-containing
964 materials into the treatment area
- 965 • If latex-related complications occur during or after a procedure, manage the reaction and
966 seek emergency assistance as indicated. Follow current medical emergency response
967 recommendations for management of anaphylaxis (NIOSH 1997).

969
970 **Hand Hygiene**

971 Hand hygiene (e.g., handwashing, hand antisepsis, or surgical hand antisepsis) significantly
972 reduces potential pathogens on the hands and is considered the single most important measure to
973 reduce the risk of transmitting organisms to patients and HCP (Steere 1975, Garner Supercedes
974 1986, Larson 1995, CDC Hand 2002). Hospital-based studies have shown that noncompliance
975 with hand hygiene practices is associated with health-care-associated infections and the spread of
976 multiresistant organisms and has been a major contributor to outbreaks (CDC Hand 2002).
977 Studies also have shown that the prevalence of health-care-associated infections decreases as
978 adherence of HCP to recommended hand hygiene measures improves (Casewell 1977, Larson
979 2000, Pittet 2000).

980
981 The microbial flora of the skin, first described in 1938, consist of resident and transient
982 microorganisms (Price 1938). Transient flora, which colonize the superficial layers of the skin,

983 are more amenable to removal by routine handwashing. They are often acquired by HCP during
984 direct contact with patients or contaminated environmental surfaces, and they are the organisms
985 most frequently associated with health-care-associated infections. Resident flora, attached to
986 deeper layers of the skin, are more resistant to removal and less likely to be associated with such
987 infections.

988
989 The preferred method for hand hygiene depends on the type of procedure, the anticipated degree
990 of contamination, and the desired persistence of antimicrobial action on the skin (Table 3). Thus,
991 for such routine dental care as examinations and non surgical procedures, either plain soap and
992 water or an antiseptic agent (e.g., antimicrobial soap or alcohol-based hand rub) is adequate.

993
994 The purpose of surgical hand antisepsis is to eliminate transient flora and reduce resident flora
995 for the duration of a procedure, should gloves become punctured or torn, so as to prevent the
996 introduction of organisms in the operative wound. Skin bacteria can rapidly multiply under
997 surgical gloves if hands are washed with soap that is not antimicrobial (Price 1938, Dewar 1973),
998 and thus, an antiseptic with antimicrobial activity (e.g., antimicrobial soap) should be used
999 before surgical procedures (Lowbury 1960, Rotter 1999, Widmer 2000). Agents used for surgical
1000 hand antisepsis should significantly reduce microorganisms on intact skin, contain a non-
1001 irritating antimicrobial preparation, have a broad spectrum of activity, be fast acting, and have a
1002 persistent effect (Garner Supercedes 1986, Larson 1990, Faoagali 1995, AORN 2002).
1003 Persistence (i.e., extended antimicrobial activity that prevents or inhibits the proliferation or
1004 survival of microorganisms after the product is applied) is important because microorganisms
1005 can colonize on hands in the moist environments underneath gloves (Larson 1995). Alcohol
1006 handrubs are rapidly germicidal when applied to the skin but must include the addition of
1007 chlorhexidine, quaternary ammonium compounds, octenidine, or triclosan to achieve persistent
1008 activity (Rotter 1999). In addition to the choice of antiseptic agent, factors that may influence the
1009 effectiveness of the surgical scrub include technique and duration as well as condition of the
1010 hands and the techniques used for drying and gloving.

1011

1012 **Table 3. Hand Hygiene**

Methods	Agent	Purpose	Area	Duration (minimum)	Indications (OSHA 1991, CDC Universal Precautions 1988, CDC HIV 1987, Garner SSI and Hand 1986, Larson 1995, Steere 1995, Larson 2000, Pittet 2000, CDC Hand 2002, Garner 1996, Mangram 1999, Doebbeling 1988)
Routine handwash	Water and non-antimicrobial detergent (e.g., plain soap*)	Remove soil and transient microorganisms	Fingertips to the wrist	15 seconds†	<ul style="list-style-type: none"> before and after treating each patient (e.g., before glove placement and after glove removal)
Routine hand antiseptics Antiseptic handwash or Antiseptic hand rub	Water and antimicrobial agent/detergent (e.g., chlorhexidine, iodine and iodophors, chloroxylenol [PCMX], triclosan) Alcohol-based hand rub [§]	Remove or destroy transient microorganisms and reduce resident flora	Fingertips to the wrist at a minimum	15 seconds† Rub hands until the agent is dry [§]	<ul style="list-style-type: none"> after barehanded touching of inanimate objects likely to be contaminated by blood or saliva before leaving the dental operator when visibly soiled[§] before regloving after removing gloves that are torn, cut, or punctured
Surgical hand antiseptics	Water and antimicrobial agent/detergent (e.g., chlorhexidine, iodine and iodophors, chloroxylenol [PCMX], triclosan) Water and non-antimicrobial detergent (e.g., plain soap*) followed by an alcohol-based hand rub with persistent activity	Remove or destroy transient microorganisms and reduce resident flora (persistent effect)	Hands and forearms up to the elbows¶	2-6 minutes Follow manufacturer instructions for alcohol-based hand rub ^{§ ¶ ¶}	<ul style="list-style-type: none"> before donning sterile, surgical gloves for surgical procedures

1013 * Pathogenic organisms have been found on or around bar soap during and after use (Kabara 1984). Use of liquid soap with hands-free dispensing controls is
1014 preferable.

1015 † Washing times of 10-15 seconds have been reported as effective in removing most transient flora from the skin. For most procedures, a vigorous, brief (at least
1016 15 seconds) rubbing together of all surfaces of premoistened lathered hands and fingers followed by rinsing under a stream of cool or tepid water is
1017 recommended (Steere 1975, Ojajärvi 1981, Garner 1985, Larson 1986, Ayliffe 1992, CDC Hand 2002). Hands should always be dried thoroughly before donning
1018 gloves.

1019 § 60-95% ethanol or isopropanol. Alcohol-based hand rubs should not be used in the presence of visible soil or organic material. If using an alcohol-based hand
1020 rub, apply adequate amount to palm of one hand and rub hands together, covering all surfaces of the hands and fingers, until hands are dry. Follow
1021 manufacturer's recommendations regarding the volume of product to use. If hands feel dry after rubbing hands together for 10–15 seconds, an insufficient
1022 volume of product likely was applied. The drying effect of alcohol can be reduced or eliminated by adding 1-3% glycerol or other skin-conditioning agents (CDC
1023 Hand 2002).

1024 ¶ Removal of all jewelry, washing as described in the second footnote (†) holding the hands above the elbows during final rinsing, and drying the hands with
1025 sterile towels (Mangram 1999, Larson 1995, CDC Hand 2002, AORN 2002).

1026 ¶¶ After application of the alcohol-based product as recommended, allow hands and forearms to dry thoroughly and immediately don sterile gloves (Hobson
1027 1998, Mulberry 2001).
1028

1029 *Selection of Antiseptic Agents*
1030 Selecting the most appropriate antiseptic agent for hand hygiene requires consideration of several
1031 factors. Essential performance characteristics of a product, such as the spectrum and persistence
1032 of activity, and whether or not the agent is fast acting, should be determined before selecting a
1033 product. Delivery system, cost per use, reliable vendor support and supply are also
1034 considerations. Because personnel acceptance is a major factor in compliance with recommended
1035 hand hygiene protocols (Larson 1982, Zimakoff 1992, CDC Hand 2002, Larson 1995), it is
1036 important to consider personnel needs including possible chemical allergies, skin integrity after
1037 repeated use, compatibility with any lotions used, and offensive agent ingredients (e.g., scent).

1038
1039 *Storage and Dispensing of Hand Care Products*
1040 Handwashing products, including plain (not antimicrobial) soap and antiseptic products, can
1041 become contaminated or support the growth of microorganisms (Larson 1995). Liquid products
1042 should be stored in closed containers and dispensed from either disposable containers or
1043 containers that are washed and dried thoroughly before refilling. Soap should not be added to a
1044 partially empty dispenser, as this practice of “topping off” may lead to bacterial contamination of
1045 the soap (Grohskopf 2001, Archibald 1997) and negate the beneficial effect of hand cleaning and
1046 disinfection.

1047
1048 *Lotions*
1049 The primary defense against infection and transmission of pathogens is healthy, unbroken skin.
1050 Frequent handwashing with soaps and antiseptic agents can cause chronic irritant contact
1051 dermatitis among DHCP. Damage to the skin changes skin flora, resulting in more frequent
1052 colonization by staphylococci and gram-negative bacteria (Larson 1998 AJIC, Ojajärvi 1977).
1053 The potential of detergents to cause skin irritation varies considerably, but it can be reduced by
1054 adding emollients. Lotions are often recommended to ease the dryness resulting from frequent
1055 handwashing and more recently to prevent dermatitis from glove use (Berndt 2000, McCormick
1056 2000). Petroleum-based lotion formulations, however, can weaken latex gloves and increase
1057 permeability. For that reason, use of lotions that contain petroleum or other oil emollients should
1058 not accompany gloving (MMWR 1993, Garner Supercedes 1986, OSHA 2001 CPL, Larson
1059 1993, Larson 1995) though could be used at the end of the work day. At the time of product
1060 selection, dental facilities should obtain information from the manufacturer regarding interaction
1061 between lotions, gloves, and antimicrobial products.

1062
1063 *Fingernails and Artificial Nails*
1064 Although the relationship between fingernail length and wound infection is unknown, keeping
1065 the nails short is considered important because most flora on the hands are found under and
1066 around the fingernails (McGinley 1988). Nails should be short enough to allow DHCP to
1067 thoroughly clean underneath them and to prevent glove tears (Larson 1995). Sharp nail edges or
1068 broken short nails are also likely to increase glove failure. Long artificial or natural nails can
1069 make donning gloves more difficult and may cause gloves to tear more readily. Hand carriage of
1070 gram-negative organisms has been shown to be greater among wearers of artificial nails than
1071 among non wearers, both before and after handwashing (Pottinger 1989, McNeil 2001, Rubin
1072 1988, Hedderwick 2000). In addition, artificial fingernails or extenders have been
1073 epidemiologically implicated in several outbreaks in hospital intensive care units and operating
1074 rooms involving fungal and bacterial infections (Passaro 1997, Foca 2000, Parry 2001,

1075 Moolenaar 2000). Freshly applied nail polish on natural nails does not increase the microbial
1076 load from periungual skin as long as fingernails are short, however, chipped nail polish may
1077 harbor more bacteria (Baumgardner 1993, Wynd 1994).

1078

1079 *Jewelry*

1080 Although total bacterial counts are higher on the skin underneath rings than on comparable areas
1081 of skin on fingers without rings, rings do not interfere with removal of bacteria by handwashing
1082 (Jacobson 1985). Whether wearing rings increases the likelihood of transmitting a pathogen is
1083 not known. Rings and decorative nail jewelry can make donning gloves more difficult, and they
1084 may cause gloves to tear more readily (Larson 1989, Field 1996). Thus, jewelry must not
1085 interfere with glove usage (e.g., ability to wear the correct-size glove, alter glove integrity).
1086 Before surgical hand antisepsis, all jewelry (e.g., rings, watch, bracelet) should be removed and
1087 kept off until the surgical procedure is complete (Mangram 1999).

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109

1110

1111

1112

1113

1114

1115

1116

1117

1118

1119

1120

1121 **Sterilization or Disinfection of Patient Care Items**
 1122 Patient care items (dental instruments, devices, and equipment) can be categorized as critical,
 1123 semicritical, or non critical based on the potential risk of infection based on their use. (Table 4)
 1124 (Spaulding 1968). Critical items used to penetrate soft tissue or bone have the highest risk of
 1125 transmitting infection and should be sterilized by heat. Semicritical items touch only mucous
 1126 membranes and have a lower risk of transmission, but because most semicritical items are heat
 1127 tolerant, they should be sterilized using heat. If a semicritical item is heat sensitive, it must, at a
 1128 minimum, be treated with high-level disinfection (CDC 1993). Noncritical patient care
 1129 instruments and equipment (e.g., blood pressure cuff, stethoscope, pulse oximeter) contact only
 1130 intact skin, which can serve as an effective barrier to microorganisms. Noncritical items pose the
 1131 least risk of transmission of infection. In most cases, cleaning followed by low-level disinfection
 1132 is appropriate for noncritical patient care items. If the item is visibly contaminated with blood, it
 1133 should be cleaned and disinfected with a tuberculocidal (i.e., intermediate-level) disinfectant
 1134 before use on another patient (CDC 1993, Rutala 2002).

1135
 1136 **Table 4. Categories of Patient-Care Items**

Category	Definition	Examples
Critical	Penetrate soft tissue, contact bone, enter into or contact the bloodstream, or other normally sterile tissue of the mouth	Surgical instruments, scalers, scalpel blades, surgical dental burs
Semicritical	Contact mucous membranes, but will not penetrate soft tissue, contact bone, enter into or contact the bloodstream, or other normally sterile tissue of the mouth	Dental mouth mirror, amalgam condenser, reusable dental impression trays, dental handpieces*
Noncritical	Contact with intact skin	Blood pressure cuff, stethoscope, pulse oximeter

1137 *Although dental handpieces are considered a semicritical item, heat sterilization is recommended (FDA
 1138 handpiece letter 1992). See section entitled Dental Handpieces and Other Devices Attached to Air or
 1139 Waterlines for detailed processing information.

1140
 1141 The three levels of disinfection (high, intermediate, and low) are used for devices and surfaces
 1142 that do not require sterility (Spaulding 1968); the intended use for patient care will determine the
 1143 necessary level of decontamination. Dental facilities should closely follow the product
 1144 manufacturer’s directions regarding concentrations and exposure time for appropriate
 1145 disinfectant activity. A summary of sterilization and disinfection methods is included in
 1146 Appendix 4.

1147
 1148 *Critical and Semicritical Patient Care Items*

1149 Instrument processing requires multiple steps to achieve sterilization or high-level disinfection.
 1150 Sterilization is a complex process requiring specialized, properly functioning equipment
 1151 adequate space, qualified personnel who are provided with ongoing training, and continuous
 1152 monitoring for quality assurance (AAMI 2002). Proper cleaning, packaging, sterilizer loading

1153 procedures, sterilization methods, and high-level disinfection methods should be followed to
1154 ensure the final product is properly processed and safe for reuse.

1155
1156 DHCP may be exposed to microorganisms on contaminated instruments and devices through
1157 percutaneous injury, non-intact skin on the hands, or contact with mucous membranes of the
1158 eyes, nose, or mouth. Contaminated instruments must be handled carefully to prevent exposure
1159 to sharp instruments that could cause a percutaneous injury. To reduce the amount of handling
1160 and the risk for exposure of DHCP, individual instruments or perforated cassette trays should be
1161 placed in a solid, rigid, covered transport tray at the point of use and the tray carried to the
1162 processing area.

1163
1164 *Instrument Processing Area*

1165 Dental health-care personnel should process all instruments in a designated central processing
1166 area to more easily control quality and ensure personnel safety (AAMI 1998). The instrument
1167 processing area should be divided into work areas for: 1) receiving, cleaning, and
1168 decontamination; 2) preparation and packaging; 3) sterilization; and 4) storage. Walls or
1169 partitions should ideally separate work areas to control traffic flow and contain contaminants
1170 generated during processing. When physical separation of these areas cannot be achieved,
1171 adequate spatial separation may be satisfactory if the personnel who process instruments are
1172 trained in appropriate work practices to prevent contamination of clean areas (AAMI 1998).
1173 Consider the needs of the dental office in determining the size of the processing areas. Space
1174 should be provided according to the volume of work anticipated and the volume of items to be
1175 stored (AAMI 2002).

1176
1177 *Receiving, Cleaning, and Decontamination Work Area*

1178 In this area, reusable instruments, supplies, and equipment are received, sorted, cleaned and
1179 decontaminated. Cleaning precedes all disinfection and sterilization processes and involves the
1180 removal of debris and organic contamination from an instrument, device, or surface. Removal of
1181 debris and contamination is usually achieved using either the physical action of scrubbing along
1182 with a surfactant or detergent/water or by an automated process (e.g., ultrasonic cleaner, washer-
1183 disinfectant) with appropriate chemical agents. If visible debris or organic matter is not removed
1184 it will interfere with microbial inactivation and may compromise the disinfection or sterilization
1185 process (Favero 2001, Parker 1995, Alfa 1998, Rutala 1998, Schulster 2002). Following
1186 cleaning, instruments should be rinsed with water to remove chemical or detergent residue.
1187 Splashing should be minimized during rinsing and cleaning (OSHA 1991).

1188
1189 Considerations in selecting cleaning methods and equipment include the efficacy of the method,
1190 process, and equipment; compatibility with the items to be cleaned; and occupational health and
1191 exposure risks. Automated cleaning equipment (e.g., ultrasonic cleaner, washer-disinfectant) does
1192 not require preprocessing of instruments and may increase productivity, improve cleaning
1193 effectiveness, and decrease worker exposure to blood and body fluids. Accordingly, using
1194 automated equipment may be more efficient and safer than manually cleaning contaminated
1195 instruments (Miller 2000).

1196
1197 If manual cleaning is necessary, placing instruments in a container and soaking them with a
1198 disinfectant/detergent or an enzymatic cleaner will prevent drying of patient material and make

1199 manual cleaning easier and less time-consuming. Using work practice controls (e.g., long-
1200 handled brush) to keep the scrubbing hand as far as possible from sharp instruments is
1201 recommended (OSHA CPL 2001). To avoid injury from sharp instruments, personnel should
1202 wear puncture-resistant, heavy-duty utility gloves when handling or manually cleaning
1203 contaminated instruments and devices (CDC 1988). If splashing is likely to occur, a face mask,
1204 eye protection or face shield, and gown or jacket should be worn (OSHA 1991).

1205
1206 Instruments should be considered contaminated and handled as such until processed through the
1207 sterilization cycle unless the instrument has been processed with an automated instrument washer
1208 with high-level disinfection cycle. Employees must not reach into trays or containers holding
1209 sharp instruments (OSHA 1991). To reduce the risk of injury, instruments could be picked-up
1210 using forceps or their contents emptied onto a towel.

1211
1212 *Preparation and Packaging*

1213 Cleaned or decontaminated instruments and other dental supplies are inspected, assembled into
1214 sets or trays, and wrapped, packaged, or placed into container systems for sterilization in this
1215 area. Critical and semicritical instruments that will not be used immediately should be wrapped
1216 or placed in rigid containers before sterilization (CDC 1993, Ninemeier 1998, AAMI
1217 1993,1996,1999, Rutala 2000). Materials for maintaining the sterility of instruments during
1218 transport and storage include wrapped perforated instrument cassettes, peel pouches of plastic
1219 and/or paper, and sterilization wraps (woven and nonwoven). The packaging material must allow
1220 penetration of the sterilization agent and maintain the sterility of the processed item after
1221 sterilization. Packaging materials must be compatible with the instrument and designed for the
1222 type of sterilization process being used (AAMI 1993,1996,1999, Rutala 2000).

1223
1224 *Sterilization Area*

1225 The sterilization area contains the sterilizers and related supplies. There should be adequate
1226 space for loading, unloading, and cool-down. This area may also include incubators for
1227 analyzing spore tests and enclosed storage for sterile items and disposable (single-use) items
1228 (Miller 1998).

1229
1230 *Sterilization Procedures*

1231 Heat-tolerant dental instruments are generally sterilized by one of the following methods: 1)
1232 steam under pressure (autoclaving); 2) dry heat; 3) unsaturated chemical vapor. All sterilization
1233 should be performed in medical sterilization equipment cleared by the FDA. Items to be
1234 sterilized should be arranged to allow for free circulation of the sterilizing agent (e.g., steam,
1235 chemical vapor, dry heat) around each one. The manufacturer's instructions for loading the
1236 sterilizer to allow proper circulation of the sterilizing agent must be followed (Miller 1998,
1237 AAMI 1998). The ability of equipment to achieve the physical parameters necessary to achieve
1238 sterilization should be monitored by mechanical, chemical, and biological indicators. Examples
1239 of recognized exposure periods for sterilization methods used in dentistry are summarized in
1240 Table 5.

1241
1242
1243
1244

1245 **Table 5. Examples of Sterilization Times and Temperatures for Packaged Items***

Method [†]	Time [§] (minutes)	Temperature °C (°F)	Biologic Monitoring
Steam autoclave • Gravity displacement • Pre-vacuum sterilizer	30 4	121 (250) 132 (270)	<i>Bacillus stearothermophilus</i>
Dry Heat • Static air • Forced air	60 120 150 12	170 (340) 160 (320) 150 (300) 190 (375)	<i>Bacillus subtilis</i>
Unsaturated chemical vapor	20	132 (270)	<i>Bacillus stearothermophilus</i>

1246 * Some parameters may vary slightly by manufacturer.

1247 † All sterilization equipment should be cleared by the FDA.

1248 § Does not include warm-up, cooling, and drying time. To avoid contamination, packages should
1249 be allowed to dry in the sterilizer before they are handled.

1250

1251 Modified from Miller CH, Palenik CJ, eds. Infection control and management of hazardous
1252 materials for the dental team, 2nd ed. 1998. St. Louis, Mosby.

1253

1254

Steam Sterilization

1255 Of all the methods available for sterilization, steam sterilization, which is very dependable, is the
1256 most widely used for critical and semicritical items that are not sensitive to heat and moisture
1257 (Miller 2001). Steam sterilization requires exposure of each item to direct steam contact at the
1258 required temperature and pressure for the specified time. Pressure serves as the means to obtain
1259 the high temperatures needed to quickly kill microorganisms. Most dental practices use table-top
1260 gravity displacement sterilizers, although pre-vacuum sterilizers are becoming more widely
1261 available.

1262

1263

Flash Steam Sterilization

1264 “Flash” or “fast” steam sterilization is a process for steam sterilizing patient care items for
1265 immediate use (AAMI 1996). A flash sterilization cycle operates at higher temperatures for
1266 shorter times and is preprogrammed to a specific time and temperature setting established by the
1267 manufacturer based on the type of sterilizer control (e.g., gravity displacement, pre-vacuum). To
1268 permit immediate contact with the steam in this short cycle, the instrument is typically
1269 unwrapped. Flash sterilization of instruments should be used only in carefully selected clinical
1270 situations (e.g., an urgent need to sterilize a particular instrument inadvertently contaminated)
1271 and when certain conditions are met: 1) thorough cleaning and drying of an instrument must
1272 precede any flash sterilization cycle; 2) all parameters, including mechanical, chemical, and
1273 biological monitors for each cycle, must be documented; and 3) flash-sterilized items must be
1274 transported immediately to the point of use so that the sterility is maintained (AORN 2002,
1275 AAMI 1996, Vesley 1992, Rutala 1993, Hood 1997, Rutala 1999). In most circumstances, the

1276 need to “flash” sterilize instruments can be prevented by efficient management of instrument
1277 inventory. Use of flash sterilization for implantable devices is not practical, as they must be
1278 quarantined and await the outcome of the biological monitoring before patient use (AORN
1279 2002).

1280

1281 *Dry-Heat Sterilization*

1282 Dry heat is used to sterilize materials that might be damaged by moist heat. Although dry heat
1283 has the advantages of having a low operating cost and being non-corrosive, it is a prolonged
1284 process and the high temperatures needed are not suitable for some patient care items and
1285 devices (Joslyn 2001).

1286

1287 Dry-heat sterilizers used in dentistry that have been cleared by the FDA include the static-air and
1288 the forced-air types:

1289 1. The static-air type is commonly called an oven-type sterilizer. Heating coils in the bottom
1290 or sides of the unit cause the hot air to rise inside the chamber through natural
1291 convection.

1292 2. The forced-air type is also known as a rapid-heat-transfer sterilizer. Heated air is
1293 circulated throughout the chamber at a high velocity, permitting a more rapid transfer of
1294 energy from the air to the instruments, thereby reducing the time needed for sterilization.

1295

1296 *Unsaturated Chemical-Vapor Sterilization*

1297 Unsaturated chemical vapor sterilization involves heating a chemical solution (0.23%
1298 formaldehyde; 72.38% ethanol plus acetone, ketone, water and other alcohols) in a closed
1299 chamber. Although unsaturated chemical vapor sterilization of carbon steel instruments (e.g.,
1300 dental burs) causes less corrosion than steam sterilization, it has disadvantages as well. State and
1301 local authorities should be consulted for hazardous waste disposal requirements for
1302 formaldehyde. Personnel should wear appropriate protective equipment to protect their skin and
1303 eyes from contact with the solution and should not breathe its vapors. Adequate room ventilation
1304 is required.

1305

1306 *Low-Temperature Sterilization*

1307 Ethylene oxide gas (ETO) has been used extensively in many larger health-care facilities as a
1308 low-temperature sterilant. Its primary advantage is that it can sterilize heat- and moisture-
1309 sensitive patient care items without deleterious effects. Extended sterilization times of 10–48
1310 hours depending on the material and stringent standards for ETO emissions may make it
1311 impractical to use this method in private practice settings. Handpieces cannot be effectively
1312 sterilized with this method due to decreased penetration of ETO gas flow through a small lumen
1313 (Pratt 1999, Parker 1995). Other types of low temperature sterilization (e.g., hydrogen peroxide
1314 gas plasma) exist but they have not been applied to dentistry or are not yet practical for dental
1315 offices.

1316

1317 *“Bead Sterilizer”*

1318 “Bead sterilizers” which provide inconsistent heating and significant temperature variation, are
1319 not acceptable. The FDA has found a risk of infection with these devices because of their
1320 potential failure to sterilize dental instruments and has required that their commercial distribution
1321 cease unless the manufacturer files a premarket approval application. If a “bead sterilizer” is

1322 employed, the user is assuming the risk of using a dental device that the FDA has deemed not to
1323 be safe and effective (FDA 1997).

1324

1325 *Heat-Sensitive Instruments and Devices and Liquid Chemical Sterilants*

1326 Heat-sensitive critical and semicritical instruments and devices can be sterilized or high-level
1327 disinfected using low-temperature sterilization (e.g., ethylene oxide, hydrogen peroxide gas
1328 plasma) or by liquid chemical germicides registered by the FDA as a “sterilant” (i.e.,
1329 sterilant/high-level disinfectant). Chemical sterilants may place health-care workers at risk and
1330 require special room ventilation. In addition, the process cannot be verified with biological
1331 indicators (Bond 1993). The use of heat-sensitive items (e.g., x-ray positioning ring, some bite
1332 blocks, plastic rulers, plastic resin applicators) requiring liquid chemical sterilization or high-
1333 level disinfection is discouraged, with heat-tolerant or disposable instruments and devices
1334 preferred. In addition, chemical sterilants should not be used on noncritical patient care items or
1335 on environmental surfaces. Sterilizing instruments using chemical sterilants may require up to 12
1336 hours of complete immersion; shorter immersion times are used to achieve high-level
1337 disinfection. Items intended to be sterilized need to be rinsed with sterile water to maintain
1338 sterility and to remove toxic or irritating residues. Subsequently, the objects need to be handled
1339 and dried with sterile gloves and towels and delivered to the use area in an aseptic manner to
1340 maintain sterility. If the instrument is intended to be stored, it should not be considered sterile. If
1341 liquid chemical sterilants must be used, manufacturer instructions for the use of chemical
1342 sterilants should be followed closely (e.g., room exhaust ventilation, 10 air exchanges per hour,
1343 closed containers) (AAMI 1996, CDC NIOSH 2001) to ensure the effectiveness of the process
1344 and the safety of DHCP. For example, although glutaraldehyde-based products can be used
1345 without tissue irritation or adverse health effects, dermatologic, eye irritation, and respiratory
1346 effects on overexposed personnel have been reported, and skin sensitization in some individuals.
1347 Adequate precautions (e.g., chemically-resistant gloves and aprons, goggles, face shields) should
1348 be taken (Ballantyne 1995, CDC NIOSH 2001).

1349

1350 *Barrier Protected Semicritical Instruments*

1351 Electronic or other high-technology semicritical instruments (e.g., digital radiography sensors,
1352 lasers, intraoral camera, electronic periodontal probe, occlusal analyzers) vary in their ability to
1353 be sterilized or high-level disinfected. Items that can not be reprocessed by immersion or
1354 sterilization techniques should be barrier protected during use using an FDA-cleared barrier. Use
1355 of a barrier, however, does not always protect the item from contamination. Studies have
1356 examined the perforation rate of commercially-available barriers applied to ultrasound probes
1357 and found high rates of perforation, and in one study, even before clinical use (Hignett 1995).
1358 Barrier-protected, medical probes failed at a higher rate than condom barriers, though both
1359 showed some degree of failure (Fritz 1993, Milki 1998, Storment 1997, Amis 2000, Rooks 1996,
1360 Odwin 1990). Another study, indicated that one brand of commercially-available plastic barriers
1361 used to protect digital radiography sensors failed at a significant rate (44%). This rate dropped to
1362 6% when latex finger cots were used in conjunction with the plastic barrier (Hokett 2000). Since
1363 the use of barrier protection does not eliminate the possibility of contamination, barrier protected
1364 semicritical items should be cleaned and high-level disinfected or sterilized between patients.
1365 The barrier does not change the classification of the device and the required level of disinfection
1366 or sterilization (Rutala 2002). Consult with the manufacturer for proper disinfection and
1367 sterilization methods.

1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413

Sterilization Monitoring

Monitoring of sterilization procedures should routinely include a combination of process parameters: mechanical, chemical, and biological (Favero 1998). These parameters evaluate the sterilizing conditions and the effectiveness of the procedure.

Mechanical techniques for monitoring sterilization include the daily assessment of cycle time and temperature by examining the temperature record chart, computer printout, visually observing the gauges, and assessing pressure via the pressure gauge (AAMI 1998, Rutala 2002). Incorrect readings could be the first indication that a problem with the sterilization cycle has occurred.

Chemical indicators monitor the parameters of time, temperature, and/or pressure. Single-parameter indicators can be applied to the outside of the package, placed inside the package, or be part of the packaging and will change color rapidly when a given parameter is reached (e.g., heat-sensitive tape). Single-parameter indicators are available for steam, dry heat, and unsaturated chemical vapor. Multiparameter indicators are used similarly but are currently available only for steam sterilizers. These indicators measure two or more parameters and provide a higher level of assurance that sterilization parameters have been achieved. Dental facilities should refer to the manufacturer instructions to define the use and proper placement of the chemical indicator. Indicator test results are received immediately upon completion of the sterilization cycle and could provide an early indication of a potential problem. If either the internal or external indicator suggests inadequate processing, the item should not be used (AORN 2002). Chemical indicators do not prove that sterilization has been achieved, only that parameters have been attained. A biological indicator (i.e., spore test) is required to directly measure the sterilization process.

Biological indicators are the most valid method for monitoring the sterilization process (Greene 1992, Favero 1998) because they assess the sterilization process directly by using the most resistant microorganisms (e.g., *Bacillus sp.* spores), and not by merely testing the physical and chemical conditions necessary for sterilization (Rutala 2002). Because the *Bacillus sp.* spores used in biological indicators are more resistant and present in greater numbers than are the common microbial contaminants found on patient care equipment, demonstrating that the biological indicator has been inactivated strongly implies that other potential pathogens in the load also have been killed (Maki 1987).

Proper functioning of sterilization cycles should be verified by the periodic use (at least weekly) of biological indicators (Garner 1985, CDC 1993, Greene 1992, Favero 1998, Rutala 2002, AORN 2002). Each load containing implantable devices should be monitored with such indicators (AAMI 1998). Implantable items should not be used until spore tests are known to be negative. The manufacturer's directions must be followed for appropriate placement and location of the biological indicator in the sterilizer. A control biological indicator (not processed through the sterilizer) from the same lot as the test indicator should be incubated in the same manner as the test biological indicator. The control biological indicator should yield positive results for bacterial growth.

1414 In-office biological monitoring is available; mail-in sterilization monitoring services (e.g., from
1415 private companies or dental schools) can also be used to test both the biological indicator and the
1416 control. Although some DHCP have expressed concern that delays due to mailing specimens
1417 might cause false negatives, studies have shown that mail delays have no significant influence on
1418 final test results (Andres 1995, Miller 1994).

1419
1420 A procedure to follow in the event of positive spore tests has been provided by CDC and the
1421 Association of Operating Room Nurses (now the Association of Perioperative Registered
1422 Nurses) (AORN 1987): If the mechanical (e.g., time, temperature, pressure) and chemical
1423 (internal or external) indicators suggest that the sterilizer is functioning properly, a single
1424 positive spore test probably does not indicate sterilizer malfunction; items other than implantable
1425 devices do not necessarily need to be recalled. The spore test should be repeated immediately
1426 and the sterilization procedures reviewed to determine whether operator error could be
1427 responsible (Garner 1986). If the repeat spore test is positive, dental facilities should not use the
1428 sterilizer until it has been inspected or repaired or the exact reason for the positive test has been
1429 found (Garner 1986, Rutala 2002). Items from suspect load(s) should be recalled, insofar as
1430 possible, rewrapped, and resterilized (AORN 1987, Garner 1986).

1431
1432 Results of biological monitoring should be recorded and sterilization monitoring records
1433 (mechanical, chemical, and biological) retained long enough to comply with state and local
1434 regulations. Such records are a component of an overall office infection control program (see
1435 section entitled Program Evaluation).

1436
1437 *Storage Area for Sterile and Clean Patient Care Items*

1438 The storage area contains the enclosed storage for sterile items and disposable (single-use) items
1439 (Miller 1998). Storage practices for wrapped sterilized instruments may be either date- or event-
1440 related. All packages containing sterile supplies must be inspected before use to verify barrier
1441 integrity and dryness. Although some health-care facilities continue to date every sterilized
1442 package and use the date-related shelf-life practice, many facilities have switched to event-
1443 related practice (Rutala 2002). This approach recognizes that the product should remain sterile
1444 indefinitely unless some event causes it to become contaminated (e.g., torn or wet packaging)
1445 (Mayworm 1984). Any package that has been dropped on the floor must be inspected for damage
1446 to the package or contents. If packaging is compromised, the instruments must be repackaged in
1447 new wrap and sterilized again. Dental supplies and instruments should be stored in closed or
1448 covered cabinets, if possible (Cardo 1999). Dental supplies and instruments should not be stored
1449 under sinks or in other locations where they can become wet.

1450
1451 *Noncritical Patient Care Items*

1452 Disinfection for noncritical patient care items (e.g., blood pressure cuff, stethoscope, pulse
1453 oximeter) is discussed in Appendix 4.

1454
1455
1456
1457
1458
1459

1460 **Environmental Infection Control**

1461 Although surfaces in the dental operator, including those of dental equipment, may become
1462 contaminated during patient care, these surfaces have not been associated with transmission of
1463 infection to either DHCP or patients. Environmental surfaces are all considered noncritical and
1464 can be divided into clinical contact and housekeeping surfaces (Table 6) (Favero 2001).
1465 Environmental surfaces carry the least risk of disease transmission and can be safely
1466 decontaminated using less rigorous methods than those used on dental patient care items
1467 (Sehulster 2001). Adequate safety for clinical contact and housekeeping surfaces can be achieved
1468 by cleaning and low- to intermediate-level disinfection (Appendix 4). As with non-critical
1469 patient care items, removal of all organic material and visible blood can be as important as the
1470 germicidal activity of the disinfecting agent (Favero 2001). If the surface cannot be adequately
1471 cleaned, it should be protected with barriers (CDC 1993).

1472
1473 Manufacturers of dental devices and equipment should provide information about material
1474 compatibility with liquid chemical germicides, whether the equipment can be safely immersed
1475 for cleaning, and how the equipment should be decontaminated if servicing is required (OSHA
1476 1991). Because of the risks associated with exposure to chemical disinfectants and contaminated
1477 surfaces, personnel who perform environmental cleaning and disinfection should wear personal
1478 protective equipment to prevent occupational exposure to infectious agents and hazardous
1479 chemicals (OSHA 1991, OSHA 1994).

1480
1481

1482 **Table 6. Categories of Noncritical Environmental Surfaces**

Type of Surface	Definition	Examples
Clinical Contact	Surfaces that are directly contacted by contaminated instruments, devices, hands, or gloves.	Light handles, switches, dental x-ray equipment, reusable containers of dental material, drawer handles, countertops, pencil, telephone handle, doorknob
Housekeeping	Surfaces that require regular cleaning and removal of soil and dust.	Floors, walls, sinks

1483

1484 *Clinical Contact Surfaces*

1485 Studies have shown that HIV is rapidly inactivated on surfaces after being exposed to commonly
1486 used chemical germicides at concentrations lower than those used in practice (Spire 1984, Martin
1487 1985, Hanson 1989, Bloomfield 1990, Druce 1995, Van Bueren 1995). Visible blood and
1488 organic material should be first removed, followed by surface disinfection (EPA List D)
1489 <http://www.epa.gov/oppad001/chemregindex.htm>. Low-level disinfectants registered with the
1490 Environmental Protection Agency (EPA) and labeled effective against HIV and HBV are
1491 appropriate for disinfecting clinical contact surfaces. In the absence of visible blood, complete
1492 inactivation of herpes simplex virus (which has similar susceptibilities to disinfectants as HIV)
1493 can be achieved within 30 seconds with a diluted hypochlorite solution (1:10 or 1:100), a
1494 phenolic, or a quaternary ammonium compound (Weber 1999). HBV is readily inactivated with
1495 a variety of germicides, including quaternary ammonium compounds (low-level disinfectants)
1496 (Prince 1993).

1497
1498 After treatment of each patient and at the completion of daily work activities, countertops and
1499 dental unit surfaces should be cleaned and disinfected using a low-level disinfectant (CDC
1500 1993).

1501
1502 Barrier protection of surfaces and equipment can be particularly effective in preventing
1503 contamination of clinical contact surfaces that are difficult to clean. Effective barriers include
1504 disposable plastic wrap, plastic sheets or tubing, and plastic-backed paper or other material
1505 impervious to moisture (Crawford 1987, Miller 2001). Because such coverings may be
1506 contaminated, they should be removed and discarded while DHCP are still gloved. After
1507 removing their gloves and performing hand hygiene, DHCP should place clean covers on these
1508 surfaces before the next patient (CDC 1986, Crawford 1987, CDC 1993).

1509
1510 *Housekeeping Surfaces*

1511 There is no evidence that HBV, HCV, or HIV has ever been transmitted from a housekeeping
1512 surface (e.g., floors, walls) in a health-care setting. Nonetheless, prompt removal of blood or
1513 body substances contamination and surface disinfection of the area is a sound infection control
1514 practice and required by OSHA. Cleaning and disinfection schedules and methods may vary
1515 according to the area (dental operatory, laboratory, bathrooms, patient waiting rooms), surface,
1516 and amount and type of contamination. Housekeeping surfaces should be cleaned and
1517 decontaminated with an EPA-registered low-level disinfectant immediately or as soon as feasible
1518 when surfaces are overtly contaminated or after any spill of blood or other potentially infectious
1519 materials; and at the end of the work shift if the surface may have become contaminated since
1520 the last cleaning (Rutala 2002, OSHA 1991).

1521
1522 *Cleaning and Disinfection Strategies for Spills of Blood*

1523 Strategies for decontaminating spills of blood and other body fluids differ by setting and by the
1524 volume of the spill (CDC 1987, Sehulster 2001). Most blood spills in dentistry are relatively
1525 small. Blood spills on either clinical contact or housekeeping surfaces should be contained and
1526 managed as quickly as possible to reduce the risk of contact by patients and DHCP. The person
1527 assigned to clean the spill should wear medical gloves and other personal protective equipment
1528 as needed. Visible organic material should be removed with absorbent material (e.g., disposable
1529 paper towels discarded in a leakproof, properly labeled container); the non-porous surface should
1530 be cleaned and then decontaminated with either a low-level disinfectant effective against HBV
1531 and HIV or an intermediate-level chemical disinfectant. If sodium hypochlorite is chosen, it is
1532 preferable to use an EPA-registered sodium hypochlorite product, but if such products are not
1533 available, a 1:100 dilution of sodium hypochlorite (approximately 1/4 cup household chlorine
1534 bleach to 1 gallon of water) is an inexpensive and effective disinfecting agent.

1535
1536 *Carpeting and Cloth Furnishings*

1537 Carpeting is harder to clean than non-porous hard-surface flooring, and it cannot be reliably
1538 disinfected, especially after spills of blood and body substances (OSHA 1991). Several studies
1539 have documented the presence of diverse microbial populations, primarily bacteria and fungi, in
1540 carpeting (Gerson 1994, Suzuki 1984, Skoutelis 1993). Cloth furnishings pose similar
1541 contamination risks in areas of direct patient care and places where contaminated materials are

1542 managed (e.g., dental operatory, laboratory, instrument processing area). For these reasons
1543 carpeted flooring and fabric-upholstered furnishings in these areas should be avoided.

1544

1545 *Regulated Medical Waste*

1546 Several studies have compared the microbial load and the diversity of microorganisms in
1547 residential waste and waste from a variety of health-care settings. There is no epidemiological
1548 evidence to suggest that general waste from hospitals; other health-care facilities, including
1549 dental facilities; or clinical/research laboratories is any more infective than residential waste.
1550 Aesthetic and emotional considerations originating fairly early in the HIV epidemic (Keene
1551 1989, Keene 1991, Rutala 1989, Rutala 1991), however, have resulted in the promulgation of
1552 federal, state, and local rules and regulations regarding medical waste management and disposal
1553 (Greene 1994, EPA 1997, Garner 1986, CDC 1996, CDC 1988).

1554

1555 *Categories of Medical Waste*

1556 The most practical approach to managing medical waste is to identify waste that represents a
1557 sufficient risk of causing infection during handling and disposal and for which some special
1558 precautions may be indicated (Garner 1985). The risk of either injury or infection from certain
1559 sharp items (e.g., needles, scalpel blades) contaminated with blood also needs to be considered.
1560 Although any item that has had contact with blood, exudates, or secretions may be infective, it is
1561 not normally considered practical or necessary to treat all such waste as infective. Federal, state,
1562 and local guidelines and regulations specify the categories of medical waste subject to regulation
1563 and outline any requirements associated with treatment and disposal. Some examples of
1564 regulated waste found in a dental office are solid waste that is soaked or saturated with blood or
1565 saliva (e.g., gauze saturated with blood following surgery), extracted teeth, surgically removed
1566 hard and soft tissues, and sharp items (e.g., needles, scalpel blades, wires) (OSHA 1991).

1567

1568 *Management of Regulated Medical Waste in Dental Health-Care Facilities*

1569 Medical waste requires careful disposal and containment before collection and consolidation for
1570 treatment. A single leak-resistant biohazard bag is usually adequate for containment of non-sharp
1571 regulated medical waste, provided the bag is sturdy and the waste can be discarded without
1572 contaminating the bag's exterior. Exterior contamination or puncturing of the bag requires
1573 placement in a second biohazard bag. All bags should be securely closed for disposal. Puncture-
1574 resistant containers located at the point of use (e.g., sharps containers) are used as containment
1575 for scalpel blades, needles, syringes, and unused sterile sharps (OSHA 1991).

1576

1577 Health-care facilities should dispose of medical waste regularly to avoid accumulation. Any
1578 facility that generates regulated medical waste should have a regulated medical waste
1579 management plan to assure health and environmental safety as per federal, state, and local
1580 regulations.

1581

1582 *Discharging Blood or Other Body Fluids to Sanitary Sewers or Septic Tanks*

1583 All containers with blood or saliva remaining (e.g., suctioned fluids) may be inactivated in
1584 accordance with state-approved treatment technologies, or the contents can be carefully poured
1585 down a utility sink drain or toilet (CDC 1988). State regulations may dictate the maximum
1586 volume of blood or other body fluids that may be discharged into the sanitary sewer. There is no
1587 evidence that bloodborne diseases have been transmitted from contact with raw or treated

1588 sewage. Many bloodborne pathogens, particularly viruses, are not stable in the environment for
1589 long periods of time (Slade 1989) and the discharge of small quantities of blood and other body
1590 fluids into the sanitary sewer is considered a safe method of disposing of these waste materials
1591 (CDC 1988).

1592

1593 **Dental Unit Waterlines, Biofilm, and Water Quality**

1594 Studies have demonstrated that dental unit waterlines (narrow-bore plastic tubing that carries
1595 water to the high-speed handpiece, air/water syringe, and ultrasonic scaler) can become
1596 colonized with a variety of microorganisms, including bacteria, fungi, and protozoa (Walker
1597 2000, Schulze-Robbecke 1995, Barbeau 1996, Atlas 1995, Kelstrup 1977, Challacombe 1995,
1598 Mayo 1990). Protected by a polysaccharide slime layer known as a glycocalyx, these
1599 microorganisms colonize and replicate on the interior surfaces of the waterline tubing and form a
1600 biofilm. Once formed, the biofilm serves as a reservoir that may substantially amplify the
1601 number of free-floating (i.e., planktonic) microorganisms in water used for dental treatment.

1602

1603 Although oral flora (Scheid 1982, Bagga 1984, Walker 2000) and human pathogens, such as
1604 *Pseudomonas aeruginosa* (Martin 1987, Pankhurst 1990, Barbeau 1996, Walker 2000),
1605 *Legionella* species (Pankhurst 1990, Atlas 1995, Walker 2000), and non-tuberculous
1606 *Mycobacterium* species (Schulze-Robbecke 1995, Walker 2000), have been isolated from dental
1607 water systems, most organisms recovered from dental waterlines are common heterotrophic
1608 water bacteria (Barbeau 1996, Mills 1986, Williams 1993), which exhibit little pathogenic
1609 potential for immunocompetent persons.

1610

1611 *Clinical Implications*

1612 Although there are very few reports of waterborne infections associated with dental water
1613 systems, a large body of scientific evidence verifies the potential for transmission of waterborne
1614 infections and disease in hospital settings and in the community. Infection or colonization due to
1615 *Pseudomonas* species or non-tuberculous mycobacteria can be transmitted to susceptible patients
1616 via direct contact with water (Jones 1985, Hollyoak 1995, Begg 1986, Laussucq 1988) or after
1617 exposure to residual waterborne contamination of inadequately reprocessed medical instruments
1618 (Struelens 1993, Kuritsky 1983, Bolan 1985). Non-tuberculous mycobacteria can also be
1619 transmitted to patients from tap water aerosols (Lessing 1993). Health-care-associated
1620 transmission of pathogenic agents such as *Legionella* species occurs primarily through the
1621 inhalation of infectious aerosols generated from potable water sources or the use of tap water in
1622 respiratory therapy equipment (Arnow 1982, Breiman 1990, Garbe 1985). Disease outbreaks in
1623 the community have also been reported from diverse environmental aerosol-producing sources,
1624 including whirlpool spas (Fallon 1990), swimming pools (Rose 1998), and grocery store mist
1625 machine (MMWR 1990). Although most of these outbreaks are associated with various species
1626 of *Legionella* bacteria and *Pseudomonas* species (Rose 1998), the aquatic fungus *Cladosporium*
1627 (Jacobs 1986) have also been implicated. Concentrations of bacterial endotoxin as high as 1000
1628 endotoxin units/ml from gram-negative water bacteria have been detected in water from
1629 colonized dental units (Putnins 2001). There are no current standards for the acceptable level of
1630 endotoxin in drinking water, but the maximum level permissible in USP sterile water for
1631 irrigation is only 0.25 endotoxin units per ml (US Pharmacopeia 1997). Although the
1632 consequences of acute and chronic exposure to aerosolized endotoxin in dental health-care
1633 settings have not been investigated, endotoxin has been associated with exacerbation of asthma

1634 and the onset of hypersensitivity pneumonitis in other occupational settings (Milton 1996, Rose
1635 1998).

1636
1637 Researchers have not demonstrated a measurable risk of serious adverse health effects among
1638 DHCP or patients from exposure to dental water. Nevertheless, several studies found DHCP to
1639 have altered nasal flora (Clark 1974) or significantly higher titers of *Legionella* antibodies in
1640 comparisons with control populations; no cases of legionellosis were identified among exposed
1641 DHCP (Fotos 1985, Reinthaler 1988). A report from Great Britain suggests that contaminated
1642 dental water in post-treatment sites may have been the source for localized *Pseudomonas*
1643 *aeruginosa* infections of two immunocompromised patients (Martin 1987). Although transient
1644 carriage of *P. aeruginosa* was observed in 78 healthy patients treated with contaminated dental
1645 treatment water, no illness was reported in this group. In this same study, a retrospective review
1646 of dental records also failed to identify any infections among healthy patients (Martin 1987).

1647
1648 *Dental Unit Water Quality*
1649 Standards for safe drinking water quality established by the EPA, the American Public Health
1650 Association (APHA) and the American Water Works Association (AWWA) set limits of no
1651 more than 500 colony-forming units (CFUs) of heterotrophic bacteria per ml of drinking water
1652 (EPA 1999, APHA 1999). Untreated or unfiltered dental unit waterlines are unlikely to meet
1653 drinking water standards (Walker 2000, Schulze-Robbecke 1995, Barbeau 1996, Atlas 1995,
1654 Kelstrup 1977, Challacombe 1995, Mayo 1990). Research has shown that microbial counts can
1655 reach as high as 200,000 CFU/ml within 5 days after installation of new dental unit waterlines
1656 (Barbeau 1996) and levels of microbial contamination as high as 10⁶ colony forming units per
1657 milliliter of dental unit water (CFU/ml) have been documented (Mayo 1990, Santiago 1994).
1658 These counts can occur because dental unit waterline factors (e.g., system design, flowrates,
1659 materials) promote bacterial growth levels and the additional development of biofilm.

1660
1661 In 1998, the Association for the Advancement of Medical Instrumentation established that water
1662 in hemodialysis units should not have more than 200 CFU/ml (Arduino 1998). In 1995, the ADA
1663 applied this health-care standard to dental units, recommending dental manufacturers provide
1664 equipment with the ability to deliver treatment water with ≤ 200 CFU/ml of unfiltered output
1665 from waterlines (Shearer 1996). Exposing patients or DHCP to water of uncertain
1666 microbiological quality, despite the lack of documented adverse health effects, is inconsistent
1667 with generally accepted infection control principles. Thus, the number of bacteria in water used
1668 as a coolant/irrigant for nonsurgical dental procedures should be as low as reasonably achievable
1669 and, at a minimum, less than the 500 CFU/ml standard for safe drinking water established by the
1670 EPA and the APHA/AWWA.

1671
1672 *Strategies to Improve the Quality of Dental Unit Water*
1673 Although there is no current epidemiological evidence of a public health problem, the presence
1674 of potential human pathogens in dental unit waterlines generates concern. Meeting the 1993
1675 recommendation that waterlines be flushed for several minutes at the beginning of the clinic day
1676 temporarily reduces the microbial load (Scheid 1982, Mayo 1990), but it does not seem to affect
1677 biofilm in the waterlines or to reliably improve the quality of water used during dental treatment
1678 (Williams 1993, Santiago 1994, Williams HN 1995). Because the recommended value of 500
1679 CFU/ml or less cannot be consistently achieved using this method, other strategies must be

1680 employed. Commercial devices and procedures designed to improve the quality of water used in
1681 dental treatment are available (Mills 2000); methods shown to be effective include self-contained
1682 water systems combined with chemical treatment, in-line microfilters, and combinations of these
1683 treatments. Simply using source water containing less than 500 CFU/ml of bacteria (e.g., tap,
1684 distilled, or sterile water) in a self-contained water system will not eliminate bacterial
1685 contamination in treatment water if biofilms in the water system are not controlled. Currently,
1686 removal or inactivation of biofilms requires the use of chemical germicides, but other
1687 technological methods may become available in the future.

1688
1689 It is well established that patient material (e.g., oral microorganisms, blood, saliva) can enter the
1690 dental water system during patient treatment (Bagga 1984, Scheid 1990). Any dental device
1691 connected to the dental water system that enters the patient's mouth (e.g., handpieces, ultrasonic
1692 scalers, air/water syringe) should be run to discharge water and air for a minimum of 20-30
1693 seconds after each patient (CDC 1993). This procedure is intended to physically flush out patient
1694 material that may have entered the turbine, air, or waterlines. Most recently manufactured dental
1695 units are engineered to passively prevent retraction of oral fluids, but older dental units are often
1696 equipped with anti-retraction valves that require periodic maintenance. Users should consult the
1697 owner's manual or contact the manufacturer to determine whether testing or maintenance of anti-
1698 retraction valves or other devices is required. Even in the presence of anti-retraction valves,
1699 flushing procedures for devices attached to air and waterlines should be followed as described.

1700 1701 *Maintenance and Monitoring of Dental Unit Water*

1702 DHCP should be trained about water quality, biofilm formation, water treatment methods, and
1703 proper maintenance protocols for water delivery systems. Water treatment and monitoring
1704 products require strict adherence to maintenance protocols, and non-compliance with treatment
1705 regimens has been associated with persistence of microbial contamination in treated systems
1706 (Williams HN 1994). Clinical monitoring of water quality can ensure that procedures are
1707 properly performed and that devices are working in accordance with the manufacturer's
1708 previously validated protocol.

1709
1710 Dentists should consult with the manufacturer of their dental unit or water delivery system to
1711 determine the best method for maintaining acceptable water quality (i.e., < 500 CFU/ml) and the
1712 recommended frequency of monitoring. Because methods used to treat dental water systems
1713 target the entire biofilm, there is no rationale for routine testing for specific organisms such as
1714 *Legionella* or *Pseudomonas* except when investigating a suspected waterborne disease outbreak
1715 (2001).

1716 1717 *Surgical Irrigation*

1718 Sterile saline or sterile water must be used as a coolant/irrigation in the performance of surgical
1719 procedures where there is a risk of microbial invasion of fascial spaces or the vascular system
1720 (see section entitled Surgical Procedures). Sterile water delivery devices should be used to
1721 deliver sterile water (CDC 1993, Garner Surgical Wound 1985). Conventional dental units
1722 cannot reliably deliver sterile water even when equipped with independent water reservoirs
1723 because the water-bearing pathway cannot be reliably sterilized. Sterile water systems for
1724 surgery and for dental implants bypass the dental unit and employ sterile disposable or
1725 autoclavable tubing. Oral surgery and implant handpieces as well as ultrasonic scalers that

1726 deliver sterile water or other sterile solutions using single-use disposable or sterilizable tubing
1727 are commercially available (Mills, 2000).

1728
1729 *Boil-Water Advisories*

1730 A boil-water advisory is a statement that the public should boil tap water before drinking it.
1731 When issued, the public should assume the water is unsafe to drink. Advisories can be issued in
1732 the event of: 1) failure of or significant interruption in water treatment processes that result in
1733 increased turbidity levels or particle counts and mechanical or equipment failure; 2) positive test
1734 results for pathogens (e.g., *Cryptosporidium*, *Giardia*, *Shigella*) in water; 3) violations of the
1735 total coliform rule or the turbidity standard of the surface water treatment rule; 4) circumstances
1736 that compromise the distribution system [e.g., water main break] coupled with an indication of a
1737 health hazard; or 5) a natural disaster (e.g., flood, hurricane, earthquake) (Working Group 1997).
1738 In recent years, increased numbers of boil-water advisories have resulted from contamination of
1739 public drinking water systems with waterborne pathogens. The most notable event was the
1740 outbreak of cryptosporidiosis in Milwaukee, Wisconsin, when the municipal water system was
1741 contaminated with the protozoan parasite *Cryptosporidium parvum*. An estimated 403,000
1742 persons became ill (MacKenzie 1994, Kaminski 1994).

1743
1744 During a boil-water advisory, water should not be delivered to patients through the dental
1745 operative unit, ultrasonic scaler, or other dental equipment that uses the public water system.
1746 This restriction does not apply if the water source is isolated from the municipal water system
1747 (e.g., it is a separate water reservoir or other water treatment device that has been cleared for
1748 marketing by the FDA). Patients should rinse with bottled or distilled water until the boil-water
1749 advisory has been cancelled. During these advisory periods, tap water should not be used to
1750 dilute germicides or for hand hygiene unless the water has been brought to a rolling boil and
1751 cooled before use (CDC 1995, CDC 1996, Working Group 1997). For hand hygiene,
1752 antimicrobial products that do not require water, such as alcohol-based hand rubs, can be used
1753 until the boil-water notice is cancelled. If hands are visibly soiled, use bottled water and soap for
1754 handwashing or a detergent-containing towelette (Larson 1995, OSHA 1991).

1755
1756 When the advisory is cancelled, the local water utility should provide guidance for proper
1757 flushing of water lines to reduce residual microbial contamination. All incoming water lines from
1758 the public water system inside the dental office (e.g., faucets and water lines to dental
1759 equipment) should be flushed. There is no consensus as to the optimal duration for flushing
1760 procedures following the cancellation of the advisory; recommendations range from 1 to 5
1761 minutes (2001, EPA Lead revisions 2000, EPA Lead final rule 2000, Working Group 1997). The
1762 length of time needed may vary with the type and length of the plumbing system leading to the
1763 office. After the incoming public water system lines are flushed, dental operative water lines
1764 should be disinfected according to the manufacturer's instructions (Working Group 1997).

1765
1766 **Program Evaluation**

1767 The primary goal of an infection control program is to prevent errors and provide a safe working
1768 environment that will reduce the risk of health-care-associated infections among patients and
1769 occupational exposures among DHCP. Medical errors are caused by faulty systems, processes,
1770 and conditions that lead people to make mistakes or fail to prevent them (IOM 1999). Effective
1771 program evaluation is a systematic way to improve and account for safe public health actions by

1772 involving procedures that are useful, feasible, ethical, and accurate. Program evaluation is an
 1773 essential organizational practice in public health; however, it is not practiced consistently across
 1774 program areas, nor is it sufficiently well-integrated into the day-to-day management of most
 1775 programs (CDC MMWR 1999). A successful infection control program depends on developing
 1776 standard operating procedures, evaluating infection control practices, routinely documenting
 1777 adverse outcomes (e.g., occupational exposures to blood) and work-related illnesses in DHCP,
 1778 and monitoring health-care-associated infections in patients. Strategies and tools to evaluate the
 1779 effectiveness of the infection control program could include periodic observational assessments,
 1780 checklists to document procedures, and routine review of occupational exposures to bloodborne
 1781 pathogens. Information gathered from the evaluation offers an opportunity to improve the
 1782 effectiveness of the infection control program and to benefit office protocols. If the assessment
 1783 determines there are deficiencies or problems in the implementation of certain infection control
 1784 procedures, a further evaluation can be performed to identify and modify the contributing
 1785 factors. The recommendations after each section in the guidelines may help in selecting infection
 1786 control issues to evaluate. Several examples of elements (performance indicators) that could be
 1787 evaluated in a dental practice are shown in Table 7.

1788
 1789 **Table 7. Examples of Elements to Evaluate**

Element	Evaluation Example
Appropriate immunizations of DHCP	Conduct an annual review of individual personnel records to ensure up-to-date immunizations.
Assessment of occupational exposures to infectious agents	Report occupational exposures to infectious agents. Document the steps that occurred around the exposure and plan how it could be prevented in the future.
Comprehensive postexposure management and medical follow-up program after occupational exposures to infectious agents	Ensure that postexposure management plan is clear, complete, and available at all times to all DHCP. All staff should understand the plan, which should include toll-free phone numbers for questions.
Adherence to hand hygiene before and after patient care	Observe and document circumstances of appropriate or inappropriate handwashing. Review findings in a safety meeting with all staff.
Proper use of personal protective equipment to prevent occupational exposures to infectious agents	Observe and document the use of barrier precautions and careful handling of sharps. Review findings in a safety meeting with all staff.
Routine and appropriate sterilization of instruments using a biologic monitoring system	Monitor paper log of steam cycle and temperature strip with each sterilization load, and examine results of weekly biologic monitoring. Take appropriate action when failure of sterilization process is noted.
Proper handling and disposal of regulated medical waste	Observe the safe disposal of regulated medical waste and be proactive regarding hazardous situations.
Health-care associated infections	Assess the unscheduled return of patients after procedures and evaluate them for an infectious process. An increasing trend may require formal evaluation.
Compliance of water in routine dental procedures with current EPA drinking water standards (fewer than 500 CFU of heterotrophic water bacteria)	Monitoring of dental water quality may be performed by the dentist using commercial self-contained test kits, or it may be accomplished by commercial water testing laboratories. The manufacturer of the dental unit or water delivery system can determine the best method for maintaining and monitoring good water quality.

1790 **Special Considerations**

1791

1792 **Dental Handpieces and Other Devices Attached to Air and Waterlines**

1793 Several semicritical dental devices that touch mucous membranes are attached to the air and/or
1794 waterlines of the dental unit. Among these devices are high- and low-speed handpieces,
1795 prophylaxis angles, ultrasonic and sonic scaling tips, air abrasion devices, and air and water
1796 syringe tips. Although there is no epidemiological evidence implicating these instruments in
1797 disease transmission (Gooch 1993), studies of high-speed handpieces using dye expulsion have
1798 confirmed the potential for retracting oral fluids into internal compartments of the device
1799 (Crawford 1988, Mills 1993, Lewis cross-contamination 1992, Lewis cross-infection 1992,
1800 Checchi 1998). This finding suggests that retained patient material may be expelled intraorally
1801 during subsequent uses. Studies using laboratory models also suggest the possibility for the
1802 retention of viral DNA inside both high-speed handpieces and prophylaxis angles; none, however,
1803 has assessed the presence of infectious virus (Lewis cross-contamination 1992, Lewis cross-
1804 infection 1992, Epstein 1995). The potential for contamination of the internal surfaces of other
1805 devices (e.g., low-speed handpiece and ultrasonic scalers), have not been studied, but restricted
1806 physical access limits their cleaning. Accordingly, any dental device that is connected to the
1807 dental water system and enters the patient's mouth should be run to discharge water, air, or a
1808 combination for a minimum of 20-30 seconds after each patient (CDC 1993). This procedure is
1809 intended to help physically flush out patient material that may have entered the turbine and air
1810 and water lines (CDC 1993, Lewis cross-contamination 1992, Lewis cross-infection 1992).

1811

1812 Heat sterilization methods (e.g., steam under pressure, unsaturated chemical vapor) can
1813 effectively sterilize dental handpieces and other intraoral devices attached to air and/or
1814 waterlines (Pratt 1999, Lewis cross-contamination 1992, Lewis cross-infection 1992, Kolstad
1815 1998). For reprocessing any dental device that can be removed from the dental unit air and/or
1816 waterlines, neither surface disinfection nor immersion in chemical germicides is an acceptable
1817 method. Ethylene oxide gas cannot adequately sterilize internal components of handpieces (Pratt
1818 1999, Parker 1995, Food and Drug 1992). In clinical evaluations of high-speed handpieces,
1819 cleaning and lubrication were the most critical factors in determining performance and durability
1820 (Kuehne 1992, Anderson 1999, Leonard 1999). Manufacturer's instructions for cleaning,
1821 lubrication, and sterilization should be followed closely to ensure both the effectiveness of the
1822 process and the longevity of handpieces.

1823

1824 Some components of dental instruments are permanently attached to dental unit waterlines.
1825 These items do not enter the patient's oral cavity but are likely to become contaminated with oral
1826 fluids during treatment procedures (e.g., handles or dental unit attachments of saliva ejectors,
1827 high-speed air evacuators, and air/water syringes.). These components should be covered with
1828 impervious barriers that are changed after each use. If the item becomes visibly contaminated
1829 during use, clean and low- to intermediate-level disinfect before use on the next patient.

1830

1831 *Saliva Ejectors*

1832 Research studies using clinical situations suggest that in about 1 in 5 cases previously suctioned
1833 dyed fluids might be retracted into the patient's mouth when a seal around the saliva ejector is
1834 created (e.g., by the patient closing her/his lips around the tip of the ejector) (Barbeau 1998,
1835 Mann 1996, Watson 1993). The CDC is not aware of any reports of adverse health effects

1836 associated with the saliva ejector, but, in light of these findings, practitioners should not ask
1837 patients to close their lips around the tip of this device to evacuate oral fluids (Mann 1996).

1838
1839

1840 **Aseptic Technique for Parenteral Medications**

1841 Safe handling of parenteral medications and fluid infusion systems are required to prevent
1842 health-care associated infections in patients undergoing conscious sedation. Parenteral
1843 medications include a single-dose ampule, vial or pre-filled syringe usually without
1844 bacteriostatic/preservative agents and are intended for use on a single patient. Multiple dose
1845 vials, used for one or more patients, may have a preservative but both containers of medication
1846 must be handled with aseptic techniques to prevent contamination.

1847
1848 Single-dose vials might pose a risk for contamination if they are punctured several times. CDC
1849 recommends using single-dose vials for parenteral medications when possible. The leftover
1850 contents of a single-use vial should be disposed of appropriately and never be combined with
1851 other medications for use on another patient (ASPH Council 2000, Green 1995). Medication
1852 from a single-dose syringe must not be administered to multiple patients even if the needle on the
1853 syringe is changed (ASA 1999).

1854
1855 The overall risk for extrinsic contamination of multiple dose vials is likely minimal, although the
1856 consequences of contamination might result in life-threatening infection (Henry 2001). If it is
1857 necessary to use a multiple dose vial, cleanse the access diaphragm of a multiple dose vial with
1858 70% alcohol before inserting a sterile device into the vial (Plott 1990, Arrington 1990). Discard a
1859 multiple dose vial if sterility is compromised (Plott 1990, Arrington 1990).

1860
1861 Do not carry medication vials, syringes, or supplies in pockets. If trays are used to deliver
1862 medications to individual patients, they must be cleaned between patients. To further reduce the
1863 chance of contamination all medication vials should be restricted to a centralized medication
1864 preparation area separate from the treatment area (CDC 2001).

1865
1866 All fluid infusion and administration sets (IV tubings and connections) are single-patient use as
1867 sterility can not be guaranteed if an infusion or administration set is used on multiple patients.
1868 Aseptic technique should be used when preparing IV infusion and administration sets, and entry
1869 into or breaks in the tubing should be minimized (ASA 1999).

1870
1871

1872 **Single-Use (Disposable) Devices**

1873 A single-use device, also called a disposable device, is intended to be used on one patient and
1874 then discarded appropriately. It is not intended to be reprocessed (cleaned, disinfected/sterilized)
1875 and used on another patient (FDA 2001). Common single-use items include saliva ejectors,
1876 syringe needles, prophylaxis angles, cups and brushes, high-volume evacuator tips, and air/water
1877 syringe tips.

1878
1879

1880
1881

1882 **Pre-procedural Mouth Rinses**

1883 Antimicrobial mouth rinses given before a dental procedure are intended to reduce the number of
1884 microorganisms the patient may release in the form of aerosols or spatter that subsequently may
1885 contaminate DHCP and equipment operatory surfaces. In addition, pre-procedural rinsing may
1886 decrease the number of microorganisms introduced in the patient's bloodstream during invasive
1887 dental procedures (Dajani 1990, Pallasch 1996).

1888
1889 The use of rotary dental and surgical instruments (e.g., handpieces, ultrasonic scalers) and air-
1890 water syringes creates a visible spray that contains primarily large-particle droplets of water,
1891 saliva, blood, microorganisms, and other debris. This spatter travels only a short distance and
1892 settles out quickly, landing either on the floor, nearby operatory surfaces, the DHCP, or the
1893 patient. The spray may also contain some aerosol. Aerosols take considerable energy to generate
1894 and consist of particles less than 10 μ in diameter that typically are not visible to the naked eye.
1895 Aerosols can remain airborne for extended periods and may be inhaled; they should not be
1896 confused with the large-particle spatter that makes up the bulk of the spray from handpieces and
1897 ultrasonic scalers. Appropriate use of dental dams (Cochran 1989), high-velocity air evacuation,
1898 and proper patient positioning should minimize the formation of droplets, spatter, and aerosols
1899 (CDC 1993).

1900
1901 To date, no scientific evidence indicates that pre-procedural mouth rinsing prevents clinical
1902 infections among DHCP or patients, but studies have shown that a pre-procedural rinse with a
1903 long-lasting antimicrobial (e.g., chlorhexidine gluconate, essential oils, povidone-iodine) can
1904 reduce the level of oral microorganisms generated during routine dental procedures with rotary
1905 instruments (e.g., dental handpieces, ultrasonic scalers) (Litsky 1970, Mohammed 1970, Wyler
1906 1971, Muir 1978, Fine 1992, Fine 1993 Am J Dent, Fine 1993 J Am Dent Assoc, Logothetis
1907 1995, Klyn 2001). Pre-procedural mouth rinses may be most beneficial before a procedure using
1908 a prophylaxis cup or ultrasonic scaler because rubber dams cannot be used to minimize aerosol
1909 and spatter generation; unless the provider has an assistant, high-volume evacuation is not
1910 commonly used (Miller 1998).

1911
1912 The science is unclear concerning the incidence and nature of bacteremias from oral procedures,
1913 the relationship of these bacteremias to disease, and the preventive benefit of antimicrobial
1914 rinses. In limited studies, no significant benefit has been shown for mouth rinsing in terms of
1915 reducing the number of oral microorganisms in dental-induced bacteremias (Brown 1998,
1916 Lockhart 1996). The current American Heart Association recommendations for preventing
1917 bacterial endocarditis during dental procedures (Dajani 1997), however, provide limited support
1918 for pre-procedural mouth rinsing with an antimicrobial as an adjunct for patients at risk of
1919 bacterial endocarditis.

1920
1921
1922 **Surgical Procedures**

1923 The oral cavity is colonized with numerous microorganisms. Surgical procedures present a
1924 greater opportunity for entry of microorganisms (i.e., exogenous and endogenous) into the
1925 vascular system and other normally sterile areas of the oral cavity (e.g., bone, subcutaneous
1926 tissue) and increased potential for localized or systemic infection. Surgical procedures involve
1927 the incision, excision, or reflection of skin or oral mucosa that exposes the normally sterile areas

1928 of the oral cavity. Examples of surgical procedures include biopsy, periodontal surgery, apical
1929 surgery, and extractions of teeth.

1930
1931 The wearing of sterile surgical gloves during surgical procedures is supported by a strong
1932 theoretical rationale (CDC 1988, CDC 1993, Mangram 1999, CDC Hand 2002). Sterile gloves
1933 minimize transmission of microorganisms from the hands of surgical personnel to patients and
1934 prevent contamination of the hands of surgical personnel with the patient's blood and body fluids
1935 (Mangram 1999). Although the effectiveness of wearing two pairs of gloves in preventing
1936 disease transmission has not been demonstrated, most studies among medical and dental
1937 personnel have shown a lower frequency of inner glove perforation and visible blood on the
1938 surgeon's hands when double gloves are worn (Gani 1990, Gerberding 1990, Short 1993,
1939 Schwimmer 1994, Tokars 1995, Patton 1995, Avery 1998, Burke 1996). In one study evaluating
1940 double gloves during oral surgical and dental hygiene procedures, the perforation of outer latex
1941 gloves was greater during longer (more than 45 minutes) than shorter procedures, with the
1942 highest rate, 10%, found during oral surgery procedures (Patton 1995). Based upon these studies,
1943 double gloving may provide additional protection from occupational blood contact. Double
1944 gloving does not appear to significantly reduce either manual dexterity or tactile sensitivity
1945 (Webb 1993, Watts 1994, Wilson 1996). Additional protection may be provided by specialty
1946 products (e.g., orthopedic surgical gloves, microsurgery gloves, glove liners) (FDA 1999).

1947
1948 Because skin bacteria can rapidly multiply under surgical gloves if hands are washed with a non-
1949 antimicrobial soap (Price 1938, Dewar 1973), an antiseptic (e.g., antimicrobial soap or alcohol-
1950 based hand rub) should be used before any surgical procedure (Lowbury 1960, Rotter 1999,
1951 Widmer 2000, CDC 2002). When performing surgical hand antisepsis using an antimicrobial
1952 soap, scrub hands and forearms for 2-6 minutes. When using an alcohol-based surgical hand-
1953 scrub product, prewash hands and forearms with a nonantimicrobial soap and dry hand and
1954 forearms completely. After application of the alcohol-based product, allow hands and forearms
1955 to dry thoroughly then immediately don sterile gloves and other personal protective equipment
1956 (e.g., surgical mask, protective eyewear, protective clothing) (Garner 1986, Larson 1990,
1957 Faoagali 1995).

1958
1959 Sterile water or other sterile irrigating solutions must be used when surgical procedures are
1960 performed in the oral cavity (CDC 1993, Garner surgical wound 1985) (see section entitled
1961 Dental Unit Water Quality). All reusable heat tolerant instruments and supplies used during the
1962 procedure must be heat sterilized and maintained in sterile packaging until the initiation of the
1963 procedure. Single-use devices should be sterile at the time of use.

1964
1965
1966 **Handling of Biopsy Specimens**
1967 To protect persons handling and transporting biopsy specimens, each specimen must be placed in
1968 a sturdy, leak-proof container with a secure lid to prevent leakage during transport (OSHA
1969 1991). Care should be taken when collecting the specimen to avoid contaminating the outside of
1970 the container. If the outside of the container becomes visibly contaminated, it should be cleaned
1971 and disinfected or placed in an impervious bag (CDC 1993). The container must be labeled with
1972 the biohazard symbol during storage, transport, shipment, and disposal (OSHA 1991, OSHA
1973 2001 CPL).

1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019

Handling of Extracted Teeth

Office Disposal

Extracted teeth, that are being discarded are subject to the containerization and labeling provisions of the Occupational Safety and Health Administration's Occupational Exposure to Bloodborne Pathogens: Final Rule in 1991 (OSHA 1991). OSHA considers extracted teeth to be potentially infectious material that should be disposed in medical waste containers. Extracted teeth may be returned to patients upon request, however, at which time they are no longer subject to the provisions of the standard (OSHA 2001 CPL). Extracted teeth containing dental amalgam should not be placed in a medical waste container that uses an incinerator for final disposal. State and local regulations should be consulted regarding disposal of the amalgam.

Educational Settings

Extracted teeth are occasionally collected for use in preclinical educational training. These teeth should be cleaned of visible blood and gross debris and maintained in a hydrated state in a closed container. A liquid chemical germicide, (e.g., glutaraldehyde, 5.25% sodium hypochlorite) will disinfect the exterior of the tooth but not the interior pulp tissue (Tate 1991, Pantera 1988). Phenol and 1:10 dilution of sodium hypochlorite are not effective disinfectants (Tate 1991). Extracted teeth must be placed in a well-constructed container with a secure lid to prevent leaking during transport, and they need to be labeled with the biohazard symbol (OSHA 1991, OSHA 2001 CPL). Before being used in an educational setting, the teeth should be sterilized to allow for safe handling. Pantera and Shuster demonstrated elimination of microbial growth using an autoclave cycle for 40 minutes (Pantera 1990), but since preclinical educational exercises simulate clinical experiences, students enrolled in dental programs should still follow standard precautions. Autoclaving teeth for preclinical laboratory exercises does not alter their physical properties sufficiently to compromise the learning experience (Pantera 1990, Parsell 1998). It is not known, however, whether autoclave sterilization of extracted teeth affects dentinal structure to the point that the chemistry and microchemical relationship between dental materials and the dentin would be affected for research purposes on dental materials (Parsell 1998).

The use of teeth that do not contain amalgam is preferred in educational settings because they can be safely autoclaved (Pantera 1990, Tate 1991). Extracted teeth containing amalgam restorations must not be heat sterilized because of the potential health hazard from mercury vaporization and exposure. If extracted teeth containing amalgam restorations are to be used, immersion in 10% formalin solution for 2 weeks should be effective in disinfecting both the internal and external structures of the teeth (Tate 1991).

Dental Laboratory

Dental prostheses, appliances, and the items used in their fabrication (e.g., impressions, occlusal rims, bite registrations) should be handled in a manner that prevents exposure of personnel to infectious agents. In turn, DHCP and dental laboratory personnel must manage these items in a manner that prevents contamination of the material during handling and storage.

When a laboratory case is sent off-site, communication between the dental office and laboratory personnel regarding the handling and status of material decontamination is important. Specific

2020 information regarding the disinfection technique (e.g., solution used, length of time) should be
2021 included with the laboratory case. This information is useful for laboratory personnel because it
2022 prevents duplication of the disinfection protocol and contamination of their environment (ADA
2023 1996, CDC 1993, Kugel 2000).

2024
2025 Dental prostheses, prosthodontic materials (e.g., occlusal rims, temporary prostheses, bite
2026 registrations), orthodontic appliances, and impressions should be cleaned, disinfected with an
2027 appropriate intermediate-level disinfectant, and thoroughly rinsed before and after being
2028 manipulated in the laboratory (ADA 1996, CDC 1993, Rutala 1998, 2001, Favero 2001).
2029 Personal protective equipment (e.g., chemically-resistant gloves, face shield, surgical mask,
2030 protective eyewear, gowns) must be worn until disinfection is accomplished (OSHA 1991, CDC
2031 1986, CDC 1987, CDC 1988, CDC 1993). DHCP are advised to consult with manufacturers
2032 regarding the stability of specific materials during disinfection.

2033
2034 Heat-tolerant items used in the mouth (e.g., metal impression tray, face bow fork) should be heat
2035 sterilized before being used on another patient (ADA 1996, CDC 1993). Laboratory items used
2036 on potentially contaminated appliances or prostheses (e.g., burs, polishing points, rag wheels)
2037 should be sterilized or high-level disinfected between cases or be disposable (Favero 2001,
2038 Rutala 1998, 2001). Items that do not normally contact the patient or the prosthetic device or
2039 appliance but frequently become contaminated and cannot withstand heat sterilization (e.g.,
2040 articulators, case pans, lathes) should be cleaned and disinfected according to the manufacturer's
2041 instructions. In most instances these items can be cleaned and disinfected with a low-level
2042 disinfectant. Pressure pots and water baths are particularly susceptible to contamination with
2043 microorganisms and should be cleaned and disinfected at least daily (Plummer 1994).
2044 Environmental surfaces should be cleaned and disinfected in the same manner as in the dental
2045 treatment area.

2046
2047 Unless waste generated in the dental laboratory (e.g., disposable trays, impression material) falls
2048 under the category of regulated medical waste, it may be discarded with general waste. Personnel
2049 should dispose of sharp items (e.g., burs, disposable blades, orthodontic wires) in puncture-
2050 resistant containers.

2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065

2066 **Part II. Recommendations**
2067 Each recommendation is categorized on the basis of existing scientific data, theoretical rationale,
2068 and applicability. The CDC system for categorizing the Recommended Infection Control
2069 Practices for Dentistry, 2003 recommendations is as follows:

2070
2071 **Category IA.** Strongly recommended for implementation and strongly supported by well-
2072 designed experimental, clinical, or epidemiologic studies.

2073
2074 **Category IB.** Strongly recommended for implementation and supported by certain experimental,
2075 clinical, or epidemiologic studies and a strong theoretical rationale.

2076
2077 **Category IC.** Required for implementation, as mandated by federal or state regulation or
2078 standard.

2079
2080 **Category II.** Suggested for implementation and supported by suggestive clinical or
2081 epidemiologic studies or a theoretical rationale.

2082
2083 **No recommendation.** Unresolved issue. Practices for which insufficient evidence or no
2084 consensus regarding efficacy exist.

2085
2086

2087 **I. Infection Control Elements of a Personnel Health Program**

2088 **A. General Recommendations**

- 2089 1. Develop a written personnel health program for DHCP that includes: education
2090 and training, immunization programs, exposure prevention and postexposure
2091 management, medical conditions, work-related illness, and associated work
2092 restrictions, contact dermatitis, latex hypersensitivity, maintenance of records,
2093 data management, and confidentiality (IB) (Bolyard 1998, ACIP 1997, American
2094 Hospital Association 1997, Gershon 2000, Herwaldt 1997).
- 2095 2. Establish referral arrangements with qualified health-care professionals to ensure
2096 prompt and appropriate provision of preventive services, occupationally-related
2097 medical conditions, and postexposure management with medical follow-up (IB,
2098 IC) (OSHA 1991, Bolyard 1998, CDC 2001, Herwaldt 1997).

2099
2100

2101 **B. Education and Training**

- 2102 1. Provide personnel, upon initial employment and periodically, with education and
2103 training regarding occupational exposure to potentially infectious agents and
2104 infection control appropriate and specific for their assigned duties (IB, IC)
2105 (Bolyard 1998, Garner 1996, Herwaldt 1997, Gershon 2000, OSHA 1991, OSHA
2106 CPL 2001, CDC 2001).
- 2107 2. Provide educational information appropriate in content and vocabulary to the
2108 educational level, literacy, and language of personnel (IB) (Bolyard 1998).

2109
2110

2111

2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157

C. Immunization Programs

1. Develop a written comprehensive policy on immunizing DHCP, including a list of all required and recommended immunizations (IB) (Bolyard 1998, ACIP 1997, AHA 1992).
2. Refer personnel to a prearranged qualified health-care professional or to their own health-care professional to receive all appropriate immunizations based on the latest recommendations and their medical history and risk for occupational exposure (IB) (Bolyard 1998, CDC immunization 1997).

D. Exposure Prevention and Postexposure Management

1. Develop a comprehensive postexposure management and medical follow-up program that includes: (IB, IC) (Bolyard 1998, CDC 2001, OSHA 1991, OSHA 2001 CPL).
 - a. Policies and procedures for prompt reporting, evaluation, counseling, treatment, and medical follow-up of occupational exposures.
 - b. Established referral mechanisms to a qualified health-care professional for medical evaluation and follow-up.

E. Medical Conditions, Work-Related Illness, and Work Restrictions

1. Develop and have readily available to all DHCP comprehensive written policies on work restriction and exclusion that include a statement of authority defining who may implement such restrictions and exclusions (IB) (Bolyard 1998, Herwaldt 1997).
2. Develop policies for work restriction and exclusion that encourage personnel to seek appropriate preventive and curative care, and report their illnesses or any medical conditions or medical treatments that may render them more susceptible to opportunistic infection or exposures and that do not penalize them with loss of wages, benefits, or job status (IB) (Bolyard 1998, Herwaldt 1997, Mangram 1999).
3. Develop policies and procedures for evaluating, diagnosing, and managing personnel or patients with suspected or known occupational contact dermatitis (IB) (CDC/NIOSH 1997).
4. Seek definitive diagnosis by a qualified health-care professional of any suspected latex allergy to carefully determine its specific etiology and appropriate treatment as well as work restrictions and accommodations (IB) (CDC/NIOSH 1997).

F. Maintenance of Records, Data Management, and Confidentiality

1. Establish, and keep updated, a confidential medical record (e.g., any immunization records and documentation of tests received as a result of an occupational exposure) for all DHCP. Dental facilities coordinating the infection control program with off-site providers may have such records maintained by these providers (IB, IC) (Bolyard 1998, OSHA 1991).
2. Ensure that all applicable current federal, state, and local laws on medical record-keeping and confidentiality are complied with (IC) (OSHA 1991, OSHA reporting 2001).

2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203

II. Preventing Transmission of Bloodborne Pathogens

A. Hepatitis B Virus Vaccination

1. Ensure that all DHCP who perform tasks involving contact with blood or blood-contaminated saliva receive the appropriate hepatitis B vaccination series (IA, IC) (OSHA 1991, CDC immunization 1997, CDC 1993, CDC 1991 comprehensive strategy).
2. Test DHCP for anti-HBs 1 to 2 months after completion of the 3-dose vaccination series (IA) (CDC Immunization 1997).
3. Revaccinate non-responders using the 3-dose series and retest for response in 1 to 2 months (IB) (CDC Immunization 1997).
4. Evaluate non-responders after second 3-dose vaccination series to determine if they are HBsAg-positive (IB) (CDC Immunization 1997).

B. Preventing and Managing Exposures to Blood

1. General Recommendations

- a. Consider sharp items (e.g., needles, scalpel blades, wires) that are contaminated with patient blood and saliva as potentially infective and establish engineering controls and work practices to prevent injuries (IB, IC) (CDC HIV 1987, CDC 1988, OSHA 1991).
- b. Implement a written, comprehensive program designed to minimize and manage employee exposure incidents to blood and body fluids (IB, IC) (OSHA 2001 CPL, OSHA 1991, CDC 2001, NIOSH 1999).

2. Engineering and Work Practice Controls

- a. Identify, evaluate and select devices with engineered safety features as they become available on the market (e.g., safer anesthetic syringes, blunt suture needle, retractable scalpel, needleless IV system) (IA, IC) (OSHA 2001 needlestick, CDC 1997 phlebotomy, CDC 1997 blunt suture needles, NIOSH 1999).
- b. Place used disposable syringes and needles, scalpel blades, and other sharp items in appropriate puncture-resistant containers located as close as practical to the area in which the items are used (IA, IC) (OSHA 1991, CDC HIV 1987, CDC 1988, CDC 1989, CDC dentistry 1993, CDC NIOSH containers 1998).
- c. Do not recap used needles using both hands or any other technique that involves directing the point of a needle toward any part of the body. Do not bend, break, or remove needles before disposal (IA, IC) (OSHA 1991, CDC HIV 1987, CDC 1988, CDC 1989, CDC dentistry 1993, NIOSH 1999).
- d. If necessary to recap needles (e.g., prior to removing from a non disposable aspirating syringe), use either a one-handed "scoop" technique or a mechanical device designed for holding the needle sheath (IA, IC) (CDC HIV 1987, CDC 1988, CDC 1989, CDC 1993, OSHA 1991).

- 2204 **3. Postexposure Prophylaxis**
2205 a. Follow current CDC recommendations for postexposure management and
2206 prophylaxis after percutaneous, mucous membrane, or non-intact skin
2207 exposure to blood or blood-contaminated saliva (IA, IC) (OSHA 1991, CDC
2208 2001, OSHA 2001 CPL).
2209

2210 **III. Preventing the Transmission of *Mycobacterium tuberculosis* (TB)**

2211 **A. General Recommendation**

- 2212 1. Educate all DHCP regarding the recognition of signs and symptoms and
2213 transmission risk of tuberculosis (IB) (CDC 1994, Cleveland 1995).
2214 2. Assess the patient for a history of TB and symptoms suggestive of TB and
2215 document on the medical history form (IB) (CDC 1994, Cleveland 1995).
2216 3. Follow current CDC recommendations for (a) developing, maintaining, and
2217 implementing a written TB infection control plan; (b) management of a patient
2218 with suspected or active TB; (c) a community risk assessment guiding employee
2219 tuberculin skin testing and follow-up; and (d) tuberculosis exposure management
2220 of personnel (IB) (CDC 1993, Cleveland 1995).
2221 4. A baseline TST (preferably using a two-step test) is recommended for all HCWs
2222 who may have contact with persons with suspected or confirmed infectious TB,
2223 regardless of the risk classification of the setting (IB) (CDC 1994).
2224

2225 **B. For patients known or suspected to have active TB:**

- 2226 1. After check-in screening, staff should wear respiratory protection and evaluate the
2227 patient in a room with a closed door. When not being evaluated, the patient should
2228 wear a surgical mask or be instructed to cover their mouth and nose when
2229 coughing or sneezing (IB) (CDC 1994, Cleveland 1995).
2230 2. Defer elective dental treatment until the patient is non infectious (IB) (CDC 1994,
2231 Cleveland 1995).
2232 3. Use respiratory protection and engineering controls in a previously identified
2233 facility if urgent dental treatment is required (IB) (CDC 1994, Cleveland 1995).
2234
2235

2236 **IV. Personal Protective Equipment**

2237 **A. Masks, Protective Eyewear, Face Shields**

- 2238 1. Wear a surgical mask and eye protection with solid side shields to protect mucous
2239 membranes of the eyes, nose, and mouth during procedures likely to generate
2240 splashing or spattering of blood or other body fluids (IB, IC) (OSHA 1991,
2241 Garner 1996, Mangram 1999, CDC HIV 1987, CDC 1988, CDC 1986, CDC
2242 1993).
2243 2. Change masks between patients, or during patient treatment when the mask
2244 becomes wet (IB, IC) (CDC 1993, OSHA 1991).
2245 3. Clean and disinfect reusable facial protective equipment (e.g., protective eyewear,
2246 face shield) between patients (IC) (OSHA 1991, CDC 1993).
2247
2248
2249

2250
2251
2252
2253
2254
2255
2256
2257
2258
2259
2260
2261
2262
2263
2264
2265
2266
2267
2268
2269
2270
2271
2272
2273
2274
2275
2276
2277
2278
2279
2280
2281
2282
2283
2284
2285
2286
2287
2288
2289
2290
2291
2292
2293
2294
2295

B. Protective Apparel

1. Wear long-sleeved protective clothing such as reusable or disposable gowns, laboratory coats, or uniforms when skin or personal clothing is likely to be soiled with blood, saliva, or other potentially infectious materials (IB, IC) (OSHA 1991, Garner 1996, Mangram 1999, CDC 1987, CDC 1988).
2. Protective apparel should be changed if visibly soiled (Mangram 1999) and should be changed immediately or as soon as feasible if penetrated by blood or other potentially infectious fluids (IB, IC) (OSHA 1991).
3. Remove barrier protection, including gloves, masks, eyewear, and gowns, before departing areas of the dental office used for laboratory or patient care activities (IC) (OSHA 1991).

C. Gloves

1. Wear medical gloves when there is a potential for contacting blood, saliva, or mucous membranes (IB, IC) (OSHA 1991, CDC 1985, 86, 87, 88).
2. Wear a new pair of medical gloves for each patient, remove them promptly after use, and wash hands immediately to avoid transfer of microorganisms to other patients or environments (IB) (CDC 1986, 87, 88, 2002, OSHA 1991).
3. Remove gloves that are torn, cut, or punctured as soon as safety permits, and wash hands before regloving (IB, IC) (OSHA 1991, Wright 1991, Dodds 1988).
4. Do not wash surgical or patient examination gloves before use or wash, disinfect, or sterilize gloves for reuse (IB, IC) (Adams 1992, Martin 1988, DeGroot-Kosolcharoen 1989, Doebbeling 1988, OSHA 1991).
5. Ensure that the task-appropriate glove in the appropriate size is readily accessible (OSHA 1991).
6. Wear sterile surgical gloves when performing surgical procedures (IB) (CDC 1988, CDC 1993, Mangram 1999, CDC Hand 2002).
7. Use puncture- and chemical-resistant/heavy-duty utility gloves for housekeeping procedures involving potential blood or saliva contact, cleaning instruments, and performing decontamination (IB) (CDC 1988).

V. Contact Dermatitis and Latex Hypersensitivity

- A. Educate DHCP about the signs, symptoms, and diagnoses of skin reactions associated with frequent hand hygiene and glove use (IB) (Bolyard 1998, ADA 1999, CDC/NIOSH 1997, Terezhalmly Personnel 1996).

VI. Hand Hygiene

A. General Considerations

1. When hands are visibly dirty or contaminated with proteinaceous material or are visibly soiled with blood or other body fluids, perform hand hygiene with either a non-antimicrobial soap and water or an antimicrobial soap and water. If hands are not visibly soiled, a non-antimicrobial soap, an antimicrobial soap, or an alcohol-based hand rub may be used (IA) (CDC Hand 2002).
2. Indications for hand hygiene include:
 - a. when hands are visibly soiled (IA, IC);

- 2296 b. after barehanded touching of inanimate objects likely to be contaminated by
- 2297 blood, saliva, or respiratory secretions (IA, IC);
- 2298 c. before and after treating each patient (IB);
- 2299 d. before donning gloves (IB); and
- 2300 e. immediately after removing gloves (IB, IC) (OSHA 1991, CDC Universal
- 2301 Precautions 1988, CDC HIV 1987, Garner 1986, Larson 1995, Steere 1995,
- 2302 Larson 2000, Pittet 2000, CDC Hand 2002, Garner 1996, Doebbeling 1988).
- 2303 3. For surgical procedures, perform surgical hand antisepsis using either:
- 2304 a) an antimicrobial soap and water or
- 2305 b) soap and water followed by alcohol-based hand rub with persistent activity
- 2306 before donning sterile gloves (IB) (Price 1938, Dewar 1973, Lowbury 1960,
- 2307 Rotter 1999, Widmer 2000, Larson 1995, Garner 1986, Larson 1990, Faogali
- 2308 1995).
- 2309 4. Store liquid hand care products in closed containers and in either disposable
- 2310 containers or containers that are washed and dried before refilling. Do not add
- 2311 soap or lotion (“topping off”) to a partially empty dispenser (IA) (Larson 1995,
- 2312 Steere 1975, Garner 1986, Archibald 1997, Grohskopf 2001).
- 2313

B. Special Considerations for Hand Hygiene and Glove Usage

- 2315 1. Use lotions to prevent skin dryness associated with handwashing at the end of the
- 2316 work day (IA) (Berndt 2000, McCormick 2000).
- 2317 2. Compatibility between lotion and antiseptic products and the effect of petroleum
- 2318 or other oil emollients on the integrity of gloves should be considered during
- 2319 product selection and glove usage (IB) (MMWR 1993, Garner Supercedes 1986,
- 2320 OSHA 2001 CPL, Larson 1993, Larson 1995).
- 2321 3. Keep nails short enough to allow thorough cleaning and to prevent glove tears (II)
- 2322 (McGinley 1988, Larson 1995).
- 2323 4. Do not wear artificial nails (IB) (Pottinger 1989, McNeil 2001, Rubin 1988,
- 2324 Hedderwick 2000, Passaro 1997, Foca 2000, Parry 2001, Moolenaar 2000). (This
- 2325 recommendation is IA when having direct contact with patients at high risk (e.g.,
- 2326 those in intensive care units, or operating rooms) (CDC 2002).
- 2327 5. Do not wear hand or arm jewelry during surgical procedures (II) (Mangram
- 2328 1999).
- 2329 6. Do not wear hand or nail jewelry during non-surgical procedures if they make
- 2330 donning gloves more difficult or compromise the appropriate fit and integrity of
- 2331 the glove. (II) (Larson 1989, Field 1996).
- 2332
- 2333
- 2334

VII. Sterilization and Disinfection of Patient Care Items

A. General Recommendations

- 2337 1. Clean and heat sterilize heat-tolerant critical and semicritical dental instruments
- 2338 before use (IA) (ADA 1996, CDC 1993, FDA 1992).
- 2339 2. Clean and, at a minimum, high-level disinfect heat-sensitive semicritical items
- 2340 (IA) (ADA 1996, CDC 1993).

- 2341
2342
2343
2344
2345
2346
2347
2348
3. After use, clean and disinfect noncritical patient care items with a low- to intermediate-level disinfectant (i.e., use an intermediate level disinfectant if visibly contaminated with blood) (II) (CDC 1993, Rutala 2002).
 4. Each worker should be informed of the possible health effects of their exposure to chemical agents used for disinfection and sterilization. The information should comply with OSHA requirements and identify the areas and tasks in which there is potential exposure (IC) (OSHA 1994).

2349
2350

B. Instrument Reprocessing Area

- 2351
2352
2353
2354
2355
2356
2357
1. Designate a central reprocessing area. Divide the instrument reprocessing area, physically (or spatially at a minimum), into distinct areas for: a) receiving, cleaning, and decontamination; b) preparation and packaging; c) sterilization; and d) storage. Do not store instruments in an area where contaminated instruments are held or cleaned (II) (AAMI 1998, Miller 1998, AAMI 2002).
 2. Train DHCP to apply work practices that prevent contamination of clean areas (II).

2358
2359

C. Receiving, Cleaning, and Decontamination Work Area

- 2360
2361
2362
2363
2364
2365
2366
2367
2368
2369
2370
2371
2372
1. Remove all visible blood and organic contamination from dental instruments and devices before sterilization or disinfection procedures (IA) (Favero 2001, Parker 1995, Alfa 1998, Rutala 1998).
 2. Use automated cleaning equipment (e.g., ultrasonic cleaner, washer-disinfector) to remove debris to improve cleaning effectiveness and decrease worker exposure to blood (IB) (CDC 1993, Miller 2000).
 3. If manual cleaning is necessary, use work practice controls (e.g., long-handled brush) that minimize contact with sharp instruments (IC) (OSHA 2001 CPL).
 4. Wear puncture- and chemical-resistant/heavy-duty utility gloves for housekeeping procedures involving potential blood or saliva contact and for instrument cleaning and decontamination procedures (IB) (CDC 1988).
 5. Wear face mask, eye protection, and gowns when splashing or spraying is anticipated during cleaning (IC) (OSHA 1991).

2373
2374

D. Preparation and Packaging

- 2375
2376
2377
2378
2379
1. Critical and semicritical items that will not be used immediately should be wrapped or placed in rigid containers before sterilization (IA) (CDC 1993, Ninemeier 1998, AAMI 1993, AAMI 1996, AAMI 1999, Rutala 2000).
 2. Use a rigid container or wrapping compatible with the type of sterilization process used (IA) (AAMI 1993, AAMI 1996, AAMI 1999, Rutala 2000).

2380
2381

E. Sterilization Procedures

2382

1. General Recommendation

- 2383
2384
2385
2386
- a. Use only FDA-cleared medical devices for sterilization and follow the manufacturer's instructions for proper use (IB) (AAMI 1998).

2387
2388
2389
2390
2391
2392
2393
2394
2395
2396
2397
2398
2399
2400
2401
2402
2403
2404
2405
2406
2407
2408
2409
2410
2411
2412
2413
2414
2415
2416
2417
2418
2419
2420
2421
2422
2423
2424
2425
2426
2427
2428
2429
2430
2431

2. Flash Sterilization

- a. Do not use flash sterilization as a routine sterilization procedure for patient care items; only when unavoidable (e.g., an item is inadvertently dropped) (IB) (Mangram 1999, Hood 1997, Rutala 1999).
- b. Do not flash sterilize implantable devices unless sterilization is verified by biological monitoring results (IA) (AORN 2002).
- c. Document the mechanical, chemical, and biological monitors for every flash sterilization cycle (IB) (AAMI 1996, Vesley 1992, Rutala 1993).

3. Processing Heat-Sensitive Instruments

- a. Use heat tolerant rather than heat-sensitive instruments whenever possible. Single-use disposable instruments are acceptable alternatives when available (IB) (Rutala 2002 draft).
- b. Use a low-temperature sterilization method (e.g., ethylene oxide, hydrogen gas plasma) or a liquid chemical germicide cleared by the FDA as a “sterilant” (i.e., sterilant/high-level disinfectant) to reprocess a heat-sensitive instrument. Follow the manufacturer’s instructions for the use of chemical sterilants (IB) (Rutala 2002).

4. Barrier Protected Semicritical Instruments

- a. Use FDA-cleared barriers (IB)
- b. Barrier protected semicritical items should be cleaned and high-level disinfected or sterilized between patients. Consult with the manufacturer for proper disinfection and sterilization methods (IB) (Rutala 2002).

F. Sterilization Monitoring

- 1. Use mechanical, chemical, and biological monitors according to the manufacturer’s instructions to ensure the effectiveness of the sterilization process (IA) (Greene 1992, Favero 1998, AAMI 1998).
- 2. Each load should be monitored with mechanical (e.g., time, temperature, pressure) and chemical indicators (II) (AAMI 1998, Rutala 2002).
- 3. Place a chemical indicator on the inside of each package. If it is not visible from the outside, place an additional chemical indicator on the outside of the package (II) (AAMI 1993, Rutala 2002).
- 4. Do not use instrument packs if mechanical or chemical indicators suggest inadequate processing (IB) (AORN 2002, AAMI 1998).
- 5. Monitor sterilizers with biological and control indicators at least weekly (IB) (Garner 1986, CDC 1993, Greene 1992, Favero 1998, Rutala 2002, AORN 2002).
- 6. Use a biologic and control indicator for every sterilizer load that contains an implantable device. Results should be verified before use of the implantable device whenever possible (IB) (AAMI 1998).
- 7. In the case of a positive spore test, repeat the test immediately and review sterilization procedures (IB) (AORN 1987, Garner 1986).
- 8. Recall (as far as possible) and reprocess all items from a suspect load(s) if a second spore test remains positive for bacterial growth (IB) (AORN 1987, Garner 1986).

- 2432 9. If spore tests remain positive, use of the sterilizer should be discontinued until it is
2433 serviced and results of retesting are satisfactory (IB) (Garner 1986, Rutala 2002).
2434 10. Maintain sterilization records (mechanical, chemical, biological) in compliance
2435 with state and local regulations (IB) (JCAHO 2001).
2436

2437 **G. Storage Area for Sterile and Clean Patient Care Items**

- 2438 1. Implement practices based on date- or event-related shelf-life for the storage
2439 of wrapped, sterilized instruments and devices (IB) (Rutala 2002, Mayworm
2440 1984).
2441 2. Examine wrapped packages of sterilized instruments before opening them to
2442 ensure the barrier wrap has not been compromised during storage (IB)
2443 (Mayworm 1984).
2444 3. Repack and re-sterilize any instrument package that is compromised (II).
2445 4. Store sterile supplies in covered or closed cabinets (IB) (Cardo 1999 in
2446 Mayhall text).
2447

2448 **VIII. Environmental Infection Control**

2449 **A. General**

- 2450 1. Follow the manufacturer's instructions for proper use of cleaning and EPA-
2451 registered hospital disinfecting products (IB) (Russell 2000, Rutala 1984,
2452 Sehulster 2001 Rutala 2002)
2453 2. Wear gloves and other personal protective equipment (as appropriate) when
2454 cleaning and disinfecting environmental surfaces (IC) (OSHA 1991, OSHA
2455 1994).
2456

2457 **B. Clinical Contact Surfaces**

- 2458 1. Clean and disinfect clinical contact surfaces that can be thoroughly cleaned using
2459 a low-level (label claims effectiveness against HIV and HBV) to intermediate-
2460 level hospital disinfectant after each patient (i.e., use an intermediate level
2461 disinfectant if visibly contaminated with blood) (IB) (CDC 1993, Rutala 2002).
2462 2. Use barriers to protect clinical contact surfaces that are difficult to clean (e.g.,
2463 switches on dental chairs) and change surface barriers between patients (II) (CDC
2464 1986, CDC 1993, Crawford 1987, Miller 2001).
2465

2466 **C. Housekeeping Surfaces**

- 2467 1. Clean and low-level disinfect housekeeping surfaces using an EPA-registered
2468 hospital disinfectant on a regular basis (e.g., as appropriate based upon the
2469 location in the facility) and when visibly soiled (IB, IC) (Rutala 2002, OSHA
2470 1991).
2471

2472 **D. Spills of Blood and Body Substances**

- 2473 1. Clean and decontaminate spills of blood or other potentially infectious materials
2474 with a hospital low-level (label claims effectiveness against HBV and HIV) to
2475 intermediate-level disinfectant depending on size of spill and surface porosity (IC)
2476 (CDC 1987, OSHA 1991, OSHA 1997).
2477

2478
2479
2480
2481
2482
2483
2484
2485
2486
2487
2488
2489
2490
2491
2492
2493
2494
2495
2496
2497
2498
2499
2500
2501
2502
2503
2504
2505
2506
2507
2508
2509
2510
2511
2512
2513
2514
2515
2516
2517
2518
2519
2520
2521
2522
2523

E. Carpet and Cloth Furnishings

1. Do not use carpeting and cloth-upholstered furnishings in dental operatories, laboratories, and instrument processing areas (IB) (Garner 1986, Gerson 1994, Suzuki 1984, Skoutelis 1993).

F. Regulated Medical Waste

1. General

- a. Develop a medical waste management program as per federal, state, and local regulations (IC) (OSHA 1991, EPA 1997).
- b. Ensure that DHCP who handle and dispose of potentially infective wastes are trained in appropriate handling and disposal methods and that they are informed of the possible health and safety hazards (IC) (OSHA 1991).

2. Management of Regulated Medical Waste in Dental Health-Care Facilities

- a. Use a leak-resistant biohazard bag to contain “non-sharp” regulated medical waste (IC) (OSHA 1991).
- b. Place sharp items (e.g., needles, scalpel blades, orthodontic bands, broken metal instruments, burs) in puncture-resistant biohazard containers. Containers should be closed immediately prior to removal or replacement to prevent spillage or protrusion of contents during handling, storage, transport, or shipping (IC) (OSHA 1991, CDC HIV 1987, CDC 1989, CDC 1993, CDC NIOSH containers 1998).

3. Discharging Blood or Other Body Fluids to Sanitary Sewers or Septic Tanks

- a. Blood, suctioned fluids or other liquid waste may be poured carefully into a drain connected to a sanitary sewer system, provided that local sewage discharge requirements are met and that the state has declared this to be an acceptable method of disposal (II) (Garner 1986, CDC 1988).

IX. Dental Unit Waterlines, Biofilm, and Water Quality

A. General Recommendations

1. Use water that meets standards set by the EPA for drinking water (fewer than 500 CFU/ml of heterotrophic water bacteria) for routine dental treatment output water (IB, IC) (EPA 1999, APHA 1999).
2. Consult with the dental unit manufacturer for appropriate methods and equipment to maintain the recommended quality of dental water (II) (Shearer 1996).
3. Follow recommendations for monitoring water quality provided by the manufacturer of the unit or waterline treatment product (II).
4. After each patient, discharge water and air for a minimum of 20-30 seconds from any dental device connected to the dental water system that enters the patient’s mouth (e.g., handpieces, ultrasonic scalers, air/water syringe) (II) (CDC 1993).
5. Consult with the dental unit manufacturer on the need for periodic maintenance of anti-retraction mechanisms (IB) (CDC 1993, Bagga 1984).

2524
2525
2526
2527
2528
2529
2530
2531
2532
2533
2534
2535
2536
2537
2538
2539
2540
2541
2542
2543
2544
2545
2546
2547
2548
2549
2550
2551
2552
2553
2554
2555
2556
2557
2558
2559
2560
2561
2562
2563
2564
2565
2566
2567
2568
2569

B. Surgical Irrigation

1. Use sterile saline or sterile water as a coolant/irrigator when performing surgical procedures; use devices specifically designed for the delivery of sterile irrigating fluids (e.g., bulb syringe, single-use disposable products, sterilizable tubing (IB) (Garner Surgical Wound 1985, CDC 1993).

C. Boil-Water Advisories

1. While a boil-water advisory is in effect:

- a. Do not deliver water from the public water system to the patient through the dental operative unit, ultrasonic scaler, or other dental equipment that uses the public water system (IC-related to municipal water utility) (CDC 1995, CDC 1996, Working Group 1997).
- b. Do not use water from the public water system for dental treatment, patient rinsing, or handwashing (IC-related to municipal water utility) (CDC 1995, CDC 1996, Working Group 1997).
- c. Use antimicrobial-containing products for handwashing, that do not require water for use, such as alcohol-based hand rubs. If hands are visibly soiled, used bottled water and soap for handwashing or a detergent-containing towelette (IB, IC) (Larson 1995, OSHA 1991).

2. When the boil-water advisory is cancelled:

- a. Follow guidance given by the local water utility on proper flushing of waterlines. If no guidance is provided, flush dental waterlines and faucets for 1-5 minutes before using for patient care (IC) (2001, EPA lead revisions 2000, EPA lead final 2000, Working Group 1997).
- b. Disinfect dental waterlines as recommended by the dental unit manufacturer (II).

X. Program Evaluation

- A. Dental facilities should establish an infection control program evaluation, based on evaluation of performance indicators at an established frequency (II) (CDC MMWR 1999, IOM 1999).

XI. Dental Handpieces and Other Devices Attached to Air and Waterlines

- A. Clean and heat sterilize handpieces and other intraoral instruments that can be removed from the air and waterlines of dental units between patients (IB, IC) (Pratt 1999, Lewis contamination 1992, Lewis cross-infection 1992, Kolstad 1998, CDC 1993, ADA 1996, FDA 1992).
- B. Follow the manufacturer's instructions for the cleaning, lubrication, and sterilization of handpieces and other intraoral instruments that can be removed from the air and waterlines of dental units (IB) (Kuehne 1992, Andersen 1999, Leonard 1999).
- C. Do not surface-disinfect, use liquid chemical sterilants, or ethylene oxide on handpieces and other intraoral instruments that can be removed from the air and waterlines of dental units (IC) (CDC 1993, FDA 1992, Pratt 1999, Parker 1995).
- D. Do not advise patients to close their lips around the tip of the saliva ejector to evacuate oral fluids (II) (Barbeau 1998, Mann 1996, Watson 1993).

2570
2571
2572
2573
2574
2575
2576
2577
2578
2579
2580
2581
2582
2583
2584
2585
2586
2587
2588
2589
2590
2591
2592
2593
2594
2595
2596
2597
2598
2599
2600
2601
2602
2603
2604
2605
2606
2607
2608
2609
2610
2611
2612
2613
2614
2615

XII. Aseptic Technique for Parenteral Medications

- A. Medication from a single-dose syringe must not be administered to multiple patients even if the needle on the syringe is changed (IA) (ASA 1999).
- B. Use single-dose vials for parenteral additives or medications when possible (II) (ASPH Council 2000, Green 1995).
- C. Do not combine the leftover content of single-use vials for later use (IA) (ASPH Council 2000, Green 1995).
- D. If multiple dose vials are used,
 - 1. Cleanse the access diaphragm of multiple dose vials with 70% alcohol before inserting a device into the vial (IA) (Plott 1990, Arrington 1990).
 - 2. Use a sterile device to access a multiple dose vial and avoid touch contamination of the device before penetrating the access diaphragm (IA) (Plott 1990, Arrington 1990).
 - 3. Refrigerate multiple dose vials after they are opened if recommended by the manufacturer (II).
 - 4. Discard multiple dose vial if sterility is compromised (IA) (Plott 1990, Arrington 1990).
- E. All fluid infusion and administration sets (IV tubings and connections) are single-patient use (IB) (ASA 1999).

XIII. Single-Use (Disposable) Devices

- A. Use single-use devices for one patient only and dispose of them appropriately (IC) (FDA 2001).

XIV. Surgical Procedures

A. When performing surgical procedures:

- 1. Use sterile surgical gloves (IB) (CDC 1988, CDC 1993, Mangram 1999, CDC Hand 2002).
- 2. Perform surgical hand antisepsis using an antimicrobial product (e.g., antimicrobial soap or soap and water followed by alcohol-based hand rub with persistent activity) before donning sterile surgical gloves (IB) (Price 1938, Dewar 1973, Lowbury 1960, Rotter 1999, Widmer 2000, Larson 1995, Garner 1986, Larson 1990, Faoagali 1995).
- 3. Use sterile water or other sterile irrigating solutions (IB) (Garner Surgical Wound 1985, CDC 1993).

XV. Handling of Biopsy Specimens

- A. Place biopsy specimens in a sturdy, leak-proof container during transport labeled with the biohazard symbol (IC) (OSHA 1991, CDC 1993, OSHA CPL 2001).
- B. Clean and disinfect the outside of a biopsy specimen container if it is visibly contaminated, or place it in an impervious bag labeled with the biohazard symbol (IC) (OSHA 1991, CDC 1993).

- 2616 **XVI. Handling of Extracted Teeth**
2617 A. Extracted teeth should be disposed of as regulated medical waste unless returned to
2618 the patient (IC) (OSHA 1991, OSHA CPL 2001).
2619 B. Extracted teeth containing amalgam should not be disposed of in regulated medical
2620 waste intended for incineration (II).
2621 C. For transport to educational institutions, clean and place extracted teeth in a
2622 leakproof, closable container labeled with a biohazard symbol and containing an
2623 appropriate disinfectant (IB, IC) (Tate 1991, OSHA 1991, OSHA CPL 2001).
2624 D. Heat sterilize teeth that do not contain amalgam before they are used for educational
2625 purposes (IB) (Pantera 1990, Parsell 1998, Tate 1991).
2626
2627

2628 **XVII. Dental Laboratory**

- 2629 A. Clean, disinfect, and rinse all dental prostheses and intermediate prosthodontic
2630 materials (e.g., occlusal rims) before and after they are manipulated in the laboratory.
2631 A chemical germicide having at least an intermediate level of activity is appropriate
2632 for such disinfection (IB) (Favero 2001, Rutala 1998, ADA 1996, CDC 1993).
2633 B. Consult with manufacturers regarding the stability of specific materials (e.g.,
2634 impression materials) relative to disinfection procedures (II).
2635 C. Use personal protective equipment until items have been decontaminated (IA, IC)
2636 (OSHA 1991, CDC 1986, CDC HIV 1987, CDC 1988, CDC 1993).
2637 D. When laboratory cases are sent off-site and upon their return, include specific
2638 information regarding the disinfection technique used (e.g., solution used, duration)
2639 (II) (ADA 1996, CDC 1993, Kugel 2000).
2640 E. Clean and heat sterilize heat-tolerant items used in the mouth (e.g., metal impression
2641 trays, face-bow forks) (IB)(ADA 1996, CDC 1993).
2642 F. Laboratory equipment (e.g., burs, polishing points, rag wheels) that touch
2643 contaminated appliances should be disposable or heat sterilized before reuse (IB)
2644 (Favero 2001, Rutala 1998).
2645 G. Follow the manufacturer's instructions for cleaning and disinfecting items that do not
2646 normally contact the patient (e.g., articulators, case pans, lathes) (II).
2647
2648
2649

2650 The CDC Division of Oral Health thanks the subject-matter experts for reviewing a preliminary
2651 draft of this guideline. The opinions of the reviewers might not be reflected in all the
2652 recommendations contained in this document.
2653
2654
2655

2655 References

- 2656
- 2657 Adams D, Bagg J, Limaye M, Parsons K, Absi EG. A clinical evaluation of glove washing and
2658 re-use in dental practice. *J Hosp Infect* 1992;20:153–62.
- 2659 Ahtone J, Goodman RA. Hepatitis B and dental personnel: transmission to patients and
2660 prevention issues. *J Am Dent Assoc* 1983;106:219–22.
- 2661 Albin MS, Bunegin L, Duke ES, Ritter RR, Page CP. Anatomy of a defective barrier: sequential
2662 glove leakage detection in a surgical and dental environment. *Crit Care Med* 1992;20:170–
2663 84.
- 2664 Alfa MJ, Olson N, Degagne P, Hizon R. New low temperature sterilization technologies:
2665 microbicidal activity and clinical efficacy. In: Rutala WA, ed. *Disinfection, sterilization, and*
2666 *antisepsis in health-care*. Champlain, NY: Polyscience Publications, 1998:67–78.
- 2667 Allmers H, Brehler R, Chen Z, Raulf-Heimsoth M, Fels H, Baur X. Reduction of latex
2668 aeroallergens and latex-specific IgE antibodies in sensitized workers after removal of
2669 powdered natural rubber latex gloves in a hospital. *Allergy Clin Immunol* 1998;102:841–6.
- 2670 Alter MJ. The epidemiology of acute and chronic hepatitis C. *Clin Liver Dis* 1997;1:559–68.
- 2671 American Dental Association Council on Scientific Affairs and the ADA Council on Dental
2672 Practice. Infection control recommendations for the dental office and the dental laboratory. *J*
2673 *Am Dent Assoc* 1996;127:672–80.
- 2674 American Dental Association, Council on Scientific Affairs. The dental team and latex
2675 hypersensitivity. *J Am Dent Assoc* 1999;130:257–64.
- 2676 American Hospital Association. Immunization: management advisory on health-care delivery.
2677 Chicago, IL:American Hospital Association;1992.
- 2678 American Public Health Association, American Water Works Association, Water Environment
2679 Foundation. In: Eaton RD, Clesceri LS, Greenberg AE, eds. *Standard methods for the*
2680 *examination of water and wastewater, 20th ed*. Washington, DC: American Public Health
2681 Association;1999:9-1–9-41.
- 2682 American Society of Anesthesiologists. Recommendations for infection control for the practice
2683 of anesthesiology, 2nd ed. 1999. Available at:
2684 <http://www.asahq.org/publicationsAndServices/infectioncontrol.pdf> Accessed January 2003.
- 2685 Amis S, Ruddy M, Kibbler CC, Economides DL, MacLean AB. Assessment of condoms as
2686 probe covers for transvaginal sonography. *J. Clin. Ultrasound* 2000;28:295-8.
- 2687 Andersen HK, Fiehn NE, Larson T. Effect of steam sterilization inside the turbine chambers of
2688 dental turbines. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1999;87:184–8.
- 2689 Andersson T, Bruze M, Bjorkner B. In vivo testing of the protection of gloves against acrylates
2690 in dentin-bonding systems on patients with known contact allergy to acrylates. *Contact*
2691 *Dermatitis* 1999;41:254–9.
- 2692 Andres MT, Tejerina JM, Fierro JF. Reliability of biologic indicators in a mail-return
2693 sterilization-monitoring service: a review of 3 years. *Quintessence Int* 1995;26:865–70.
- 2694 Archibald LK, Corl A, Shah B, et.al. *Serratia marcescens* outbreak associated with extrinsic
2695 contamination of 1% chlorxylenol soap. *Infect Control Hosp Epidemiol* 1997;18:704–9.
- 2696 Arduino MJ, Favero MS. Microbiologic aspects of hemodialysis systems. In: *Dialysis*. Arlington,
2697 VA.: Association for the Advancement of Medical Instrumentation;1998:17–23. AAMI
2698 Standards and Recommended Practices;vol. 3.
- 2699 Arnow PM, Chou T, Weil D, Shapiro EN, Kretzschmar C. Nosocomial Legionnaires' disease
2700 caused by aerosolized tap water from respiratory devices. *J Infect Dis* 1982;146:460–7.

2701 Arrington ME, Gabbert KC, Mazgaj PW, Wolf MT. Multidose vial contamination in anesthesia.
2702 Aana J 1990;58:462–6.

2703 ASPH Council on Professional Affairs. ASHP guidelines on quality assurance for pharmacy-
2704 prepared sterile products. *Am J Health Syst Pharm* 2000;57:1150–69.

2705 Association for the Advancement of Medical Instrumentation. Good hospital practice: Steam
2706 sterilization and sterility assurance. AAMI. Arlington, VA, 1993.

2707 Association for the Advancement of Medical Instrumentation. Flash sterilization: steam
2708 sterilization of patient care items for immediate use. Arlington, VA: AAMI, 1996 in
2709 ANSI/AAMI ST37-1996.

2710 Association for the Advancement of Medical Instrumentation. Safe use and handling of
2711 glutaraldehyde-based products in health care facilities. Arlington, VA: AAMI, 1996 in
2712 ANSI/AAMI ST58-1996.

2713 Association for the Advancement of Medical Instrumentation. Steam sterilization and sterility
2714 assurance using table-top sterilizers in office-based, ambulatory-care medical, surgical, and
2715 dental facilities. Arlington, VA: AAMI, 1998 in ANSI/AAMI ST42-1998.

2716 Association for the Advancement of Medical Instrumentation. Ethylene oxide sterilization in
2717 healthcare facilities: Safety and effectiveness. AAMI. Arlington, VA, 1999.

2718 Association for the Advancement of Medical Instrumentation. Steam sterilization and sterility
2719 assurance in health care facilities. Arlington, VA: AAMI, 2002 in ANSI/AAMI ST46-2002.

2720 Association of Perioperative Registered Nurses. AORN standards and recommended practices
2721 for perioperative nursing. Denver, CO: AORN, 1987. Section III:14.1-III:14.11.

2722 Association of Perioperative Registered Nurses. AORN Recommended Practices Committee.
2723 Recommended practices for surgical hand scrubs. *AORN J* 1999;69:842, 845–50.

2724 Association of Perioperative Registered Nurses. Recommended practices for sterilization in
2725 perioperative practice settings. In: Fogg D, Parker N, Shevlin D, eds. 2002 standards,
2726 recommended practices, and guidelines, Denver, CO: AORN, 2002:333–42.

2727 Atlas RM, Williams JF, Huntington MK. Legionella contamination of dental-unit waters. *Appl*
2728 *Environ Microbiol* 1995;61:1208–13.

2729 Avery CM, Hjort A, Walsh S, Johnson PA. Glove perforation during surgical extraction of
2730 wisdom teeth. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1998;86:23–5.

2731 Ayliffe GAJ, Fraise AP, Geddes AM, Mitchell K, eds. Control of hospital infections: a practical
2732 handbook. 4th ed. London, England: Arnold, 2000:115–18.

2733 Bagga BS, Murphy RA, Anderson AW, Punwani I. Contamination of dental unit cooling water
2734 with oral microorganisms and its prevention. *J Am Dent Assoc* 1984;109:712–6.

2735 Ballantyne B. Toxicology of glutaraldehyde: review of studies and human health effects.
2736 Danbury, CT.: Union Carbide, 1995.

2737 Barbeau J, Tanguay R, Faucher E, et al. Multiparametric analysis of waterline contamination in
2738 dental units. *Appl Environ Microbiol* 1996;62:3954–9.

2739 Barbeau J, ten Bokum L, Gauthier C, Prevost AP. Cross-contamination potential of saliva
2740 ejectors used in dentistry. *J Hosp Infect* 1998;40:303–11.

2741 Baumann MA, Rath B, Fischer JH, Iffland R. The permeability of dental procedure and
2742 examination gloves by an alcohol based disinfectant. *Dent Mater* 2000;16:139–44.

2743 Baumgardner CA, Maragos CS, Walz J, Larson E. Effects of nail polish on microbial growth of
2744 fingernails. Dispelling sacred cows. *AORN J* 1993;58:84–8.

2745 Baur X, Jager D. Airborne antigens from latex gloves. *Lancet* 1990;335:912.

2746 Baur X, Chen Z, Allmers H. Can a threshold limit value for natural rubber latex airborne
2747 allergens be defined? *J Allergy Clin Immunol* 1998;101(1 pt 1):24–7.

2748 Begg N, O’Mahony M, Penny P, Richardson AE. *Mycobacterium chelonae* associated with a
2749 hospital hydrotherapy pool. *Community Med* 1986;8:348–50.

2750 Bell DM. Occupational risk of human immunodeficiency virus infection in health-care
2751 personnel: an overview. *Am J Med* 1997;102(suppl 5B):9–15.

2752 Beltrami EM, Kozak A, Williams IT, Saekhou AM, Kalish ML, Nainan OV, et al. Transmission
2753 of HIV and hepatitis C virus from a nursing home patient to a health care worker. *Am J Infect*
2754 *Control* (in press)

2755 Berky ZT, Luciano WJ, James WD. Latex glove allergy: a survey of the US Army Dental Corps.
2756 *JAMA* 1992;268:2695–7.

2757 Berndt U, Wigger-Alberti W, Gabard B, Elsner P. Efficacy of a barrier cream and its vehicle as
2758 protective measures against occupational irritant contact dermatitis. *Contact Dermatitis*
2759 2000;42:77–80.

2760 Bernoulli C, Siegfried J, Baumgartner G, et al. Danger of accidental person-to-person
2761 transmission of Creutzfeldt-Jakob disease by surgery. *Lancet* 1977;1:478–9.

2762 Blanquet-Grossard F, Sazdovitch V, Jean A, et al. Prion protein is not detectable in dental pulp
2763 from patients with Creutzfeldt-Jakob disease. *J Dent Res* 2000;79:700.

2764 Bloomfield SF, Smith-Burchnell CA, Dalgleish AG. Evaluation of hypochlorite-releasing
2765 disinfectants against the human immunodeficiency virus (HIV). *J Hosp Infect* 1990;15:273–
2766 8.

2767 Bolan G, Reingold AL, Carson LA, et al. Infections with *Mycobacterium chelonae* in patients
2768 receiving dialysis and using processed hemodialyzers. *J Infect Dis* 1985;152:1013–19.

2769 Bolyard EA, Hospital Infection Control Practices Advisory Committee. Guidelines for infection
2770 control in health care personnel, 1998. *Am J Infect Control* 1998;26:289–354.

2771 Bond WW. Biological indicators for a liquid chemical sterilizer: a solution to the instrument
2772 reprocessing problem? *Infect Control Hosp Epidemiol* 1993;14:309–12.

2773 Breiman RF, Fields BS, Sanden GN, Volmer L, Meier A, Spika JS. Association of shower use
2774 with Legionnaires’ disease. Possible role of amoebae. *JAMA* 1990;263:2924–26.

2775 Brown AR, Papasian CJ, Shultz P, Theisen FC, Shultz RE. Bacteremia and intraoral suture
2776 removal: can an antimicrobial rinse help? *J Am Dent Assoc* 1998;129:1455–61.

2777 Brown P, Gajdusek DC, Gibbs CJ Jr, Asher DM. Potential epidemic of Creutzfeldt-Jakob disease
2778 from human growth hormone therapy. *N Engl J Med* 1985;313:728–31.

2779 Brown P, Gibbs CJ Jr, Rodgers-Johnson P, et al. Human spongiform encephalopathy: the
2780 National Institutes of Health series of 300 cases of experimentally transmitted disease. *Ann*
2781 *Neurol* 1994;35:513–29.

2782 Brown P. Environmental causes of human spongiform encephalopathy. In: Baker HF, Ridley
2783 RM, eds. *Prion diseases*. Totowa, NJ: Humana Press Inc, 1996:139–54.

2784 Bubak ME, Reed CE, Fransway AF, et al. Allergic reactions to latex among health-care workers.
2785 *Mayo Clin Proc* 1992;67:1075–9.

2786 Burke FJ, Wilson NH. The incidence of undiagnosed punctures in non-sterile gloves. *Br Dent J*
2787 1990;168:67–71.

2788 Burke FJ, Baggett FJ, Lomax AM. Assessment of the risk of glove puncture during oral surgery
2789 procedures. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1996;82:18–21.

2790 Cappuccio WR, Lees PS, Breyse PN, Margolick JB. Evaluation of integrity of gloves used in a
2791 flow cytometry laboratory. *Infect Control Hosp Epidemiol* 1997;18:423–5.

2792 Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in
2793 health care workers after percutaneous exposure. Center for Disease Control and Prevention
2794 Needlestick Surveillance Group. N Engl J Med 1997;337:1485-90.
2795 Cardo DM, Sehulster LM. Central sterile supply. In: Mayhall CG, ed. Infect. Control and Hosp.
2796 Epidemiol. Philadelphia: Lippincott Williams & Wilkins, 1999:1023-30.
2797 Carlton JE, Dodson TB, Cleveland JL, Lockwood SA. Percutaneous injuries during oral and
2798 maxillofacial surgery procedures. J Oral Maxillofac Surg 1997;55:553-6.
2799 Carp RI. Transmission of scrapie by oral route: effect of gingival scarification. Lancet
2800 1982;1:170-1.
2801 Casewell M, Phillips I. Hands as route of transmission for *Klebsiella* species. Br Med J
2802 1977;2:1315-7.
2803 CDC. Recommended infection control practices for dentistry. MMWR 1986;35:237-42.
2804 CDC. Recommended infection control practices for dentistry, 1993. MMWR 1993;41(No. RR-
2805 8):1-12.
2806 CDC Update: Fatal degenerative neurologic disease in patients who received pituitary-derived
2807 human growth hormone. MMWR 1985;34:359-60, 365-6.
2808 CDC. Epidemiologic notes and reports: Hepatitis B among dental patients -- Indiana. MMWR
2809 1985;34:73-5.
2810 CDC. Recommendation for prevention of HIV transmission in health-care settings. MMWR
2811 1987;36(suppl No. 2S):6S-7S.
2812 CDC. Outbreak of hepatitis B associated with an oral surgeon, New Hampshire. MMWR
2813 1987;36:132-3.
2814 CDC. Rapidly progressive dementia in a patient who received a cadaveric dura mater graft.
2815 MMWR 1987;36:49-50, 55.
2816 CDC. Recommendations for prevention of HIV transmission in health-care settings. MMWR
2817 1987;36(No. 2S): 1S-18S.
2818 CDC. Update: universal precautions for prevention of transmission of human immunodeficiency
2819 virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR
2820 1988;37:377-82, 387-8.
2821 CDC. Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis
2822 B virus to health-care and public-safety workers. MMWR 1989;38(No. S-6):1-36.
2823 CDC. Epidemiologic notes and reports: Legionnaires' disease outbreak associated with a grocery
2824 store mist machine-Louisiana, 1989. MMWR 1990;39:108-10.
2825 CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United
2826 States through universal childhood vaccination. MMWR 1991;40(No. RR-13).
2827 CDC. Recommendations for preventing transmission of human immunodeficiency virus and
2828 hepatitis B virus to patients during exposure-prone invasive procedures. MMWR
2829 1991;40(RR-8):1-8.
2830 CDC. Investigations of patients who have been treated by HIV-infected health-care workers--
2831 United States. MMWR 1993;42:329-31, 337.
2832 CDC. Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health-care
2833 facilities, 1994. MMWR 1994;43(No. RR-13).
2834 CDC. Self-reported tuberculin skin testing among IHS and BOP dentists. MMWR 1994;43:209-
2835 11.

2836 CDC. Assessing the public health threat associated with waterborne cryptosporidiosis: report of a
2837 workshop. MMWR 1995;44:1–19. Available at:
2838 <http://www.cdc.gov/mmwr/preview/mmwrhtml/00037331.htm>. Accessed January 2003.
2839 CDC. Surveillance for Creutzfeldt-Jakob disease-United States. MMWR 1996;45:665–8.
2840 CDC. Surveillance for waterborne-disease outbreaks-United States, 1993-1994. MMWR
2841 1996;45(No. SS-1):1–33. Available at:
2842 <http://www.cdc.gov/mmwr/preview/mmwrhtml/00040818.htm>. Accessed January 2003.
2843 CDC. Update: provisional Public Health Service recommendations for chemoprophylaxis after
2844 occupational exposure to HIV. MMWR 1996;45(No. 22):468–72.
2845 CDC. Immunization of health-care workers—recommendations of the Advisory Committee on
2846 Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory
2847 Committee (HICPAC). MMWR 1997;46(No. RR-18):1–42.
2848 CDC. Evaluation of safety devices for preventing percutaneous injuries among health-care
2849 workers during phlebotomy procedures – Minneapolis, St. Paul, New York City, and San
2850 Francisco, 1993-1995. MMWR 1997;46:20–5.
2851 CDC. Evaluation of blunt suture needles in preventing percutaneous injuries among health-care
2852 workers during gynecologic surgical procedures – New York City, March 1993-June 1994.
2853 MMWR 1997;46:25–9.
2854 CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and
2855 HCV-related chronic disease. MMWR 1998;47(No. RR-19):1–38.
2856 CDC. Public Health Service guidelines for the management of health-care worker exposure to
2857 HIV and recommendations for postexposure prophylaxis. MMWR 1998;47(No. RR-7):1–33.
2858 CDC. Prevention and treatment of tuberculosis among patients infected with human
2859 immunodeficiency virus: principles of therapy and revised recommendations. MMWR
2860 1998;47(No. RR-20).
2861 CDC. Framework for Program Evaluation in Public Health. MMWR 1999;58(No. RR-11).
2862 CDC. Recommendations for preventing transmission among chronic hemodialysis patients.
2863 MMWR 2001;50(No. RR-5):1-43.
2864 CDC. Updated US Public Health Service guidelines for the management of occupational
2865 exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis.
2866 MMWR 2001;50(No. RR-11).
2867 CDC. Guideline for hand hygiene in health-care settings: Recommendations of the Healthcare
2868 Infection Control Practices Advisory Committee and the HICPAAC/SHEA/APIC/IDSA
2869 Hand Hygiene Task Force. MMWR 2002;51(No. RR-16):1-46.
2870 CDC. Probable Variant Creutzfeldt-Jakob disease in a U.S. Resident -- Florida, 2002. MMWR
2871 2002;51(41):927–9.
2872 CDC. New variant CJD [fact sheet]. Available at:
2873 http://www.cdc.gov/ncidod/diseases/cjd/cjd_fact_sheet.htm. Accessed January 2003.
2874 CDC. Preventing occupational HIV transmission to health-care personnel [fact sheet]. Available
2875 at <http://www.cdc.gov/hiv/pubs/facts/hcwprev.htm>. Accessed January 2003.
2876 CDC. CDC and Florida Department of Health investigate a likely case of new variant Creutzfeldt
2877 Jakob disease in a U.K. citizen residing in the U.S. Available at:
2878 <http://www.cdc.gov/od/oc/media/pressrel/r020418.htm>. Accessed January 2003.
2879 CDC. NIOSH Alert (June 1997). Preventing allergic reactions to natural rubber latex in the
2880 workplace. Cincinnati, OH: US Department of Health and Human Services, Public Health

2881 Service, CDC, 1997. DHHS (NIOSH) Publication No. 97-135. Available at:
 2882 <http://www.cdc.gov/niosh/latexalt.html> Accessed January 2003.

2883 CDC NIOSH. Selecting, evaluating, and using sharps disposal containers. Cincinnati, OH: US
 2884 Department of Health and Human Services, Public Health Service, CDC, 1998. DHHS
 2885 (NIOSH) Publication No. 97-111.

2886 CDC. NIOSH Alert (November 1999): Preventing needlestick injuries in health care settings.
 2887 Cincinnati, OH: US Department of Health and Human Services, Public Health Service, CDC,
 2888 1999. DHHS (NIOSH) Publication No. 2000-108. Available at:
 2889 <http://www.cdc.gov/niosh/2000-108.html>. Accessed January 2003.

2890 CDC NIOSH. Glutaraldehyde. Occupational hazards in hospitals. Cincinnati, OH: US
 2891 Department of Health and Human Services, Public Health Service, CDC, 2001. DHHS
 2892 (NIOSH) Publication No. 2001-115.

2893 Challacombe SJ, Fernandes LL. Detecting Legionella pneumophila in water systems: a
 2894 comparison of various dental units. *J Am Dent Assoc* 1995;126:603-8.

2895 Chamberland ME. HIV transmission from health care worker to patient: what is the risk? *Ann*
 2896 *Intern Med* 1992;116:871-3.

2897 Checchi L, Montebugnoli L, Samaritani S. Contamination of the turbine air chamber: a risk of
 2898 cross infection. *J Clin Periodontol* 1998;25:607-11.

2899 Chiarello LA, Bartley J. Prevention of blood exposure in health-care personnel. *Semin Infect*
 2900 *Control* 2001;1:30-43.

2901 Ciesielski C, Marianos D, Ou CY, et al. Transmission of human immunodeficiency virus in a
 2902 dental practice. *Ann Intern Med* 1992;116:798-805.

2903 Clark A. Bacterial colonization of dental units and the nasal flora of dental personnel. *Proc Roy*
 2904 *Soc Med* 1974;67(12 pt 1):1269-70.

2905 Cleveland JL, Gooch BF, Bolyard EA, Simone PM, Mullan RJ, Marianos DW. TB infection
 2906 control recommendations from the CDC, 1994: considerations for dentistry. United States
 2907 Centers for Disease Control and Prevention. *J Am Dent Assoc* 1995;126:593-9.

2908 Cleveland JL, Lockwood SA, Gooch BF, et al. Percutaneous injuries in dentistry: an
 2909 observational study. *J Am Dent Assoc* 1995;126:745-51.

2910 Cleveland JL, Siew C, Lockwood SA, Gruninger SE, Gooch BF, Shapiro CN. Hepatitis B
 2911 vaccination and infection among U.S. dentists, 1983-1992. *J Am Dent Assoc*
 2912 1996;127:1385-90.

2913 Cleveland JL, Gooch BF, Lockwood SA. Occupational blood exposure in dentistry: a decade in
 2914 review. *Infect Control Hosp Epidemiol* 1997;18:717-21.

2915 Cleveland JL, Gooch BF, Shearer BG, Lyerla RL. Risk and prevention of hepatitis C virus
 2916 infection. Implications for dentistry. *J Am Dent Assoc* 1999;130:641-7.

2917 Cochran MA, Miller CH, Sheldrake MA. The efficacy of the rubber dam as a barrier to the
 2918 spread of microorganisms during dental treatment. *J Am Dent Assoc* 1989;119:141-4.

2919 Collins S, Law MG, Fletcher A, Boyd A, Kaldor J, Masters CL. Surgical treatment and risk of
 2920 sporadic Creutzfeldt-Jakob disease: a case-control study. *Lancet* 1999;353:693-7.

2921 Cooper BW, Krusell A, Tilton RC, Goodwin R, Levitz RE. Seroprevalence of antibodies to
 2922 hepatitis C virus in high-risk hospital personnel. *Infect Control Hosp Epidemiol* 1992;13:82-
 2923 5.

2924 Crawford JJ. Clinical asepsis in dentistry. Mesquite, TX: Oral Medicine Press, 1987:27-35.

2925 Crawford JJ, Broderius C. Control of cross-infection risks in the dental operatory: prevention of
 2926 water retraction by bur cooling spray systems. *J Am Dent Assoc* 1988;116:685-7.

- 2927 Dajani AS, Bisno AL, Chung KJ, et al. Prevention of bacterial endocarditis: Recommendations
2928 by the American Heart Association. JAMA 1990;264:2919–22.
- 2929 Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: Recommendations
2930 by the American Heart Association. JAMA 1997;277:1794–801.
- 2931 DeGroot-Kosolcharoen J, Jones JM. Permeability of latex and vinyl gloves to water and blood.
2932 Am J Infect Control 1989;17:196–201.
- 2933 Dewar NE, Gravens DL. Effectiveness of sepiisol antiseptic foam as a surgical scrub agent. Appl
2934 Microbiol 1973;26:544–9.
- 2935 Dillard SF, Hefflin B, Kaczmarek RG, Petsonk EL, Gross TP. Health effects associated with
2936 medical glove use. Reports from the FDA adverse effect surveillance program. AORN J
2937 2002;76:88–96.
- 2938 Dodds RD, Guy PJ, Peacock AM, Duffy SR, Barker SG, Thomas MH. Surgical glove
2939 perforation. Br J Surg 1988;75:966–8.
- 2940 Doebbeling BN, Pfaller MA, Houston AK, Wenzel RP. Removal of nosocomial pathogens from
2941 the contaminated glove. Ann Intern Med 1988;109:394–8.
- 2942 Druce JD, Jardine D, Locarnini SA, Birch CJ. Susceptibility of HIV to inactivation by
2943 disinfectants and ultraviolet light. J Hosp Infect 1995;30:167–80.
- 2944 Duffy P, Wolf J, Collins G, DeVoe AG, Streeten B, Cowen D. Possible person-to-person
2945 transmission of Creutzfeldt-Jakob disease. N Engl J Med 1974;290:692–3.
- 2946 Epstein JB, Rea G, Sibau L, Sherlock CH, Le ND. Assessing viral retention and elimination in
2947 rotary dental instruments. J Am Dent Assoc 1995;126:87–92.
- 2948 Fallon RJ, Rowbotham TJ. Microbiological investigations into an outbreak of Pontiac fever due
2949 to *Legionella micdadei* associated with use of a whirlpool. J Clin Pathol 1990;43:479–83.
- 2950 Faoagali J, Fong J, George N, Mahoney P, O'Rourke V. Comparison of the immediate, residual,
2951 and cumulative antibacterial effects of Novaderm R,* Novascrub R,* Betadine Surgical
2952 Scrub, Hibiclens, and liquid soap. Am J Infect Control 1995;23:337–43.
- 2953 Favero MS. Current issues in hospital hygiene and sterilization technology. J Infect Control
2954 (Asia Pacific Edition) 1998;1:8–10.
- 2955 Favero MS. Developing indicators for sterilization. In: Rutala W, ed. Disinfection, sterilization,
2956 and antisepsis in health care. Washington, DC: Association for Professionals in Infection
2957 Control and Epidemiology, Inc., 1998:119–32.
- 2958 Favero MS, Bond WW. Chemical disinfection of medical and surgical material. In: Block SS,
2959 ed. Disinfection, sterilization and preservation, 4th ed. Philadelphia: Lea & Febiger,
2960 2001:881–917.
- 2961 Field EA, McGowan P, Pearce PK, Martin MV. Rings and watches: should they be removed
2962 prior to operative dental procedures? J Dent 1996;24:65–9.
- 2963 Fine DH, Furgang D, Korik I, Olshan A, Barnett ML, Vincent JW. Reduction of viable bacteria
2964 in dental aerosols by preprocedural rinsing with an antiseptic mouthrinse. Am J Dent
2965 1993;6:219–21.
- 2966 Fine DH, Mendieta C, Barnett ML, et al. Efficacy of preprocedural rinsing with an antiseptic in
2967 reducing viable bacteria in dental aerosols. J Periodontol 1992;63:821–4.
- 2968 Fine DH, Yip J, Furgang D, Barnett ML, Olshan AM, Vincent J. Reducing bacteria in dental
2969 aerosols: pre-procedural use of an antiseptic mouth rinse. J Am Dent Assoc 1993;124:56–8.
- 2970 Fisher AA. Allergic contact reactions in health personnel. J Allergy Clin Immunol 1992;90:729–
2971 38.

- 2972 Foca M, Jakob K, Whittier S, et al. Endemic *Pseudomonas aeruginosa* infection in a neonatal
2973 intensive care unit. *N Engl J Med* 2000;343:695–700.
- 2974 Fotos PG, Westfall HN, Snyder IS, Miller RW, Mutchler BM. Prevalence of Legionella-specific
2975 IgG and IgM antibody in a dental clinic population. *J Dent Res* 1985;64:1382–5.
- 2976 Fritz S, Hust MH, Ochs C, Gratwohl I, Staiger M, Braun B. Use of a latex cover sheath for
2977 transesophageal echocardiography (TEE) instead of regular disinfection of the echoscope?
2978 *Clin. Cardiol.* 1993;16:737-40.
- 2979 Gajdusek DC, Zigas V. Degenerative disease of the central nervous system in New Guinea. The
2980 endemic occurrence of “kuru” in the native population. *N Engl J Med* 1957;257:974–8.
- 2981 Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. *Science*
2982 1977;197:943–60.
- 2983 Gani JS, Anseline PF, Bissett RL. Efficacy of double versus single gloving in protecting the
2984 operating team. *Aust NZ J Surg* 1990;60:171–5.
- 2985 Garbe PL, Davis BJ, Weisfeld JS, et al. Nosocomial Legionnaires disease: epidemiologic
2986 demonstration of cooling towers as a source. *JAMA* 1985;254:521–4.
- 2987 Garner JS, Favero MS. Guideline for handwashing and hospital environmental control. Atlanta,
2988 GA: US Department of Health and Human Services, Public Health Service, Centers for
2989 Disease Control, 1985. Also Garner JS, Favero MS. CDC guideline for handwashing and
2990 hospital environmental control, 1985. *Infect Control* 1986;7:231–43.
- 2991 Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control
2992 Practices Advisory Committee. *Infect Control Hosp Epidemiol* 1996;17:53–80.
- 2993 Garner JS. CDC guideline for prevention of surgical wound infections, 1985. Supersedes
2994 guideline for prevention of surgical wound infections published in 1982 (Originally
2995 published in November 1985). Revised. *Infect Control* 1986;7:193–200.
- 2996 Gerberding JL, Littell C, Tarkington A, Brown A, Schecter WP. Risk of exposure of surgical
2997 personnel to patients’ blood during surgery at San Francisco General Hospital. *N Engl J Med*
2998 1990;322:1788–93.
- 2999 Gerberding JL. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus,
3000 hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood
3001 exposure: final report from a longitudinal study. *J Infect Dis* 1994;170:1410–7.
- 3002 Gerson SL, Parker P, Jacobs MR, Creger R, Lazarus HM. Aspergillosis due to carpet
3003 contamination. *Infect Control Hosp Epidemiol* 1994;15(4 pt 1):221–3.
- 3004 Gershon RR, Karkashian CD, Grosch JW, et al. Hospital safety climate and its relationship with
3005 safe work practices and workplace exposure incidents. *Am J Infect Control* 2000;28:211–
3006 21. Gooch B, Marianos D, Ciesielski C, et al. Lack of evidence for patient to patient
3007 transmission of HIV in a dental practice. *J Am Dent Assoc* 1993;124:38–44.
- 3008 Gooch BF, Cardo DM, Marcus R, et al. Percutaneous exposures to HIV–infected blood among
3009 dental workers enrolled in the CDC Needlestick Study. *J Am Dent Assoc* 1995;126:1237–42.
- 3010 Gooch BF, Siew C, Cleveland JL, Gruninger SE, Lockwood SA, Joy ED. Occupational blood
3011 exposure and HIV infection among oral and maxillofacial surgeons. *Oral Surg Oral Med Oral*
3012 *Pathol Oral Radiol Endod* 1998;85:128–34.
- 3013 Goodman RA, Ahtone JL, Finton RJ. Hepatitis B transmission from dental personnel to patients:
3014 unfinished business. *Ann Intern Med* 1982;96:119.
- 3015 Goodwin D, Fannin SL, McCracken BB. An oral surgeon-related hepatitis B outbreak. *Calif*
3016 *Morb* 1976;14.

- 3017 Green KA, Shouldachi B, Schoer K, Moro D, Blend R, McGeer A. Gadolinium-based MR
3018 contrast media: potential for growth of microbial contaminants when single vials are used for
3019 multiple patients. *Am J Roentgenol* 1995;165:669–71.
- 3020 Greene R, Miele DJ, Slavik NS. Technical assistance manual: state regulatory oversight of
3021 medical waste treatment technologies, 2nd ed. State and Territorial Association on
3022 Alternative Treatment Technologies;1994.
- 3023 Greene VW. Control of sterilization process. In: Russell AD, Hugo WB, Ayliffe GAF, eds.
3024 Principles and practice of disinfection, preservation, and sterilization. Oxford, England.
3025 Blackwell Scientific Publications, 1992:605–24.
- 3026 Grohskopf LA, Roth VR, Feikin DR, et al. *Serratia liquefaciens* bloodstream infections from
3027 contamination of epoetin alfa at a hemodialysis center. *N Engl J Med* 2001;344:1491–7.
- 3028 Gruninger SE, Siew C, Chang SB, et al. Human immunodeficiency virus type I. Infection among
3029 dentists. *J Am Dent Assoc* 1992;123:57–64.
- 3030 Gruninger SE, Siew C, Azzolin KL, Meyer DM. Update of hepatitis C infection among dental
3031 professionals (abstract 1825). *J Dent Res* 2001;80 (AADR Abstracts):264.
- 3032 Hadler SC, Sorley DL, Acree KH, et al. An outbreak of hepatitis B in a dental practice. *Ann*
3033 *Intern Med* 1981;95:133–8.
- 3034 Hanson PJ, Gor D, Jeffries DJ, Collins JV. Chemical inactivation of HIV on surfaces. *BMJ*
3035 1989;298:862–64.
- 3036 Harte J, Davis R, Plamondon T, Richardson B. The influence of dental unit design on
3037 percutaneous injury. *J Am Dent Assoc* 1998;129:1725–31.
- 3038 Health Resources and Services Administration, Bureau of Health Professions. U.S. Health
3039 Workforce Personnel Factbook. Rockville, MD: Health Resources and Services
3040 Administration, 2000. Available at: <ftp://ftp.hrsa.gov/bhpr/nationalcenter/factbook/fb601.pdf>
3041 Accessed January 2003.
- 3042 Hedderwick SA, McNeil SA, Lyons MJ, Kauffman CA. Pathogenic organisms associated with
3043 artificial fingernails worn by health-care workers. *Infect Control Hosp Epidemiol*
3044 2000;21:505–9.
- 3045 Heilman DK, Jones RT, Swanson MC, Yunginger JW. A prospective, controlled study showing
3046 that rubber gloves are the major contributor to latex aeroallergen levels in the operating
3047 room. *J Allergy Clin Immunol* 1996;98:325–30.
- 3048 Henry B, Plante-Jenkins C, Ostrowska K. An outbreak of *Serratia marcescens* associated with
3049 the anesthetic agent propofol. *Am J Infect Control* 2001;29:312–5.
- 3050 Hermes CB, Spackman GK, Dodge WW, Salazar A. Effect of powder-free latex examination
3051 glove use on airborne powder levels in a dental school clinic. *J Dent Educ* 1999;63:814–20.
- 3052 Herwaldt LA, Pottinger JM, Carter CD, Barr BA, Miller ED. Exposure workups. *Infect Control*
3053 *Hosp Epidemiol* 1997;18:850–71.
- 3054 Hignett M, Claman P. High rates of perforation are found in endovaginal ultrasound probe
3055 covers before and after oocyte retrieval for *in vitro* fertilization-embryo transfer. *J. Assist.*
3056 *Reprod. Genet.* 1995;12:606-9.
- 3057 Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt-Jakob disease and
3058 other human prion diseases with tonsil biopsy specimens. *Lancet* 1999;353:183–9.
- 3059 Hobson DW, Woller W, Anderson L, Guthery E. Development and evaluation of a new alcohol-
3060 based surgical hand scrub formulation with persistent antimicrobial characteristics and
3061 brushless application. *Am J Infect Control* 1998;26:507–12.

3062 Hokett SD, Honey JR, Ruiz F, Baisden MK, and Hoen MM. Assessing the effectiveness of direct
3063 digital barrier sheaths and finger cots. JADA 2000. 131;463-467.

3064 Hollyoak V, Allison D, Summers J. *Pseudomonas aeruginosa* wound infection associated with a
3065 nursing home's whirlpool bath. Commun Dis Rep Rev 1995;5(7):R100-2.

3066 Hood E, Stout N, Catto B. Flash sterilization and neurosurgical site infections: Guilt by
3067 association. Am. J. Infect. Control 1997;25:156.

3068 Hunt LW, Fransway AF, Reed CE, et al. An epidemic of occupational allergy to latex involving
3069 health care workers. J Occup Environ Med 1995;37:1204-9.

3070 Ingrosso L, Pisani F, Pocchiari M. Transmission of the 263K scrapie strain by the dental route. J
3071 Gen Virol 1999;80(pt 11):3043-7.

3072 Institute of Medicine. To err is human;building a safe health system. National Academy Press.
3073 Washington, D.C. 1999.

3074 Ippolito G, Puro V, De Carli G.. The risk of occupational human immunodeficiency virus in
3075 health care workers. Italian Multicenter Study. The Italian Study Group on Occupational
3076 Risk of HIV Infection. Arch Intern Med 1993;153:1451-8.

3077 Ippolito G, Puro V, Petrosillo N, De Carli G, Micheloni G, Magliano E. Simultaneous infection
3078 with HIV and hepatitis C virus following occupational conjunctival blood exposure. JAMA
3079 1998;280:28.

3080 Jacobs RL, Thorner RE, Holcomb JR, Schwietz LA, Jacobs FO. Hypersensitivity pneumonitis
3081 caused by *Cladosporium* in an enclosed hot-tub area. Ann Intern Med 1986;105:204-6.

3082 Jacobson G, Thiele JE, McCune JH, Farrell LD. Handwashing: ring-wearing and number of
3083 microorganisms. Nurs Res 1985;34:186-8.

3084 Johnson RT, Gibbs CJ Jr. Creutzfeldt-Jakob disease and related transmissible spongiform
3085 encephalopathies. N Engl J Med 1998;339:1994-2004.

3086 Joint Commission for the Accreditation of Healthcare Organizations. Comprehensive
3087 accreditation manual for hospitals, JCAHO, Chicago, IL. 2001.

3088 Jones F, Bartlett CL. Infections associated with whirlpools and spas. Soc Appl Bacteriol Symp
3089 Ser 1985;14:61S-6S.

3090 Jordan SL, Stowers MF, Trawick EG, Theis AB. Glutaraldehyde permeation: choosing the
3091 proper glove. Am J Infect Control 1996;24:67-9.

3092 Joslyn LJ. Sterilization by heat. In: Block SS, ed. Disinfection, sterilization and preservation, 4th
3093 ed. Philadelphia: Lea & Febiger, 2001:695-728.

3094 Kabara JJ, Brady MB. Contamination of bar soaps under "in-use" conditions. J Environ Pathol
3095 Toxicol Oncol 1984;5(4-5):1-14.

3096 Kahn RL, Donovan TE, Chee WW. Interaction of gloves and rubber dam with a poly (vinyl
3097 siloxane) impression material: a screening test. Int J Prosthodont 1989;2:342-46.

3098 Kaminski JC. *Cryptosporidium* and the public water supply. N Engl J Med 1994;331:1529-30.

3099 Keene J. Medical waste management: public pressure versus sound science. Hazard Mat Control
3100 1989:29-36.

3101 Keene JH. Medical waste: a minimal hazard. Infect Control Hosp Epidemiol 1991;12:682-5.

3102 Kelstrup J, Funder-Nielsen T, Theilade J. Microbial aggregate contamination of water lines in
3103 dental equipment and its control. Acta Pathol Microbiol Scand [B] 1977;85:177-83.

3104 King HO. Kuru. Epidemiological developments. Lancet 1975;2:761-3.

3105 Klein RS, Phelan JA, Freeman K, et al. Low occupational risk of human immunodeficiency virus
3106 infection among dental professionals. N Engl J Med 1988;318:86-90.

- 3107 Klein RC, Party E, Gershey EL. Virus penetration of examination gloves. *Biotechniques*
3108 1990;9:196–9.
- 3109 Klein RS, Freeman K, Taylor PE, Stevens CE. Occupational risk for hepatitis C virus infection
3110 among New York City dentists. *Lancet* 1991;338:1539–42.
- 3111 Klyn SL, Cummings DE, Richardson BW, Davis RD. Reduction of bacteria-containing spray
3112 produced during ultrasonic scaling. *Gen Dent* 2001;49:648–52.
- 3113 Kolstad RA. How well does the Chemiclave sterilize handpieces? *J Am Dent Assoc*
3114 1998;129:985–91.
- 3115 Kondo K, Kuroiwa Y. A case control study of Creutzfeldt-Jakob disease: association with
3116 physical injuries. *Ann Neurol* 1982;11:377–81.
- 3117 Korniewicz DM, Laughon BE, Butz A, Larson E. Integrity of vinyl and latex procedure gloves.
3118 *Nurs Res* 1989;38:144–6.
- 3119 Kotilainen HR, Brinker JP, Avato JL, Gantz NM. Latex and vinyl examination gloves. Quality
3120 control procedures and implications for health care workers. *Arch Intern Med*
3121 1989;149:2749–53.
- 3122 Kuehne JS, Cohen ME, Monreo SB. Performance and durability of autoclavable high speed
3123 handpieces. *Naval Dent Res Inst PR* 1992(May);92–103.
- 3124 Kugel G, Perry RD, Ferrari M, Lalicata P. Disinfection and communication practices: a survey of
3125 U. S. dental laboratories. *J Am Dent Assoc* 2000;131:786–92.
- 3126 Kuritsky JN, Bullen MG, Broome CV, Silcox VA, Good RC, Wallace RJ Jr. Sternal wound
3127 infections and endocarditis due to organisms of the *Mycobacterium fortuitum* complex. *Ann*
3128 *Intern Med* 1983;98:938–9.
- 3129 Lanphear BP, Linnemann CC Jr, Cannon CG, DeRonde MM, Pandy L, Kerley LM. Hepatitis C
3130 virus infection in healthcare workers: risk of exposure and infection. *Infect Control Hosp*
3131 *Epidemiol* 1994;15:745–50.
- 3132 Larson E, Killien M. Factors influencing handwashing behavior of patient care personnel. *Am J*
3133 *Infect Control* 1982;10:93–9.
- 3134 Larson E, Leyden JJ, McGinley KJ, Grove GL, Talbot GH. Physiologic and microbiologic
3135 changes in skin related to frequent handwashing. *Infect Control* 1986;7:59–63.
- 3136 Larson E. Handwashing: it's essential- even when you use gloves. *Am J Nurs* 1989;89:934–9.
- 3137 Larson EL, Butz AM, Gullette DL, Laughon BA. Alcohol for surgical scrubbing? *Infect Control*
3138 *Hosp Epidemiol* 1990;11:139–43.
- 3139 Larson E, Anderson JK, Baxendale L, Bobo L. Effects of a protective foam on scrubbing and
3140 gloving. *Am J Infect Control* 1993;21:297–301.
- 3141 Larson EL. APIC guideline for handwashing and hand antisepsis in health care settings. *Am J*
3142 *Infect Control* 1995;23:251–69.
- 3143 Larson EL, Norton Hughes CA, Pyrak JD, et al. Changes in bacterial flora associated with skin
3144 damage on hands of health care personnel. *Am J Infect Control* 1998;26:513–21.
- 3145 Larson EL, Early E, Cloonan P, Sugrue S, Parides M. An organizational climate intervention
3146 associated with increased handwashing and decreased nosocomial infections. *Behav Med*
3147 2000;26:14–22.
- 3148 Laussucq S, Baltch AL, Smith RP, et al. Nosocomial *Mycobacterium fortuitum* colonization
3149 from a contaminated ice machine. *Am Rev Respir Dis* 1988;138:891–4.
- 3150 Leonard DL, Charlton DG. Performance of high-speed dental handpieces subjected to simulated
3151 clinical use and sterilization. *J Am Dent Assoc* 1999;130:1301–11.

- 3152 Lessing MP, Walker MM. Fatal pulmonary infection due to *Mycobacterium fortuitum*. J Clin
3153 Pathol 1993;46:271–2.
- 3154 Levin ML, Maddrey WC, Wands JR, Mendeloff AI. Hepatitis B transmission by dentists. JAMA
3155 1974;228:1139–40.
- 3156 Lewis DL, Arens M, Appleton SS, et al. Cross-contamination potential with dental equipment.
3157 Lancet 1992;340:1252–4.
- 3158 Lewis DL, Boe RK. Cross-infection risks associated with current procedures for using high-
3159 speed dental handpieces. J Clin Microbiol 1992;30:401–6.
- 3160 Liberski PP, Gajdusek DC. Kuru: forty years later, a historical note. Brain Pathol 1997;7:555–60.
- 3161 Litsky BY, Mascis JD, Litsky W. Use of an antimicrobial mouthwash to minimize the bacterial
3162 aerosol contamination generated by the high-speed drill. Oral Surg Oral Med Oral Pathol
3163 1970;29:25–30.
- 3164 Lockhart PB. An analysis of bacteremias during dental extractions. A double-blind, placebo-
3165 controlled study of chlorhexidine. Arch Intern Med 1996;156:513–20.
- 3166 Logothetis DD, Martinez-Welles JM. Reducing bacterial aerosol contamination with a
3167 chlorhexidine gluconate pre-rinse. J Am Dent Assoc 1995;126:1634–9.
- 3168 Lowbury EJ, Lilly HA. Disinfection of the hands of surgeons and nurses. Br Med J 1960;1445–
3169 50.
- 3170 MacKenzie WR, Hoxie NJ, Proctor ME, et al. A massive outbreak in Milwaukee of
3171 cryptosporidium infection transmitted through the public water supply. N Engl J Med
3172 1994;331:161–7.
- 3173 Maki DG, Hassemer CA. Flash sterilization: carefully measured haste. Infect Control
3174 1987;8:307–10.
- 3175 Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of
3176 surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee.
3177 Infect Control Hosp Epidemiol 1999;20:250–78.
- 3178 Mann GL, Campbell TL, Crawford JJ. Backflow in low-volume suction lines: the impact of
3179 pressure changes. J Am Dent Assoc 1996;127:611–5.
- 3180 Martin LS, McDougal JS, Loskoski SL. Disinfection and inactivation of the human T
3181 lymphotropic virus type III/lymphadenopathy-associated virus. J Infect Dis 1985;152:400–
3182 3.
- 3183 Martin MV. The significance of the bacterial contamination of dental unit water systems. Br
3184 Dent J 1987;163:152–4.
- 3185 Martin MV, Dunn HM, Field EA, et al. A physical and microbiological evaluation of the re-use
3186 of non-sterile gloves. Br Dent J 1988;165:321–4.
- 3187 Mast EE, Alter MJ. Prevention of hepatitis B virus infection among health-care workers. In: Ellis
3188 RW, ed. Hepatitis B vaccines in clinical practice. West Point, NY: Marcel Dekker,
3189 1993:295–307.
- 3190 Matis BA, Valadez D, Valadez E. The effect of the use of dental gloves on mixing vinyl
3191 polysiloxane putties. J Prosthodont 1997;6:189–92.
- 3192 Mayo JA, Oertling KM, Andrieu SC. Bacterial biofilm: a source of contamination in dental air-
3193 water syringes. Clin Prev Dent 1990;12(2):13–20.
- 3194 Mayworm D. Sterile shelf life and expiration dating. J Hosp Supply Process Distrib
3195 1984;2(6):32-5.

3196 McCormick RD, Buchman TL, Maki DG. Double-blind, randomized trial of scheduled use of a
3197 novel barrier cream and an oil-containing lotion for protecting the hands of health care
3198 workers. *Am J Infect Control* 2000;28:302–10.

3199 McGinley KJ, Larson EL, Leyden JJ. Composition and density of microflora in the subungual
3200 space of the hand. *J Clin Microbiol* 1988;26:950–3.

3201 McNeil SA, Foster CL, Hedderwick SA, Kauffman CA. Effect of hand cleansing with
3202 antimicrobial soap or alcohol-based gel on microbial colonization of artificial fingernails
3203 worn by health care workers. *Clin Infect Dis* 2001;32:367–72.

3204 Mellstrom GA, Lindberg M, Boman A. Permeation and destructive effects of disinfectants on
3205 protective gloves. *Contact Dermatitis* 1992;26:163–70.

3206 Merchant VA, Molinari JA, Pickett T. Microbial penetration of gloves following usage in routine
3207 dental procedures. *Am J Dent* 1992;5:95–6.

3208 Milki AA, Fisch JD. Vaginal ultrasound probe cover leakage: implications for patient care.
3209 *Fertil. Steril.* 1998;69:409-11.

3210 Miller CH, Sheldrake MA. The ability of biological indicators to detect sterilization failures. *Am*
3211 *J Dent* 1994;7:95–7.

3212 Miller CH, Palenik DJ. Aseptic techniques. In: Miller CH, Palenik DJ, eds. *Infection control and*
3213 *management of hazardous materials for the dental team*, 2nd ed. St. Louis: Mosby, 1998:207.

3214 Miller CH, Byrne BE. Infection control strategies for the dental office. In: Ciancio SG, ed.
3215 *Dental therapeutics*, 2nd ed. Chicago: ADA Publications, 2000:543–58.

3216 Miller CH, Tan CM, Beiswanger MA, Gaines DJ, Setcos JC, Palenik CJ. Cleaning dental
3217 instruments: measuring the effectiveness of an instrument washer/disinfector. *Am J Dent*
3218 2000;13:39–43.

3219 Miller CH, Palenik CJ. Sterilization, disinfection, and asepsis in dentistry. In: Block SS, ed.
3220 *Disinfection, sterilization, and preservation*, 5th ed. Philadelphia;Lippincott Williams &
3221 Wilkins, 2001:617–41.

3222 Mills SE, Lauderdale PW, Mayhew RB. Reduction of microbial contamination in dental units
3223 with povidone-iodine 10%. *J Am Dent Assoc* 1986;113:280–4.

3224 Mills SE, Kuehne JC, Bradley DV Jr. Bacteriological analysis of high-speed handpiece turbines.
3225 *J Am Dent Assoc* 1993;124:59–62.

3226 Mills SE. The dental unit waterline controversy: defusing the myths, defining the solutions. *J Am*
3227 *Dent Assoc* 2000;131:1427–41.

3228 Milton DK, Wypij D, Kriebel D, Walters MD, Hammond SK, Evans JS. Endotoxin exposure-
3229 response in a fiberglass manufacturing facility. *Am J Ind Med* 1996;29:3–13.

3230 Mikitka D, Mills SE, Dazey SE, Gabriel ME. Tuberculosis infection in US Air Force dentists.
3231 *Am J Dent* 1995 Feb;8(1):33-6.

3232 Mitsui T, Iwano K, Masuko K, et al. Hepatitis C virus infection in medical personnel after
3233 needlestick accident. *Hepatology* 1992;16:1109–14.

3234 Mohammed CI, Monserrate V. Preoperative oral rinsing as a means of reducing air
3235 contamination during use of air turbine handpieces. *Oral Surg Oral Med Oral Pathol*
3236 1970;29:291–4.

3237 Monticello MV, Gaber DJ. Glove resistance to permeation by a 7.5% hydrogen peroxide
3238 sterilizing and disinfecting solution. *Am J Infect Control* 1999;27:364–6.

3239 Moolenaar RL, Crutcher M, San Joaquin VH, et al. A prolonged outbreak of *Pseudomonas*
3240 *aeruginosa* in a neonatal intensive care unit: did staff fingernails play a role in disease
3241 transmission? *Infect Control Hosp Epidemiol* 2000;21:80–5.

- 3242 Morgan DJ, Adams D. Permeability studies on protective gloves used in dental practice. *Br Dent*
3243 *J* 1989;166:11–3.
- 3244 Muir KF, Ross PW, MacPhee IT, Holbrook WP, Kowolik MJ. Reduction of microbial
3245 contamination from ultrasonic scalers. *Br Dent J* 1978;145:76–8.
- 3246 Mulberry G, Snyder AT, Heilman J, Pyrek J, Stahl J. Evaluation of a waterless, scrubless
3247 chlorhexidine gluconate/ethanol surgical scrub for antimicrobial efficacy. *Am J Infect*
3248 *Control* 2001;29:377–82.
- 3249 Murray CA, Burke FJT, McHugh S. An assessment of the incidence of punctures in latex and
3250 non-latex dental examination gloves in routine clinical practice. *Br Dent J* 2001;190:377–80.
- 3251 Nash KD. How infection control procedures are affecting dental practice today. *J Am Dent*
3252 *Assoc* 1992;123:67–73.
- 3253 Nikawa H, Hamada T, Tamamoto M, Abekura H, Murata H. Perforation of dental gloves during
3254 prosthodontic treatments as assessed by the conductivity and water inflation tests. *Int J*
3255 *Prosthodont* 1996;9:362–6.
- 3256 Nikawa H, Hamada T, Tamamoto M, Abekura H. Perforation and proteinaceous contamination
3257 of dental gloves during prosthodontic treatments. *Int J Prosthodont* 1994;7:559–66.
- 3258 Ninemeier JD. Central service technical manual. Chicago: International Association of
3259 Healthcare Central Service Materiel Management, 1998.
- 3260 Ojajärvi J, Mäkelä P, Rantasalo I. Failure of hand disinfection with frequent hand washing: a
3261 need for prolonged field studies. *J Hyg (Lond)* 1977;79:107–19.
- 3262 Ojajärvi J. The importance of soap selection for routine hygiene in hospital. *J Hyg (Camb)*
3263 1981;86:275–83.
- 3264 Odwin CS, Fleischer AC, Kepple DM, Chiang DT. Probe covers and disinfectants for
3265 transvaginal transducers. *J. Diagnostic Med. Sonography* 1990;6:130-5.
- 3266 Olsen RJ, Lynch P, Coyle MB, Cummings J, Bokete T, Stamm WE. Examination gloves as
3267 barriers to hand contamination in clinical practice. *JAMA* 1993;270:350–3.
- 3268 Otis LL, Cottone JA. Prevalence of perforations in disposable latex gloves during routine dental
3269 treatment. *J Am Dent Assoc* 1989;118:321–4.
- 3270 Pallasch TJ, Slots J. Antibiotic prophylaxis and the medically compromised patient. *Periodontol*
3271 *2000* 1996;10:107–38.
- 3272 Pankhurst CL, Philpott-Howard JN, Hewitt JH, Casewell MW. The efficacy of chlorination and
3273 filtration in the control and eradication of *Legionella* from dental chair water systems. *J Hosp*
3274 *Infect* 1990;16:9–18.
- 3275 Panlilio AL, Shapiro CN, Schable CA, et al. Serosurvey of human immunodeficiency virus,
3276 hepatitis B virus, and hepatitis C virus infection among hospital-based surgeons. Serosurvey
3277 Study Group. *J Am Coll Surg* 1995;180:16–24.
- 3278 Pantera EA Jr, Schuster GS. Sterilization of extracted human teeth. *J Dent Educ* 1990;54:283–5.
- 3279 Parker HH, Johnson RB. Effectiveness of ethylene oxide for sterilization of dental handpieces. *J*
3280 *Dent* 1995;23:113–5.
- 3281 Parry MF, Grant B, Yukna M, et al. *Candida* osteomyelitis and diskitis after spinal surgery: an
3282 outbreak that implicates artificial nail use. *Clin Infect Dis* 2001;32:352–7.
- 3283 Parsell DE, Stewart BM, Barker JR, Nick TG, Karns L, Johnson RB. The effect of steam
3284 sterilization on the physical properties and perceived cutting characteristics of extracted
3285 teeth. *J Dent Educ* 1998;62:260–3.
- 3286 Passaro DJ, Waring L, Armstrong R, et al. Postoperative *Serratia marcescens* wound infections
3287 traced to an out-of-hospital source. *J Infect Dis* 1997;175:992–5.

- 3288 Patton LL, Campbell TL, Evers SP. Prevalence of glove perforations during double-gloving for
3289 dental procedures. *Gen Dent* 1995;43:22–6.
- 3290 Pitten FA, Herdemann G, Kramer A. The integrity of latex gloves in clinical dental practice.
3291 *Infection* 2000;28:388–92.
- 3292 Pittet D, Hugonnet S, Harbarth S, et al. Effectiveness of a hospital-wide programme to improve
3293 compliance with hand hygiene. *Infection Control Programme. Lancet* 2000;356:1307–12.
- 3294 Plott RT, Wagner RF Jr., Tyring SK. Iatrogenic contamination of multidose vials in simulated
3295 use. A reassessment of current patient injection technique. *Arch Dermatol* 1990;126:1441–4.
- 3296 Plummer KD, Wakefield CW. Practical infection control in dental laboratories. *Gen Dent*
3297 1994;42:545–8.
- 3298 Polish LB, Tong MJ, Co RL, Coleman PJ, Alter MJ. Risk factors for hepatitis C virus infection
3299 among health care personnel in a community hospital. *Am J Infect Control* 1993;21:196–200.
- 3300 Pottinger J, Burns S, Manske C. Bacterial carriage by artificial versus natural nails. *Am J Infect*
3301 *Control* 1989;17:340–4.
- 3302 Pratt LH, Smith DG, Thornton RH, Simmons JB, Depta BB, Johnson RB. The effectiveness of
3303 two sterilization methods when different precleaning techniques are employed. *J*
3304 *Dent* 1999;27:247–8.
- 3305 Price PB. New studies in surgical bacteriology and surgical technique. *JAMA* 1938;111:1993–6.
- 3306 Prince DL, Prince HN, Thraenhart O, Muchmore E, Bonder E, Pugh J. Methodological
3307 approaches to disinfection of human hepatitis B virus. *J Clin Microbiol* 1993;31:3296–3304.
- 3308 Puro V, Petrosillo N, Ippolito G. Risk of hepatitis C seroconversion after occupational exposures
3309 in health care workers. Italian Study Group on Occupational Risk of HIV and Other
3310 Bloodborne Infections. *Am J Infect Control* 1995;23:273–7.
- 3311 Putnins EE, Di Giovanni D, Bhullar AS. Dental unit waterline contamination and its possible
3312 implications during periodontal surgery. *J Periodontol* 2001;72:393–400.
- 3313 Ready MA, Schuster GS, Wilson JT, Hanes CM. Effects of dental medicaments on examination
3314 glove permeability. *J Prosthet Dent* 1989;61:499–503.
- 3315 Redd JT, Baumbach J, Kohn WG. Patient-to-patient transmission of HBV in a dental setting.
3316 2003. (personal communication)
- 3317 Reingold AL, Kane MA, Murphy EL, Checko P, Francis DP, Maynard JE. Transmission of
3318 hepatitis B by an oral surgeon. *J Infect Dis* 1982;145:262–8.
- 3319 Reinthaler FF, Mascher F, Stunzner D. Serological examinations for antibodies against
3320 *Legionella* species in dental personnel. *J Dent Res* 1988;67:942–3.
- 3321 Reitz CD, Clark NP. The setting of vinyl polysiloxane and condensation silicone putties when
3322 mixed with gloved hands. *J Am Dent Assoc* 1988;116:371–5.
- 3323 Richards JM, Sydiskis RJ, Davidson WM, Josell SD, Lavine DS. Permeability of latex gloves
3324 after contact with dental materials. *Am J Orthod Dentofacial Orthop* 1993;104:224–9.
- 3325 Rimland D, Parkin WE, Miller GB Jr, Schrack WD. Hepatitis B outbreak traced to an oral
3326 surgeon. *N Engl J Med* 1977;296:953–8.
- 3327 Robert L, Chamberland ME, Cleveland JL, et al. Investigation of patients of health care workers
3328 infected with HIV: The Centers for Disease Control and Prevention database. *Ann Intern*
3329 *Med* 1995;122:653–7.
- 3330 Rooks VJ, Yancey MK, Elg SA, Brueske L. Comparison of probe sheaths for endovaginal
3331 sonography. *Obstet. Gynecol.* 1996;87:27-9.
- 3332 Rose CS, Martyny JW, Newman LS, et al. "Lifeguard lung": endemic granulomatous
3333 pneumonitis in an indoor swimming pool. *Am J Public Health* 1998;88:1795–800.

- 3334 Rotter M. Hand washing and hand disinfection. In: Mayhall CG, ed. Hospital epidemiology and
3335 infection control, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999, 1339–55.
- 3336 Rubin DM. Prosthetic fingernails in the OR. A research study. *AORN J* 1988;47:944–5, 948.
- 3337 Rutala WA, Odette RL, Samsa GP. Management of infectious waste by US hospitals. *JAMA*
3338 1989;262:1635–40.
- 3339 Rutala WA, Weber DJ. Mismatch between science and policy. *N Engl J Med* 1991;325:578–82.
- 3340 Rutala WA, Gergen MF, Weber DJ. Evaluation of a rapid readout biological indicator for flash
3341 sterilization with three biological indicators and three chemical indicators. *Infect. Control*
3342 *Hosp. Epidemiol.* 1993;14:390-4.
- 3343 Rutala WA, APIC guideline for selection and use of disinfectants. 1994, 1995, and 1996 APIC
3344 Guidelines Committee. Association for Professionals in Infection Control and Epidemiology,
3345 Inc. *Am J Infect Control* 1996;24:313–42.
- 3346 Rutala WA, Weber DJ. Clinical effectiveness of low-temperature sterilization technologies.
3347 *Infect Control Hosp Epidemiol* 1998;19:798–804.
- 3348 Rutala WA, Weber DJ, Chappell KJ. Patient injury from flash-sterilized instruments. *Infect.*
3349 *Control Hosp. Epidemiol.* 1999;20:458.
- 3350 Rutala WA, Weber DJ. Choosing a sterilization wrap. *Infect. Control Today* 2000;4:64,70.
- 3351 Rutala WA, Weber DJ, and HICPAC. Guideline for cleaning, disinfection, and sterilization in
3352 health-care. 2002 (in development).
- 3353 Santiago JI, Huntington MK, Johnston AM, Quinn RS, Williams JF. Microbial contamination of
3354 dental unit waterlines: short- and long-term effects of flushing. *Gen Dent* 1994;42:528–35.
- 3355 Sartori M, La Terra G, Aglietta M, Manzin A, Navino C, Verzetti G. Transmission of hepatitis C
3356 via blood splash into conjunctiva. *Scand J Infect Dis* 1993;25:270–1.
- 3357 Scheid RC, Kim CK, Bright JS, Whitely MS, Rosen S. Reduction of microbes in handpieces by
3358 flushing before use. *J Am Dent Assoc* 1982;105:658–60.
- 3359 Scheid RC, Rosen S, Beck FM. Reduction of CFUs in high-speed handpiece water lines over
3360 time. *Clin Prev Dent* 1990;12(2):9–12.
- 3361 Schulze-Robbecke R, Feldmann C, Fischeider R, Janning B, Exner M, Wahl G. Dental units: an
3362 environmental study of sources of potentially pathogenic mycobacteria. *Tuber Lung Dis*
3363 1995;76:318–23.
- 3364 Schwimmer A, Massoumi M, Barr CE. Efficacy of double gloving to prevent inner glove
3365 perforation during outpatient oral surgical procedures. *J Am Dent Assoc* 1994;125:196–8.
- 3366 Sehulster L. Draft Guideline for environmental infection control in health-care facilities, 2001.
3367 *Federal Register* 2001;66:13539–40.
- 3368 Shapiro CN. Occupational risk of infection with hepatitis B and hepatitis C virus. *Surg Clin*
3369 *North Am* 1995;75:1047–56.
- 3370 Shaw FE Jr, Barrett CL, Hamm R, et al. Lethal outbreak of hepatitis B in a dental practice.
3371 *JAMA* 1986;255:3260–4.
- 3372 Shearer BG. Biofilm and the dental office. *J Am Dent Assoc* 1996;127:181–9.
- 3373 Short LJ, Bell DM. Risk of occupational infection with blood-borne pathogens in operating and
3374 delivery room settings. *Am J Infect Control* 1993;21:343–50.
- 3375 Siew C, Chang SB, Gruninger SE, Verrusio AC, Neidle EA. Self-reported percutaneous injuries
3376 in dentists: implications for HBV, HIV, transmission risk. *J Am Dent Assoc* 1992;123:36–44.
- 3377 Siew C, Gruninger SE, Miaw C, Neidle EA. Percutaneous injuries in practicing dentists. A
3378 prospective study using a 20-day diary. *J Am Dent Assoc* 1995;126:1227–34.

- 3379 Skoutelis AT, Westenfelder GO, Beckerdite M, Phair JP. Hospital carpeting and epidemiology of
3380 *Clostridium difficile*. Am J Infect Control 1993;22:212–7.
- 3381 Slade JE, Pike EB, Eglin RP, Colbourne JS, Kurtz JB. The survival of human immunodeficiency
3382 virus in water, sewage, and sea water. Water Sci Technol 1989;21:55–9.
- 3383 Smart ER, Macleod RI, Lawrence CM. Allergic reactions to rubber gloves in dental patients:
3384 report of three cases. Br Dent J 1992;172:445–7.
- 3385 Smith WH, Davies D, Mason KD, Onions JP. Intraoral and pulmonary tuberculosis following
3386 dental treatment. Lancet 1982;1:842–4.
- 3387 Snyder HA, Settle S. The rise in latex allergy: implications for the dentist. J Am Dent Assoc
3388 1994;125:1089–97.
- 3389 Spaulding EH. Chemical disinfection of medical and surgical materials In: Lawrence CA, Block
3390 SS, eds. Disinfection, sterilization and preservation. Philadelphia:Lea & Febiger, 1968:517–
3391 31.
- 3392 Spire B, Barré-Sinoussi F, Montagnier L, Chermann JC. Inactivation of lymphadenopathy
3393 associated virus by chemical disinfectants. Lancet 1984;2:899–901.
- 3394 Steere AC, Mallison GF. Handwashing practices for the prevention of nosocomial infections.
3395 Ann Intern Med 1975;83:683–90.
- 3396 Storment JM, Monga M, Blanco JD. Ineffectiveness of latex condoms in preventing
3397 contamination of the transvaginal ultrasound transducer head. South. Med. J. 1997;90:206-8.
- 3398 Struelens MJ, Rost F, Deplano A, et al. *Pseudomonas aeruginosa* and *Enterobacteriaceae*
3399 bacteremia after biliary endoscopy: an outbreak investigation using DNA macrorestriction
3400 analysis. Am J Med 1993;95:489–98.
- 3401 Suzuki A, Namba Y, Matsuura M, Horisawa A. Bacterial contamination of floors and other
3402 surfaces in operating rooms: a five-year survey. J Hyg (Lond) 1984;93:559–66.
- 3403 Swanson MC, Bubak ME, Hunt LW, Yunginger JW, Warner MA, Reed CE. Quantification of
3404 occupational latex aeroallergens in a medical center. J Allergy Clin Immunol 1994;94(3 pt
3405 1):445–551.
- 3406 Tarlo SM, Sussman G, Contala A, Swanson MC. Control of airborne latex by use of powder-free
3407 latex gloves. J Allergy Clin Immunol 1994;93:985–9.
- 3408 Tate WH, White RR. Disinfection of human teeth for educational purposes. J Dent Educ
3409 1991;55:583–5.
- 3410 Terezhalmay GT, Molinari JA. Personal protective equipment and barrier techniques. In: Cottone
3411 JA, Terezhalmay GT, Molinari JA, eds. Practical infection control in dentistry, 2nd ed.
3412 Baltimore: Williams & Wilkins, 1996:136–45.
- 3413 Thadani V, Penar PL, Partington J, et al. Creutzfeldt-Jakob disease probably acquired from a
3414 cadaveric dura mater graft. Case report. J Neurosurg 1988;69:766–9.
- 3415 Thomas DL, Gruninger SE, Siew C, Joy ED, Quinn TC. Occupational risk of hepatitis C
3416 infections among general dentists and oral surgeons in North America. Am J Med
3417 1996;100:41–5.
- 3418 Tokars JI, Culver DH, Mendelson MH, et al. Skin and mucous membrane contacts with blood
3419 during surgical procedures: risk and prevention. Infect Control Hosp Epidemiol
3420 1995;16:703–11.
- 3421 Trape M, Schenck P, Warren A. Latex gloves use and symptoms in health care workers 1 year
3422 after implementaion of a policy restricting the use of powdered gloves. Am J Infect Control
3423 2000;28:352–8.

3424 Turjanmaa K, Reunala T, Alenius H, Brummer-Korvenkontio H, Palosuo T. Allergens in latex
3425 surgical gloves and glove powder. *Lancet* 1990;336:1588.

3426 US Census Bureau. 2001 Statistical Abstract of the United States. Available at
3427 <http://www.census.gov/prod/2002pubs/01statab/labor.pdf> Accessed January 2003.

3428 US Department of Health and Human Services, Food and Drug Administration. 21 CFR Part
3429 800. Medical devices, patient examination and surgeon's gloves. Adulteration, final rule.
3430 *Federal Register* 1990;55:51254–8.

3431 US Department of Health and Human Services, Food and Drug Administration. Dental
3432 handpiece sterilization. Rockville, MD: US Food and Drug Administration. 1992.

3433 US Department of Health and Human Services, Food and Drug Administration. 21 CFR Part
3434 872.6730 Dental devices;miscellaneous devices;endodontic dry heat sterilizer;final rule.
3435 *Federal Register* 1997;62:2900–3.

3436 US Department of Health and Human Services, Food and Drug Administration. Guidance for
3437 Industry and FDA - Medical Glove Guidance Manual, 1999. Available at:
3438 http://www.fda.gov/cdrh/dsma/135.html#_Toc458914315 Accessed January 2003.

3439 US Department Of Health and Human Services, Food and Drug Administration. Labeling
3440 recommendations for single-use devices reprocessed by third parties and hospitals;final
3441 guidance for industry and FDA, July 30, 2001.

3442 US Department of Health and Human Services, Office for Civil Rights. 45 CFR Parts 160 and
3443 164. Standards for Privacy of Individually Identifiable Health Information; Final Rule.
3444 *Federal Register* 2000. Available at: <http://www.hhs.gov/ocr/hipaa/finalreg.html>. Accessed
3445 January 2003.

3446 US Department Of Health and Human Services. Oral Health in America: a report of the Surgeon
3447 General. Rockville, MD: US Department of Health and Human Services, National Institute
3448 of Dental and Craniofacial Research, National Institutes of Health, 2000.

3449 US Department of Labor, Occupational Safety and Health Administration. 29 CFR Part
3450 1910.1030. Occupational exposure to bloodborne pathogens; final rule. *Federal Register*
3451 1991;56(235):64004–182.

3452 US Department of Labor, Occupational Safety and Health Administration. Hazard
3453 Communication 29 CFR 1910.1200. *Federal Register* 1994; 59:17479.

3454 US Department of Labor, Occupational Health and Safety Administration. OSHA Memorandum
3455 from Stephen Mallinger. EPA registered disinfectants for HIV/HBV. Washington, DC:US
3456 Department of Labor, 1997.

3457 US Department of Labor, Occupational Health and Safety Administration. Occupational
3458 exposure to bloodborne pathogens; needlestick and other sharps injuries; final rule. 29 CFR
3459 Part 1910.1030. *Federal Register* 2001;66(12):5317–25.

3460 US Department of Labor, Occupational Safety and Health Administration. 29 CFR Part
3461 1904;1952. Occupational injury and illness recording and reporting requirements. *Federal*
3462 *Register* 2001;66:5916–6135.

3463 US Department of Labor, Occupational Safety and Health Administration. Enforcement
3464 procedures for the Occupational Exposure to Bloodborne Pathogens CPL 2–2.69;November
3465 27, 2001.

3466 US Environmental Protection Agency. 40 CFR Part 60. Standards of performance for new
3467 stationary sources and emission guidelines for existing sources: hospital/medical/infectious
3468 waste incinerators;final rule. *Federal Register* 1997;62:48347–91.

- 3469 US Environmental Protection Agency. 815-R-99-020, Lead and copper rule: summary of
3470 revisions. 2000;1-38. Available at:
3471 http://www.epa.gov/safewater/lcrmr/compliance_dates.pdf. Accessed January 2003.
- 3472 US Environmental Protection Agency. 65 CFR Part 141 and 142. National primary drinking
3473 water regulations for lead and copper;final rule. Federal Register 2000;Volume:1949-2015.
3474 Available at: <http://www.epa.gov/fedrgstr/EPA-GENERAL/2000/January/Day-12/g3.htm>.
3475 Accessed January 2003.
- 3476 US Environmental Protection Agency. National primary drinking water regulations, 1999.
3477 Available at: <http://www.epa.gov/OGWDW/wot/appa.html>. City, State:Environmental
3478 Protection Agency. Accessed January 2003.
- 3479 United States Pharmacopeial Convention. Sterile water for irrigation. In: United States
3480 Pharmacopeial Convention. United States pharmacopeia and national formulary (USP 24-NF
3481 19). Rockville, MD: United States Pharmacopeial Convention, 1997:1753.
- 3482 Van Bueren J, Simpson RA, Salman H, Farrelly HD, Cookson BD. Inactivation of HIV-1 by
3483 chemical disinfectants: sodium hypochlorite. *Epidemiol Infect* 1995;115:567-79.
- 3484 Van Duijn CM, Delasnerie-Laupretre N, Masullo C, et al. Case-control study of risk factors of
3485 Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU) Collaborative
3486 Study Group of Creutzfeldt-Jacob disease (CJD). *Lancet* 1998;351:1081-5.
- 3487 Vesley D, Langholz AC, Rohlfing SR, Foltz WE. Fluorimetric detection of a *Bacillus*
3488 *stearothermophilus* spore-bound enzyme, α -D-glucosidase, for rapid identification of flash
3489 sterilization failure. *Appl. Environ. Microbiol.* 1992;58:717-9.
- 3490 Walker JT, Bradshaw DJ, Bennett AM, Fulford MR, Martin MV, Marsh PD. Microbial biofilm
3491 formation and contamination of dental-unit water systems in general dental practice. *Appl*
3492 *Environ Microbiol* 2000;66:3363-7.
- 3493 Watson CM, Whitehouse RL. Possibility of cross-contamination between dental patients by
3494 means of the saliva ejector. *J Am Dent Assoc* 1993;124:77-80.
- 3495 Watts D, Tassler PL, Dellon AL. The effect of double gloving on cutaneous sensibility, skin
3496 compliance and suture identification. *Contemp Surg* 1994;44:289-92.
- 3497 Webb JM, Pentlow BD. Double gloving and surgical technique. *Ann R Coll Surg Engl*
3498 1993;75:291-2.
- 3499 Weber DJ, Barbee SL, Sobsey MD, Rutala WA. The effect of blood on the antiviral activity of
3500 sodium hypochlorite, a phenolic, and a quaternary ammonium compound. *Infect Control*
3501 *Hosp Epidemiol* 1999;20:821-7.
- 3502 Wells WF. Airborne contagion and air hygiene. Cambridge, MA:Harvard University Press,
3503 Cambridge, Mass. 1955.
- 3504 Werner BG, Grady GF. Accidental hepatitis-B-surface-antigen-positive inoculations: Use of e
3505 antigen to estimate infectivity. *Ann Intern Med* 1982;97:367-9.
- 3506 Widmer AF. Replace hand washing with use of a waterless alcohol hand rub? *Clin Infect Dis*
3507 2000;31: 136-43.
- 3508 Will RG, Ironside JW, Seidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK.
3509 *Lancet* 1996;347:921-5.
- 3510 Williams HN, Kelley J, Folineo D, Williams GC, Hawley CL, Sibiski J. Assessing microbial
3511 contamination in clean water dental units and compliance with disinfection protocol. *J Am*
3512 *Dent Assoc* 1994;125:1205-11.
- 3513 Williams HN, Johnson A, Kelley JI, et al. Bacterial contamination of the water supply in newly
3514 installed dental units. *Quintessence Int* 1995;26:331-7.

3515
3516 Williams JF, Johnston AM, Johnson B, Huntington MK, Mackenzie CD. Microbial
3517 contamination of dental unit waterlines: prevalence, intensity and microbiological
3518 characteristics. *J Am Dent Assoc* 1993;124:59–65.
3519 Wilson SJ, Sellu D, Uy A, Jaffer MA. Subjective effects of double gloves on surgical
3520 performance. *Ann R Coll Surg Engl* 1996;78:20–2.
3521 Working Group on Waterborne Cryptosporidiosis. *Cryptosporidium and water: a public health*
3522 *handbook* 1997;(Boil-Water Advisories pp. 50–53,73). Available at:
3523 <http://www.cdc.gov/ncidod/diseases/crypto/crypto.pdf>. Accessed January 2003.
3524 World Health Organization. Bovine spongiform encephalopathy. Updated June 2001. Available
3525 at: <http://www.who.int/mediacentre/factsheets/fs113/en/>. Accessed January 2003.
3526 World Health Organization. Infection control guidelines for transmissible spongiform
3527 encephalopathies: report of a WHO consultation, Geneva, Switzerland, 23-26 March 1999.
3528 Available at: <http://www.who.int/emc-documents/tse/whocdscsraph2003c.html>. Accessed
3529 January 2003.
3530 Wright JG, McGeer AJ, Chyatte D, Ransohoff DF. Mechanisms of glove tears and sharp injuries
3531 among surgical personnel. *JAMA* 1991;266:1668–71.
3532 Wyler D, Miller RL, Micik RE. Efficacy of self-administered preoperative oral hygiene
3533 procedures in reducing the concentration of bacteria in aerosols generated during dental
3534 procedures. *J Dent Res* 1971;50:509.
3535 Wynd CA, Samstag DE, Lapp AM. Bacterial carriage on the fingernails of OR nurses. *AORN J*
3536 1994;60:796, 799–805.
3537 Yassin MS, Lierl MB, Fischer TJ, O'Brien K, Cross J, Steinmetz C. Latex allergy in hospital
3538 employees. *Ann Allergy* 1994;72:245–9.
3539 Zaza S, Reeder JM, Charles LE, Jarvis WR. Latex sensitivity among perioperative nurses.
3540 *AORN J* 1994;60:806–12.
3541 Zimakoff J, Kjelsberg AB, Larson SO, Holstein B. A multicenter questionnaire investigation of
3542 attitudes toward hand hygiene, assessed by the staff in fifteen hospitals in Denmark and
3543 Norway. *Am J Infect Control* 1992;20:58–64.
3544

3544 **Appendix 1**

3545

3546

3547 **Sample Resources for Infection Control Guidelines and Documents**

3548

3549

Advisory Committee on Immunization Practices	http://www.cdc.gov/nip/ACIP/default.htm
American Dental Association	http://www.ada.org/
Association for Professionals in Infection Control and Epidemiology, Inc.	http://www.apic.org/resc/guidlist.cfm
CDC Division of Healthcare Quality Promotion	http://www.cdc.gov/ncidod/hip/
CDC Division of Oral Health, Infection Control	http://www.cdc.gov/OralHealth/infection_control/index.htm
CDC Morbidity and Mortality Weekly Report	http://www.cdc.gov/mmwr/
CDC Recommends...Prevention Guidelines System	http://www.phppo.cdc.gov/cdcRecommends/AdvSearchV.asp
Food and Drug Administration	http://www.fda.gov
Immunization Action Coalition	http://www.immunize.org/acip/
Infectious Diseases Society of America	http://www.idsociety.org/PG/toc.htm
National Institute for Occupational Safety and Health	http://www.cdc.gov/niosh/homepage.html
Occupational Safety and Health Administration, Dentistry	http://www.osha.gov/html/a-z-index.html#B
Organization for Safety and Asepsis Procedures	http://www.osap.org/
Society for Healthcare Epidemiology of America, Inc.	http://www.shea-online.org/PositionPapers.html

3550

3551

3552

3553

3554

3554 **Appendix 2. Immunobiologics and schedules for health-care personnel (modified from ACIP**
 3555 **recommendations [CDC Immunization 1997]): Immunizing agents strongly recommended for**
 3556 **health-care personnel[#]**
 3557

Generic name	Primary booster dose schedule	Indications	Major precautions and contraindications	Special considerations
Hepatitis B recombinant vaccine	Two doses IM in the deltoid muscle, 4 wk apart; 3 rd doses 5 mo after 2 nd ; booster doses not necessary	Health-care personnel at risk of exposure to blood and body fluids	History of anaphylactic reaction to common bakers yeast. No apparent adverse effects to developing fetus, not contraindicated in pregnancy	No therapeutic or adverse effects on HBV-infected persons; cost-effectiveness of prevaccination screening for susceptibility to HBV depends on costs of vaccination and antibody testing and prevalence of immunity in the group of potential vaccines; health-care personnel who have ongoing contact with patients or blood should be tested 1-2 mo after completing the vaccination series to determine serologic response
Influenza vaccine (inactivated whole or split virus)	Annual single-dose vaccination IM with current (either whole or split-virus) vaccine	Health-care personnel with contact with high-risk patients or working in chronic care facilities; personnel with high-risk medical conditions and/or ≥65 yr	History of anaphylactic hypersensitivity after egg ingestion or to egg protein	Recommended during 2 nd and 3 rd trimesters of pregnancy. No evidence of maternal or fetal risk when vaccine was given to pregnant women with underlying conditions that rendered them at high risk for serious influenza complications
Measles live-virus vaccine	One dose SC; 2 nd dose at least 1 mo later	Health-care personnel born in or after 1957 without documentation of (a) receipt of two doses of live vaccine on or after their 1 st birthday, (b) physician-diagnosed measles, or (c) laboratory evidence of immunity; vaccine should be considered for all personnel, including those born before 1957, who have no proof of immunity	Pregnancy; immuno-compromised* state (including HIV-infected persons with severe immuno-suppression); history of anaphylactic reactions after gelatin ingestion or receipt of neomycin; or recent receipt of immune globulin	MMR is the vaccine of choice if recipients are also likely to be susceptible to rubella and/or mumps; persons vaccinated between 1963 and 1967 with (a) a killed measles vaccine alone, (b) killed vaccine followed by live vaccine, or (c) a vaccine of unknown type should be revaccinated with two doses of live measles vaccine
Mumps live-virus vaccine	One dose SC; no booster	Health-care personnel believed to be susceptible can be vaccinated; adults born before 1957 can be considered immune	Pregnancy; immuno-compromised* state; history of anaphylactic reaction after gelatin ingestion or receipt of neomycin	MMR is the vaccine of choice if recipients are also likely to be susceptible to measles and rubella

Rubella live-virus vaccine	One dose SC; no booster	Health-care personnel, both male and female, who lack documentation of receipt of live vaccine on or after their 1 st birthday, or of laboratory evidence of immunity; adults born before 1957 can be considered immune, except women of childbearing age	Pregnancy; immuno-compromised* state; history of anaphylactic reaction after receipt of neomycin	Women pregnant when vaccinated or who become pregnant within 3 mo of vaccination should be counseled on the theoretic risks to the fetus, the risk of rubella vaccine-associated malformations in these women is negligible; MMR is the vaccine of choice if recipients are also likely to be susceptible to measles or mumps
Varicella-zoster live-virus vaccine	Two 0.5-ml doses SC 4-8 wk apart if ≥ 13 yr	Health care personnel without reliable history of varicella or laboratory evidence of varicella immunity	Pregnancy; immuno-compromised* state; history of anaphylactic reaction after receipt of neomycin or gelatin; salicylate use should be avoided for 6 wk after vaccination	Because 71%-93% of persons without a history of varicella are immune, serologic testing before vaccination may be cost-effective

3558
3559 (IM, intramuscularly; SC, subcutaneously; HBV, hepatitis B virus; MMR, measles, mumps and rubella)
3560 *Persons immunocompromised because of immune deficiencies, HIV infection, leukemia, lymphoma,
3561 generalized malignancy; immunosuppressive therapy with corticosteroids, alkylating drugs,
3562 antimetabolites; or radiation.
3563 #Adapted from Bolyard EA, Hospital Infection Control Practices Advisory Committee. Guidelines for
3564 infection control in health care personnel, 1998. Am J Infect Control 1998;26:289-354.
3565
3566

3566 **Appendix 3. Modified from CDC Personnel Health Guideline, 1998. Summary of suggested work**
 3567 **restrictions for health care personnel exposed to or infected with infectious diseases of importance**
 3568 **in health care settings, in the absence of state and local regulations (modified from ACIP**
 3569 **recommendations) (Bolyard 1998)**
 3570

Disease/problem	Work restriction	Duration
Conjunctivitis	Restrict from patient contact and with the patient's environment	Until discharge ceases
Cytomegalovirus infection	No restriction	
Diarrheal disease		
Acute state (diarrhea with other symptoms)	Restrict from patient contact, contact with the patient's environment, or food handling	Until symptoms resolve
Convalescent state, <i>Salmonella</i> spp.	Restrict from care of high-risk patients	Until symptoms resolve; consult with local and state health authorities regarding need for negative stool cultures
Diphtheria	Exclude from duty	Until antimicrobial therapy completed and 2 culture obtained 24 hours apart are negative
Enteroviral infection	Restrict from care of infants, neonates, and immunocompromised patients and their environments	Until symptoms resolve
Hepatitis A	Restrict from patient contact, contact with patient's environment and food handling	Until 7 days after onset of jaundice
Hepatitis B		
Personnel with acute or chronic hepatitis B surface antigenemia who do not perform exposure-prone procedures	No restriction*; refer to state regulations. Standard precautions should always be utilized	
Personnel with acute or chronic hepatitis B e antigenemia who perform exposure-prone procedures	Do not perform exposure-prone invasive procedures until counsel from an expert review panel has been sought; panel should review and recommend procedures the worker can perform, taking into account specific procedures as well as skill and technique of worker; standard precautions should always be observed. Refer to state and local regulations or recommendations.**	Until hepatitis B e antigen is negative
Hepatitis C	No restriction*; Standard precautions should always be utilized#	
Herpes simplex		
Genital	No restriction	
Hands (herpetic whitlow)	Restrict from patient contact and contact with the patient's environment	Until lesions heal
Orofacial	Evaluate to need to restriction from care of high-risk patients	

3571

Human immunodeficiency virus Personnel who do not perform exposure-prone procedures Personnel who perform exposure-prone procedures	No restriction*; refer to state regulations. Standard precautions should always be utilized Do not perform exposure-prone invasive procedures until counsel from an expert review panel has been sought; panel should review and recommend procedures the worker can perform, taking into account specific procedures as well as skill and technique of worker; standard precautions should always be observed. Refer to state and local regulations or recommendations.**	
Measles Active Postexposure (susceptible personnel)	Exclude from duty Exclude from duty	Until 7 days after the rash appears From 5 th day after 1 st exposure through 21 st day after last exposure and/or 4 days after rash appears
Meningococcal infection	Exclude from duty	Until 24 hours after start of effective therapy
Mumps Active Postexposure (susceptible personnel)	Exclude from duty Exclude from duty	Until 9 days after onset of parotitis From 12 th day after 1 st exposure through 26 th day after last exposure or until 0 days after onset of parotitis
Pediculosis	Restrict from patient contact	Until treated and observed to be free of adult and immature lice
Pertussis Active Postexposure (asymptomatic personnel) Postexposure (symptomatic personnel)	Exclude from duty No restriction, prophylaxis recommended Exclude from duty	Until 5 days after start of effective antimicrobial therapy
Rubella Active Postexposure (susceptible personnel)	Exclude from duty Exclude from duty	Until 5 days after rash appears From 7 th day after 1 st exposure through 21 st day after last exposure
Scabies <i>Staphylococcus aureus</i> infection Active, draining skin lesions Carrier state	Restrict from contact with patients and patient's environment or food handling No restriction unless personnel are epidemiologically linked to transmission of the organism	Until lesions have resolved

Streptococcal infection, group A	Restrict from patient care, contact with patient's environment, or food handling	Until 24 hours after adequate treatment started
Tuberculosis		
Active disease	Exclude from duty	Until proved noninfectious
PPD converter	No restriction	
Varicella		
Active	Exclude from duty	Until all lesions dry and crust
Post exposure (susceptible personnel)	Exclude from duty	From 10 th day after 1 st exposure through 21 st day (28 th day if VZIG given) after last exposure
Zoster		
Localized, in healthy person	Cover lesions, restrict from care of high-risk patients†	Until all lesions dry and crust
Generalized or localized in immunosuppressed person	Restrict from patient contact	Until all lesions dry and crust
Postexposure (susceptible personnel)	Restrict from patient contact	
Viral respiratory infection, acute febrile	Consider excluding from the care of high risk patients‡ or contact with their environment during community outbreak of RSV and influenza	Until acute symptoms resolve

3572

3573 * Unless epidemiologically linked to transmission of infection

3574 † Those susceptible to varicella and who are at increased risk of complications of varicella, such as neonates and immunocompromised persons of any age.

3575 ‡ High-risk patients as defined by the ACIP for complications of influenza

3577 # CDC Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. MMWR Oct 16, 1998. Vol. 47;No. RR-19:1-39

3579 ** CDC. Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure-prone invasive procedures. MMWR 1991;40(RR-8):1-8.

3581

3582 **Appendix 4. Methods for Sterilizing and Disinfecting Patient-Care Items and Environmental Surfaces**

Process*	Definition	Method		Example	Application in Health-Care	
					Patient-Care Items	Environmental Surfaces
Sterilization	Destroys all microorganisms, including bacterial spores	Heat automated	High temp	Steam, Dry heat, Unsaturated chemical vapor	Heat tolerant critical and semicritical	Not applicable
			Low temp	Ethylene oxide gas, Plasma sterilization	Heat tolerant or heat sensitive critical and semicritical	
		Liquid immersion		Chemical sterilant§ (e.g., glutaraldehyde, hydrogen peroxide, hydrogen peroxide and peracetic acid)	Heat sensitive critical or semicritical	
High-Level Disinfection	Destroys all microorganisms, but not necessarily high numbers of bacterial spores	Heat automated		Washer disinfectant	Heat-sensitive semicritical	
		Liquid immersion		Chemical sterilant§ (e.g., glutaraldehydes, ortho-phthalaldehyde, hydrogen peroxide)		
Intermediate-Level Disinfection	Destroys vegetative bacteria, most fungi, and most viruses; does inactivate <i>Mycobacterium tuberculosis var. bovis</i> .¶ Not necessarily capable of killing bacterial spores	Liquid contact		Hospital disinfectant with label claim of tuberculocidal activity (e.g., chlorine-containing products, quaternary ammonium compounds with alcohol, phenolics, bromides, iodophors, EPA-registered chlorine-based product**) <ul style="list-style-type: none"> • Hospital disinfectant with no label claim regarding tuberculocidal activity†† • Sanitizers 	Noncritical with visible blood	Clinical contact surfaces Blood spills on housekeeping surfaces
Low-Level Disinfection	Destroys most vegetative bacteria, some fungi, and some viruses. Does not inactivate <i>Mycobacterium tuberculosis var. bovis</i> .¶					(e.g., quaternary ammonium compounds, some phenolics, some iodophors)

3583 * The US Environmental Protection Agency (EPA) and the US Food and Drug Administration (FDA) regulate chemical germicides used in health-care settings.
3584 The FDA regulates chemical sterilants used on critical and semicritical devices, and the EPA regulates disinfectants used on noncritical surfaces. FDA also
3585 regulates medical devices, including sterilizers. The following Internet sites can be used to obtain more information on chemical germicides and medical devices:
3586 <http://www.epa.gov/oppad001/chemregindex.htm> and <http://www.fda.gov/cdrh/index.html> and <http://www.fda.gov/cdrh/ode/germlab.html>.

3587
3588 § Contact time is the single important variable distinguishing sterilization from high level disinfection with a liquid chemical sterilant/disinfectant agent. The
3589 FDA defines a high-level disinfectant as a sterilant used under the same contact conditions as sterilization except for a shorter immersion time (Food and Drug
3590 Administration 2000).
3591

3592 ¶ The tuberculocidal claim is used as a benchmark to measure germicidal potency. Tuberculosis is transmitted via the airborne route rather than by environmental
3593 surfaces and, accordingly, the use of such products on environmental surfaces plays no role in preventing the spread of TB in any setting. Because mycobacteria
3594 have among the highest intrinsic levels of resistance among the vegetative bacteria, viruses, and fungi, any germicide with a tuberculocidal claim on the label
3595 (e.g., an intermediate-level disinfectant) is considered capable of inactivating a broad spectrum of pathogens, including much less resistant organisms such as
3596 bloodborne pathogens (e.g., hepatitis B [HBV], hepatitis C virus [HCV], and HIV). It is this broad-spectrum capability, rather than the product's specific potency
3597 against mycobacteria, that is the basis for protocols and regulations dictating use of tuberculocidal chemicals for surface disinfection.
3598

3599 ** Commercial chlorine-based products that are EPA-registered as intermediate-level disinfectants are available. In the absence of an EPA-registered chlorine-
3600 based product, a fresh solution of sodium hypochlorite (household bleach) is an inexpensive and effective intermediate-level germicide. Concentrations ranging
3601 from 500 to 800 ppm of chlorine (a 1:100 dilution of bleach and tap water or approximately ¼ cup of bleach to 1 gallon of water) are effective on environmental
3602 surfaces that have been cleaned of visible contamination. Appropriate personal protective equipment (e.g., gloves, goggles) should be worn when preparing
3603 hypochlorite solutions (OSHA 1991, Sehulster 2002). Caution should be exercised, because chlorine solutions are corrosive to metals, especially aluminum.
3604

3605 †† Germicides labeled as “hospital disinfectant” must pass potency tests for activity against three representative microorganisms:–*Pseudomonas aeruginosa*,
3606 *Staphylococcus aureus*, and *Salmonella choleraesuis*.
3607

3608 §§ EPA-registered low-level disinfectants that are effective against HIV and HBV.

3609 **Appendix 5. Additional Research**

3610

3611 Although the number of published studies concerning dental infection control has
3612 increased in recent years, many questions regarding infection control practices remain
3613 unanswered. Several concerns must still be addressed by researchers in industry and by
3614 clinical investigators.

3615

3616 **Infection Control Elements of a Personnel Health Program**

- 3617 1. Conduct epidemiological investigations of DHCP to determine their risk of
3618 occupationally acquired infections.

3619

3620 **Preventing Transmission of Bloodborne Pathogens**

- 3621 1. Conduct prospective seroprevalence studies that will further define the risk of
3622 occupational hepatitis C infection among DHCP.
3623 2. Develop and evaluate new devices with safety features and protective barriers.
3624 3. Better define the epidemiology of blood contacts among DHCP and the
3625 effectiveness of prevention measures.

3626

3627 **Transmissible Spongiform Encephalopathies**

- 3628 1. Determine the potential for prion infection in the oral tissues of patients with
3629 Creutzfeldt-Jacob disease (or variant CJD).

3630

3631 **Personal Protective Equipment**

- 3632 1. Identify the generation of bioaerosols (size, pathogen, area of contamination)
3633 during patient care procedures and the effectiveness of personal protective
3634 equipment.
3635 2. Conduct studies to determine the efficacy of gloves related to material
3636 compatibility and duration of use.

3637

3638 **Contact Dermatitis and Latex Hypersensitivity**

- 3639 1. Describe the current prevalence of irritant contact dermatitis to different
3640 chemicals in dentistry.
3641 2. Conduct research to determine the specific protein allergens in latex.
3642 3. Conduct research to develop latex alternative materials.

3643

3644 **Hand Hygiene**

- 3645 1. Determine the most appropriate agents for hand hygiene categories.
3646 2. Determine how antimicrobial soaps or waterless alcohol-based handrubs compare
3647 with plain (non-antimicrobial) soap in preventing transmission of organisms
3648 during routine dental procedures.
3649 3. Assess the impact of nail polish and hand jewelry on the effectiveness of hand
3650 hygiene.
3651 4. Study the effect of alcohol-based hand hygiene products on reducing latex
3652 proteins on the hands after latex glove usage.

3653

3654

- 3655 **Sterilization or Disinfection of Patient-Care Items**
- 3656 1. Investigate the applicability of other types of low-temperature sterilization
- 3657 procedures (e.g., hydrogen peroxide gas plasma) in dentistry.
- 3658 2. Determine the appropriate barrier protection and chemical disinfection methods
- 3659 for heat-sensitive semicritical patient care items.
- 3660 3. Determine the frequency of surface contamination on barrier-protected items
- 3661 (e.g., x-ray sensors, intraoral camera wands).
- 3662
- 3663 **Environmental Infection Control**
- 3664 1. Explore new ways to inactivate medical waste and to minimize its volume.
- 3665
- 3666 **Dental Unit Waterlines, Biofilm, and Water Quality**
- 3667 1. Determine the association between exposure to endotoxin in dental treatment
- 3668 water and compromised respiratory function in patients and dental health-care
- 3669 workers. There is currently very little data upon which to base any risk assessment
- 3670 for persons exposed to dental treatment water and aerosols containing large
- 3671 numbers of microorganisms and their associated byproducts.
- 3672 2. Support research to identify safe, effective, and economical approaches to
- 3673 improving the quality of water used in dental treatment.
- 3674
- 3675 **Program Evaluation**
- 3676 1. Develop surrogate measures (e.g., process measurements, performance indicators)
- 3677 for health-care-associated infections in dental settings that can demonstrate the
- 3678 impact of interventions (e.g., compliance, effectiveness, cost-effectiveness)
- 3679 2. Develop methods for evaluating interventions.
- 3680
- 3681 **Dental Handpieces and Other Devices Attached to Air and Waterlines**
- 3682 1. Determine the potential for internal contamination of low-speed handpieces,
- 3683 including the motor, and other devices connected to dental air and water supplies.
- 3684
- 3685 **Single-Use Devices**
- 3686 1. Evaluate the effects of repetitive reprocessing cycles on burs and endodontic files.
- 3687 2. Evaluate methods for removal of organic material from dental rotary instruments
- 3688 (e.g., carbide and diamond burs) and endodontic files.
- 3689
- 3690 **Pre-procedural Mouth Rinses**
- 3691 1. Continue to assess the clinical effects of bacteremias induced by dental
- 3692 procedures, induced bacteremias and the possible benefits of pre-procedural
- 3693 mouth rinsing.
- 3694 2. Conduct research to determine the effectiveness of pre-procedural mouth rinses in
- 3695 reducing contamination in dental aerosols and spatter.
- 3696 3. Conduct research to determine the infectious disease risks associated with dental
- 3697 aerosols.
- 3698
- 3699
- 3700

3701
3702
3703
3704
3705
3706
3707
3708
3709
3710

Surgical Procedures

1. Determine the most effective hand hygiene agents for surgical hand scrubs.
2. Further assess the effectiveness of double gloving.

Handling of Extracted Teeth

1. Further investigate the effectiveness of specific methods to disinfect/sterilize extracted teeth.
2. Determine the effects of autoclave sterilization on the dentinal structure of extracted teeth with respect to research on dental materials.

3710 **Appendix 6. Glossary of Terms**

3711

3712 **Administrative controls:** the use of administrative measures (i.e., policies and
3713 procedures and enforcement measures) to reduce the risk of exposure to infectious
3714 persons.

3715 **Aerosol:** particles of respirable size (<10 µm) generated by both humans and
3716 environmental sources that can remain viable and airborne for extended periods in the
3717 indoor environment; commonly generated in dentistry during use of handpieces,
3718 ultrasonic scalers, and air/water syringes.

3719 **Airborne transmission:** a means of spreading infection in which airborne droplet nuclei
3720 (small-particle residue of evaporated droplets ≤ 5 µm in size containing
3721 microorganisms that remain suspended in air for long periods of time) are inhaled by
3722 the susceptible host.

3723 **Air abrasion:** the application of a mixture of small abrasive particles by air blast to
3724 prepare a cavity in a tooth or remove deposits from teeth.

3725 **Alcohol-based hand rub:** an alcohol-containing preparation designed for application to
3726 the hands for reducing the number of viable microorganisms on the hands. In the
3727 United States, such preparations usually contain 60-95% ethanol or isopropanol.
3728 Because these products do not remove soil, application must be preceded by a soap-
3729 and-water wash when used on soiled hands.

3730 **Allergen:** an antigen, a substance capable of inducing allergy or specific hypersensitivity.

3731 **Allergic contact dermatitis(type IV [delayed] hypersensitivity):** a type IV
3732 hypersensitivity resulting from contact with a chemical allergen (e.g., poison ivy,
3733 certain components of patient care gloves), generally localized to the contact area.

3734 **Anaphylaxis:** an immediate and severe allergic reaction to a substance (e.g., food or
3735 drugs).

3736 **Antibody:** a protein found in the blood that is produced in response to foreign substances
3737 (e.g., bacteria or viruses) invading the body. Antibodies protect the body from disease
3738 by binding to these organisms and destroying them.

3739 **Antigen:** a foreign substance (e.g., bacteria or viruses) in the body that is capable of
3740 triggering an immune response, usually the production of antibodies.

3741 **Antibody to HBsAg (anti-HBs):** an indicator of past infection with, and immunity to,
3742 hepatitis B virus, passive antibody from HBIG (hepatitis B immune globulin), or
3743 immune response from hepatitis B vaccine.

3744 **Antimicrobial soap:** a soap (detergent) containing an antiseptic.

3745 **Antiseptic handwash:** washing the hands with water and soap or other detergents
3746 containing an antiseptic agent.

3747 **Antiseptic hand rub:** application of an antiseptic handrub product to all surfaces of the
3748 hands to reduce the number of microorganisms present.

3749 **Antiseptics:** antimicrobial substances applied to the skin to reduce the number of
3750 microbial flora.

3751 **Asepsis:** the absence of infection or infectious materials or agents, prevention of contact
3752 with microorganisms.

3753 **Autoclave:** an instrument for sterilization using moist heat under pressure.

3754 **Asymptomatic:** without symptoms, or producing no symptoms.

3755 **Bacteria:** tiny one-celled organisms present throughout the environment that can be seen
3756 only with a microscope. Although not all bacteria are harmful, some cause disease.
3757 **Bacterial count:** method of estimating the number of bacteria per unit sample. The term
3758 also refers to the estimated number of bacteria per unit sample, usually expressed as
3759 colony-forming units (CFUs) per square centimeter (cm²) per milliliter (ml).
3760 **Bacterial endocarditis:** a microbial infection of the endocardium or the heart valves.
3761 **Barrier material:** material that prevents the penetration of microorganisms, particulates,
3762 and fluids.
3763 **Bead sterilizer (endodontic dry heat sterilizer):** a device that used small glass beads
3764 (1.2–1.5 mm diameter) and high temperature (217–232°C) for brief exposures (e.g.,
3765 45 seconds) to inactivate microorganisms.
3766 **Bioburden:** the microbial or organic material on a surface or object prior to
3767 decontamination, also known as “bioload” or “microbial load.”
3768 **Biofilm:** microbial communities characterized by cells attached to a substrate or to each
3769 other, are embedded in a matrix of extracellular polymeric substances (glycocalyx),
3770 and exhibit increased resistance to dislodgement and the effects of antimicrobial
3771 agents.
3772 **Biological indicator:** a device to monitor the sterilization process that consists of a
3773 standardized, viable population of microorganisms (usually bacterial spores) known
3774 to be resistant to the mode of sterilization being monitored. Biological indicators are
3775 intended to demonstrate whether the conditions were adequate to achieve
3776 sterilization.
3777 **Bloodborne pathogens:** disease-producing microorganisms spread by contact with blood
3778 or other body fluids contaminated with blood from an infected person.
3779 **Bloodborne pathogens standard:** a standard developed, promulgated, and enforced by
3780 the Occupational Safety and Health Administration (OSHA) directing employers to
3781 protect employees from occupational exposure to blood and other potentially
3782 infectious material.
3783 **Central processing or central service department:** the department within a health-care
3784 facility that processes, issues, and controls professional supplies and equipment, both
3785 sterile and nonsterile, for some or all patient care areas.
3786 **Chemical indicator:** a material containing a chemical that changes color or form with
3787 exposure to heat, steam, or ethylene oxide; used to monitor exposure of items to heat-
3788 or gas-sterilizing agents.
3789 **Chemical sterilant:** chemicals used for the purpose of destroying all forms of microbial
3790 life including fungal and bacterial spores.
3791 **Cleaning:** the removal of visible soil and organic contamination from a device or surface,
3792 using either the physical action of scrubbing with a surfactant or detergent and water
3793 or an energy-based process (e.g., ultrasonic cleaners) with appropriate chemical
3794 agents.
3795 **Clinical contact surface:** environmental surfaces that are directly contacted or touched
3796 by 1) contaminated instruments, devices, and dental materials; 2) contaminated hands
3797 or gloves; or 3) droplet and spatter generated during patient care (e.g., light handles,
3798 switches on the dental chair).
3799 **Colony:** a mass of cells that originated from one cell or one colony-forming unit.
3800 **Colony-forming unit (CFU):** the original cells that begin multiplication to form a

3801 colony. The minimum number of separable cells on the surface of or in semi-solid
3802 agar medium which gives rise to a visible colony of progeny is on the order of tens of
3803 millions. CFUs may consist of pairs, chains, and clusters as well as single cells and
3804 are often expressed as colony-forming units per milliliter (CFU/ml).

3805 **Contaminant:** substance that results in impurity by contact or mixture.

3806 **Contaminated:** state of having been actually or potentially in contact with
3807 microorganisms. As used in health care, it generally refers to microorganisms that
3808 could be capable of producing disease or infection.

3809 **Control biological indicator:** a biological indicator from the same lot as a test indicator
3810 that is left unexposed to the sterilization cycle and then incubated to verify the
3811 viability of the test indicator. The control indicator should yield positive results for
3812 bacterial growth.

3813 **Creutzfeldt-Jakob disease (CJD):** an infectious degenerative neurological disorder of
3814 humans thought to be transmitted by abnormal isoforms of neural proteins called
3815 prions. CJD is one of a group of related diseases known as transmissible spongiform
3816 encephalopathies (TSEs).

3817 **Critical items:** dental instruments or devices that penetrate normally sterile areas of the
3818 mouth (e.g., soft tissue, contact bone, enter into or contact the bloodstream).

3819 **Decontaminate hands:** To reduce bacterial counts on hands by performing antiseptic
3820 hand rub or antiseptic handwash.

3821 **Decontamination:** A process or treatment that renders a medical device, instrument, or
3822 environmental surface safe to handle.

3823 **Dental health-care personnel:** all paid and unpaid personnel in the dental health-care
3824 setting who have the potential for exposure to infectious materials, including body
3825 substances and contaminated supplies, equipment, environmental surfaces, water, or
3826 air.

3827 **Dental treatment water:** Nonsterile water used for dental therapeutic purposes,
3828 including irrigation of nonsurgical operative sites and cooling of high speed and
3829 ultrasonic instruments.

3830 **Dental unit waterlines:** Small bore tubing, usually plastic, used to deliver dental
3831 treatment water through a dental unit.

3832 **Detergents:** compounds that possess a cleaning action and have hydrophilic and
3833 lipophilic parts. Although products used for handwashing or antiseptic handwash in a
3834 health-care setting represent various types of detergents, the term “soap” is used to
3835 refer to such detergents in this guideline.

3836 **Disinfectant:** a chemical agent used on inanimate objects to destroy virtually all
3837 recognized pathogenic microorganisms, but not necessarily all microbial forms (e.g.,
3838 bacterial spores).

3839 **Disinfection:** a process of microbial inactivation, generally less lethal than sterilization,
3840 that eliminates virtually all recognized pathogenic microorganisms but not necessarily
3841 all microbial forms (e.g., bacterial spores).

3842 **Distilled water:** water heated to the boiling point, vaporized, cooled, condensed, and
3843 collected so that no impurities are reintroduced.

3844 **Droplet nuclei:** small pathogen-containing particles of respiratory secretions expelled
3845 into the air by coughing, which are reduced by evaporation to small dry particles that

3846 can remain airborne for long periods; one possible mechanism for transmission of
3847 infection from one individual to another.

3848 **Droplets:** small particles of moisture that may be generated when a person coughs or
3849 sneezes or when water is converted to a fine mist by an aerator or shower head.

3850 Intermediate in size between drops and droplet nuclei, these particles, tend to quickly
3851 settle out from the air so that any risk of disease transmission is generally limited to
3852 persons in close proximity to the droplet source.

3853 **Dry heat sterilizer:** an instrument for sterilizing with heated air.

3854 **Endotoxin:** the lipopolysaccharides found in the cell walls of Gram-negative bacteria,
3855 whose toxic character resides in their lipid portion. Endotoxins can produce pyrogenic
3856 reactions in exposed persons.

3857 **Engineering controls:** controls that isolate or remove a hazard from the workplace.

3858 **Event-related packaging:** a storage practice that recognizes that a package and its
3859 contents should remain sterile until some event causes the item(s) to become
3860 contaminated.

3861 **Exposure:** the condition of being subjected to something (e.g., an infectious agent) that
3862 could have a harmful effect.

3863 **Exposure time:** period of time during a sterilization process in which items are exposed
3864 to the sterilant at the specified parameters. In steam sterilization, exposure time is the
3865 period in which items are exposed to saturated steam at the specified temperature.

3866 **Flash steam sterilization:** process designed for the steam sterilization of unwrapped
3867 critical patient care items for immediate use.

3868 **Germicide:** a chemical agent manufactured for the purpose of destroying
3869 microorganisms. Some chemicals indicate the type of microorganism destroyed
3870 (prefix), with the use the suffix "-cide" (e.g., virucide, fungicide, bactericide,
3871 sporicide, tuberculocide).

3872 **Glycocalyx:** the polysaccharide material produced by bacteria that forms the structural
3873 matrix of biofilm.

3874 **Hand antisepsis:** refers to either antiseptic handwash or antiseptic hand rub. A process
3875 for the removal of soil and transient microorganisms from the hands.

3876 **Hand hygiene:** a general term that applies to handwashing, antiseptic handwash,
3877 antiseptic hand rub, and surgical hand antisepsis.

3878 **Handwashing:** washing hands with plain (non-antimicrobial) soap and water.

3879 **Health-care personnel:** all paid and unpaid persons working in health-care settings who
3880 have the potential for exposure to infectious materials, including body substances,
3881 and contaminated medical (including dental) equipment and supplies, environmental
3882 surfaces, or air.

3883 **Health-care-associated infection:** any infection associated with a medical or surgical
3884 intervention. The term "healthcare-associated" replaces "nosocomial," which is
3885 limited to adverse infectious outcomes occurring in hospitals.

3886 **Hepatitis B surface antigen (HBsAg):** surface antigen(s) of hepatitis B virus detectable
3887 in large quantity in serum of infected persons.

3888 **Hepatitis B e antigen (HBeAg):** antigen correlates with hepatitis B virus replication, as a
3889 marker of increased infectivity.

3890 **Heterotrophic bacteria:** those bacteria that require an organic carbon source for growth,
3891 i.e., they derive energy and carbon from organic compounds. The modifier

3892 "mesophilic" describes bacteria that grow best within the middle ranges of
3893 environmental temperature.

3894 **Heterotrophic plate count bacteria (HPC bacteria):** bacteria that can be grown on
3895 non-selective heterotrophic agar plates.

3896 **High-level disinfection:** a disinfection process that inactivates vegetative bacteria,
3897 mycobacteria, fungi, and viruses but not necessarily high numbers of bacterial spores.
3898 The FDA further defines a high-level disinfectant as a sterilant used under the same
3899 contact conditions except for a shorter contact time.

3900 **Housekeeping surfaces:** environmental surfaces (e.g., floors, walls, ceilings) not
3901 involved in direct delivery of patient care in health-care facilities.

3902 **Hypersensitivity:** a condition in which the body has an exaggerated response to a
3903 substance (e.g., food or drug). Also known as allergy.

3904 **Idiopathic:** describes an infectious disease or other complication resulting from medical
3905 or dental treatment.

3906 **Immunity:** protection against a disease. Indicated by the presence of antibodies in the
3907 blood, immunity can usually be determined by a laboratory test.

3908 **Immunization:** The process by which a person becomes immune, or protected, against a
3909 disease. This term is often used interchangeably with vaccination or inoculation.

3910 **Immunoglobulin (Ig):** a protein that functions as an antibody in the blood that fights
3911 infection.

3912 **Implantable device:** according to the Food and Drug Administration (FDA), "device that
3913 is placed into a surgically or naturally formed cavity of the human body if it is
3914 intended to remain there for a period of 30 days or more" [21 CFR 812.3(d)].

3915 **Independent water reservoir:** A container used to hold water or other solutions and
3916 supply it to handpieces and air/water syringes attached to a dental unit. The
3917 independent reservoir, which isolates the unit from the public water system, may be
3918 provided as original equipment or as a retrofit device on all modern dental units.

3919 **Infectious microorganisms:** microorganisms capable of producing infection in
3920 susceptible hosts.

3921 **Intermediate-level disinfection:** a disinfection process that inactivates vegetative
3922 bacteria, most fungi, mycobacteria, and most viruses (particularly the enveloped
3923 viruses) but not bacterial spores.

3924 **Irritant contact dermatitis:** the development of dry, itchy, irritated areas on the skin,
3925 which can result from frequent handwashing and gloving as well as exposure to
3926 chemicals.

3927 **Latex allergy (type I [immediate] hypersensitivity):** a systemic immune reaction to the
3928 proteins found in natural rubber latex.

3929 **Latex:** a milky white fluid extracted from the rubber tree *Hevea brasiliensis* that contains
3930 the rubber material cis-1,4 polyisoprene.

3931 **Low-level disinfection:** a process that will inactivate most vegetative bacteria, some
3932 fungi, and some viruses but cannot be relied on to inactivate resistant microorganisms
3933 (e.g., mycobacteria or bacterial spores).

3934 **Mechanical indicator:** automated devices (e.g., graphs, gauges, printouts) that monitor
3935 the sterilization process.

3936 **Medical waste:** waste sufficiently capable of causing infection during handling and
3937 disposal (e.g., pathology and anatomy waste, blood, other body fluid specimens) to
3938 merit special handling and disposal.

3939 **Mesophilic:** that which favors a moderate temperature. For mesophilic bacteria, a
3940 temperature range of 20–55°C (68–131°F) is favorable for growth and proliferation.

3941 **Microfilter:** Membrane filter used to trap microorganisms suspended in water. Filters are
3942 usually installed on dental unit waterlines near the point of use as a retrofit device.
3943 Microfiltration commonly occurs at 0.03 to 10 µm. Sediment filters commonly found
3944 in dental unit water filter regulators range from 20 to 90 µm and do not function as
3945 microbiological filters.

3946 **Microorganisms:** As used in health care, the term generally refers to bacteria, fungi,
3947 viruses, and bacterial spores of microscopic size.

3948 **N-95 respirator:** NIOSH (National Institute of Occupational Safety and Health)-certified
3949 respirator that meets minimum filtration performance criteria for respiratory
3950 protection in TB areas.

3951 **Noncritical devices or items:** these medical devices or surfaces come into contact with
3952 only intact skin. The risk of infection from using these devices is low.

3953 **Nosocomial:** describes an infection acquired in a hospital as a result of medical care (see
3954 definition for health-care-associated infection).

3955 **Occupational exposure:** blood or other potentially infectious material that contact either
3956 parenterally or the skin, eye, or mucous membrane during the performance of an
3957 employee’s duty.

3958 **Occupational and environmental health service:** a medical practice that specializes in
3959 recognizing and resolving workplace hazards and treating job-related diseases. The
3960 practitioner can assist a dental office in developing an exposure control plan and in
3961 implementing postexposure management protocols.

3962 **Opportunistic infection:** an infection caused by a microorganism that does not
3963 ordinarily cause disease but does, under certain host conditions (e.g., impaired
3964 immune response).

3965 **Particulate respirator:** a respirator that removes small particles from the air. Several
3966 types of particulate respirators are available for use against tuberculosis (e.g., N-95).

3967 **Parts per million (ppm):** a measure of concentration in solution. A 5.25% chlorine
3968 bleach solution (undiluted as supplied by the manufacturer) contains approximately
3969 50,000 parts per million of free available chlorine.

3970 **Percutaneous injury:** an injury that penetrates the skin (e.g., needlestick, or cut with a
3971 sharp object).

3972 **Performance criteria:** the measure for judging how well a function operates as expected
3973 for its intended patient care purpose.

3974 **Persistent activity:** the prolonged or extended activity that prevents or inhibits the
3975 proliferation or survival of microorganisms after application of the product. This
3976 activity may be demonstrated by sampling a site several minutes or hours after
3977 application and demonstrating bacterial antimicrobial effectiveness when compared
3978 with a baseline level. In the past, this property was also called “residual activity.”
3979 Both substantive and non-substantive active ingredients can show a persistent
3980 antimicrobial effect if they lower the number of bacteria significantly during the
3981 handwashing period.

3982 **Personal protective equipment (PPE):** the specialized clothing or equipment worn by
3983 an employee for protection against a hazard (e.g., gloves, mask, eyewear, gown).

3984 **Plain or non-antimicrobial soap:** detergents that do not contain antimicrobial agents or
3985 contain very low concentrations of such agents that are effective solely as
3986 preservatives.

3987 **Planktonic:** free-floating or weakly swimming organisms suspended in a bulk fluid.

3988 **Postexposure prophylaxis:** the administration of medications following an occupational
3989 exposure in an attempt to prevent infection.

3990 **Potable (drinking) water:** water suitable for drinking per applicable public health
3991 standards.

3992 **Pre-procedural mouth rinse:** a mouth rinse used before a dental procedure to reduce the
3993 number of microorganisms.

3994 **Prion:** a modified form of a normal cell surface component known as a prion protein, a
3995 pathogenic form of the protein that is both less soluble and more resistant to enzyme
3996 degradation than the normal form. It is associated with the transmission of diseases
3997 known as transmissible spongiform encephalopathies (TSEs).

3998 **Pyrogen:** a fever-producing substance such as bacterial endotoxin (lipopolysaccharide).

3999 **Qualified health-care professional:** any health care provider who can provide
4000 counseling and perform all medical evaluations and procedures in accordance with
4001 the most current recommendations of the US Public Health Service, including
4002 postexposure prophylaxis when indicated.

4003 **Reprocessing (of medical or dental instruments):** the procedures or steps taken to
4004 make a medical or dental instrument safe for use on the next patient. Reprocessing
4005 encompasses both cleaning and the final or terminal step (i.e., sterilization or
4006 disinfection), which is determined by the intended use of the instrument.

4007 **Reservoir of infection:** an alternate or passive living host or inanimate carrier that
4008 harbors pathogenic microorganisms without harm to itself and serves as a source from
4009 which persons or animals can be infected.

4010 **Resident flora:** species of microorganisms that are always present on or in the body and
4011 are not easily removed by mechanical friction.

4012 **Retraction:** The entry of oral fluids and microorganisms into waterlines through negative
4013 water pressure.

4014 **Sanitizer:** an agent that reduces microbial contamination to safe levels as judged by
4015 public health standards or requirements.

4016 **Semicritical items:** dental instruments and devices that come into contact with mucous
4017 membranes but do not penetrate normally sterile areas of the mouth (e.g., soft tissue,
4018 bone, bloodstream).

4019 **Single-use (disposable) device:** a device intended to be used on one patient and then
4020 discarded appropriately. These items are not intended to be reprocessed (cleaned,
4021 disinfected, or sterilized) and used on another patient.

4022 **Spatter:** visible drops of liquid or body fluid that are expelled forcibly into the air and
4023 settle out quickly, as distinguished from particles of an aerosol, which remain
4024 airborne indefinitely.

4025 **Standard precautions:** A set of combined precautions that include the major
4026 components of universal precautions (designed to reduce the risk of transmission of
4027 bloodborne pathogens) and body substance isolation (designed to reduce the risk of

4028 transmission of pathogens from moist body substances). Similar to universal
4029 precautions, standard precautions are used for care of all patients regardless of their
4030 diagnosis or presumed infection status.

4031 **Steam sterilization:** sterilization process that uses saturated steam under pressure as the
4032 sterilizing agent for a specified exposure time and at a specified temperature.

4033 **Sterilant:** an agent that destroys all forms of microbiological life, including fungal and
4034 bacterial spores.

4035 **Sterile/sterility:** state of being free from all living microorganisms. In practice, usually
4036 described as a probability function, e.g., the probability of a surviving microorganism
4037 being 1 in 1,000,000.

4038 **Sterile water:** water that is sterilized and contains no antimicrobial agents.

4039 **Sterilization:** the use of a physical or chemical procedure to destroy all microbial life,
4040 including bacterial endospores.

4041 **Sterilizer, gravity-displacement type:** type of steam sterilizer in which incoming steam
4042 displaces residual air through a port or drain in or near the bottom (usually) of the
4043 sterilizer chamber. In most table-top sterilizers in dental offices, the steam is
4044 generated by heating a measured amount of water introduced into the bottom of the
4045 sterilization chamber.

4046 **Sterilizer, pre-vacuum type:** type of steam sterilizer that depends upon one or more
4047 pressure and vacuum excursions at the beginning of the cycle to remove air and draw
4048 in saturated steam produced by a separate steam generator.

4049 **Surfactants:** surface-active agents that reduce surface tension, they make water “wetter.”
4050 They also help cleaning by loosening, emulsifying, and holding soil in suspension,
4051 which can then be more readily rinsed away. Can be classified by their net ionic
4052 charge, as anionic (negative), cationic (positive) or nonionic (none).

4053 **Surgical hand antisepsis:** antiseptic handwash or antiseptic hand rub performed
4054 preoperatively by surgical personnel to eliminate transient flora and reduce resident
4055 hand flora. Antiseptic detergent preparations often have persistent antimicrobial
4056 activity.

4057 **Surgical hand scrub:** an antiseptic-containing preparation that substantially reduces the
4058 number of microorganisms on intact skin; it is broad-spectrum, fast-acting, and
4059 persistent.

4060 **Surgical procedure:** procedure involving the incision, excision, or reflection of skin or
4061 oral mucosa that exposes the normally sterile areas of the oral cavity. Examples
4062 include biopsy, periodontal surgery, apical surgery, and extractions of teeth.

4063 **Transient flora:** microorganisms that may be present in or on the body under certain
4064 conditions and for certain lengths of time; they are more amenable to removal by
4065 mechanical friction than resident flora.

4066 **Transmissible spongiform encephalopathies (TSEs):** a group of rapidly progressive,
4067 invariably fatal, degenerative neurological disorders affecting both humans and
4068 animals that are caused by infection with prions.

4069 **Transmission-based precautions:** a set of practices that apply to patients with
4070 documented or suspected infection or colonization with highly transmissible or
4071 epidemiologically important pathogens for which precautions beyond the standard
4072 precautions are needed to interrupt transmission in health-care settings.

4073 **Tuberculin skin test (TST):** a method used to evaluate the likelihood that a person is
4074 infected with *M. tuberculosis*.

4075 **Tuberculosis infection, latent:** a condition in which living tubercle bacilli (*M.*
4076 *tuberculosis*) are present in the body but the disease is not clinically active. Infected
4077 persons usually have positive tuberculin skin test, but they have no symptoms related
4078 to the infection and are not infectious. Infected persons remain at lifelong risk for
4079 developing disease, however, if they are not given preventive therapy.

4080 **Turbidity:** cloudiness.

4081 **Ultrasonic cleaner:** a device that removes debris by a process called cavitation, in which
4082 waves of acoustic energy are propagated in aqueous solutions to disrupt the bonds
4083 that hold particulate matter to surfaces.

4084 **Unsaturated chemical vapor sterilizer:** an instrument for sterilization that uses hot
4085 ethyl alcohol and formaldehyde vapors under pressure.

4086 **Vaccination:** inoculation with a vaccine.

4087 **Vaccine:** a suspension of infectious agents or some part of them, given for the purpose of
4088 establishing resistance to an infectious disease.

4089 **Vegetative bacteria:** a state of quiescence, which is achieved when certain bacteria (i.e.,
4090 gram-positive bacilli) are resting. Denotes the portion of a cell cycle during which the
4091 cell is not involved in replication.

4092 **Ventilation:** the process of supplying and removing air by natural or mechanical means
4093 to and from any space; such air may be conditioned.

4094 **Washer disinfectant:** an automatic unit designed to clean and thermally disinfect
4095 instruments. The unit uses a high-temperature cycle rather than a chemical bath.

4096 **Waterless antiseptic agent:** An antiseptic agent that does not require use of exogenous
4097 water. After applying such an agent, the person rubs the hands together until the agent
4098 has dried.

4099 **Wicking:** absorption of a liquid by capillary action along a thread or through the material
4100 (e.g., the enhanced penetration of liquids through undetected holes in a glove).

4101 **Work practice controls:** controls that reduce the likelihood of exposure by altering the
4102 manner in which a task is performed (e.g., recapping of needles using a “scoop
4103 technique” instead of two hands).